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The catalytic subunit EZH2 of Polycomb Repressive complex 2 (PRC2) is
responsible for placing the histone H3 lysine 27 trimethylation (H3K27me3)
histone modification at nucleosomes, a mark associated with silenced genes. This
histone modification can be found at domains that also carry marks usually
associated with a transcriptionally active state, such as H3K4me3 and H3K4me1.
Genes that bear this overlap of repressive and active marks around their
promoters and/or enhancers are known as bivalent or poised genes, thought to be
in a state of readiness for transcriptional silencing or activation upon stimulation
by additional factors during differentiation. However, it is not known how much
of Polycomb repression relies on H3K27me3 alone and whether the binding of
PRC2 itself plays a part that is independent of this histone modification. It
has further been suggested that PRC2 may interact with chromatin organisers
and be involved in long-range chromatin interactions. Recently, it has also
been noted that poised enhancers are already looped to contact their respective
promoters, in a PRC2 dependent manner, before gene activation occurs. Again,
it is not yet known whether these contacts depend on H3K27me3 or whether
they are mediated by the protein complex itself. To address these questions, I
used CRISPR/Cas9 gene editing to generate both a knock out and catalytically
inactive form of EZH2 in mouse embryonic stem cells, both in the presence
and absence of its less active paralogue, EZH1. By performing gene expression,
chromatin conformation, and differentiation assays, I aimed to identify roles of
PRC2 that may be independent of the histone mark that it catalyses and that may
mediate the role of PRC2 in genome organisation, as well as seeking to further
elucidate the role of PRC2 throughout development. The findings of this project
showed that some catalytic activity of PRC2 was required for the maintenance
of Polycomb gene silencing in mESCs. Interestingly, the levels of H3K27me3
that required to maintain repression were much lower than those that are found
at these genes in wild-type conditions. I found that not only was the activity of
i
EZH1 sufficient to maintain the silencing of Polycomb bound genes in mESCs, but
also for the majority of RING1b recruitment to these sites, and the maintenance of
the PRC2-dependent enhancer-promoter contact at the Lhx5 locus. Furthermore,
I found that throughout differentiation EZH1 was able to maintain the repression
of genes that were silenced in undifferentiated mESCs, but EZH2 and robust
H3K27me3 methylation was required to allow for the correct upregulation of
certain developmental genes required for transition to the neural lineage. This
failure to upregulate such a large number of genes was somewhat unexpected as
PRC2 is known as a repressive complex and this may suggest it also possesses
some gene activating functions. Based on these findings I concluded that while the
low catalytic activity of EZH1 is sufficient to maintain a Polycomb repressive state
at target genes in a steady state environment such as undifferentiated mESCs,
the activity of EZH2 is required in the dynamic conditions of cell differentiation




One of the biggest questions that has interested biologists since the earliest days
of research in this field is how a complex adult individual composed of a multitude
of highly specialised organs and tissues can arise from a single cell. As this single
cell divides and develops into an embryo, every subsequent cell that is generated
contains the exact same genetic information, and yet these cells can go on to fulfil
an extremely diverse set of functions. This is achieved by precisely controlling
the subset of genes that are active, or expressed, in each cell, giving it its distinct
characteristics within the organism. Each cell in the embryo becomes more and
more specialised throughout development as the set of genes it expresses becomes
more and more selective and fine-tuned. The process by which this happens is
still not fully understood, but it relies on many different layers of regulation. One
such layer involved the structure that is formed by the DNA and proteins known
as histones. DNA is the molecule within the cell that carries all the genetic
information. This is an extremely long molecule and is contained within the
nucleus of the cell by being packaged in an efficient and organised way. This
packaging involves the aforementioned histones, which form a globular structure,
around which the DNA can be wound, forming what is known as a nucleosome.
These nucleosomes form across the length of the DNA resulting in what is termed
the beads on a string structure of the chromatin fibre. This string of nucleosomes
can then coil together into a condensed and regular structure enabling the DNA
to be efficiently packed into a small space. The state of this chromatin around the
position of a given gene has a strong effect on whether this gene is active or not.
If the chromatin is tightly packed with the nucleosomes being very close together
across the gene, it is more difficult for this gene to be expressed. If the chromatin
is more loosely packed and the DNA becomes more accessible with more widely
spaced nucleosomes, then the gene will be much more readily expressed. An
additional factor governing this process is the state of the histones themselves.
These proteins can be modified by the addition of small molecules that can act
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as signals or markers of the state of gene expression in that region, among other
things. These small molecules are placed onto the histones by a large family of
proteins that are collectively known as chromatin modifiers.
My PhD focuses on one of these chromatin modifiers, which is responsible for
placing a histone mark that is usually associated with an inactive state of gene
expression. This chromatin modifier, known as PRC2, is a complex of multiple
separate proteins that have to fit together into a complex in order to be able to
place its mark on histones. PRC2 is important for acquiring the correct patterns
of gene expression during embryo development and in stem cells, a type of cell
that has not yet become specialised, it helps maintain this unspecialised state by
keeping genes involved in the development of an adult organism in an inactive
state. There are two main types of PRC2 that exist in the cell, one that places
high levels of its mark on histones, and one that is less active and only capable
of placing only very low amounts of the mark.
By studying PRC2 and its interaction with chromatin, as well as the gene
expression patterns in stem cells, I aimed to increase our knowledge of how this
complex functions and how much of its role in cells relies of the mark that it places
on histones. I also sought to further our understanding of what PRC2 is required
for during development, by studying its influence on gene expression throughout
the stages of differentiation that occur as stem cells progressively transition into
specialised nerve cells. I found that although PRC2 does need to be able to place
its histone mark to be able to have an influence on gene expression, a surprisingly
small amount of this mark appears to be sufficient for this effect in stem cells. I
also showed that although the less active type of PRC2 is able to maintain most
of the complex’s function in stem cells, as these cells transition into nerve cells
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All living organisms rely on regulation of the expression of their genes in order to
maintain everyday cellular function, respond to external and internal stimuli and,
in the case of more complex organisms, undergo the transition from a single-cell
zygote to a fully developed individual. While all cells in a multi-cellular organism
have the same DNA sequence and set of genes at their disposal, a vast diversity
of different patterns of expression of these genes arises during development from
the single-cell zygote onwards, allowing for the specification of different cell types
required to perform a plethora of different functions. This divergence of cell
types throughout development eventually came to be understood to be based
on changes of gene expression that were clonally heritable and did not rely on
alterations in the DNA sequence. The regulation of gene expression throughout
these processes is controlled by a number of different factors from signalling
cascades and transcription factors, the chemical and physical characteristics of
the chromatin fibre down to the DNA sequence itself. These factors work in
combination to form highly complex regulatory networks that fine tune gene
expression patterns for the specific needs of each cell type.
These systems of gene regulation are often associated with epigenetics. The
field of epigenetics arose as a branch of research dedicated to elucidating the
relationship between genotype and phenotype. The first definition was provided
by Waddington who coined the term in the 1940’s, and established epigenetics as
“the branch of biology that studies the causal interactions between genes and their
products which bring the phenotype into being” (Waddington, 1968; Waddington,
2012; Dupont et al., 2009). Much work has been done in this field since its
inception, and our understanding of these systems has been further refined giving
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rise to today’s revised definition of epigenetics as: “the study of mitotically
and/or meiotically heritable changes in gene function that cannot be explained by
changes in DNA sequence” (Riggs and Porter 1996, (Felsenfeld, 2014)) with the
nuance that the newly established epigenetic state should arise from a transient
mechanism that is distinct from that required for the maintenance of this state
(Berger et al., 2009).
To date many molecular mechanisms have been identified as being involved in
this epigenetic regulation of gene expression, most of which involve chemical
modifications of DNA or changes to the highly complex DNA-protein structure
known as chromatin. In recent years, the term epigenetic has partially fallen out
of use in discussions concerning systems of gene regulation, particularly those
involving the chemical modification of the chromatin proteins known as histones,
as many of them have been found not to be stably inherited.
1.1 Chromatin and histone modifications
1.1.1 Chromatin fibre
Chromatin is the three-dimensional molecular structure made up of DNA and
protein that governs packaging and spatial organisation of the genome in the
nucleus. The proteins associated with DNA to create chromatin are histones.
Two copies of each of the four core histones, H2A, H2B, H3 and H4, assemble
into a globular octamer around which 147 base pairs (bp) of DNA wind to create
a nucleosome (Burlingame et al., 1985; Luger et al., 1997). An additional histone,
H1, known as the linker histone plays a crucial role in the integrity of nucleosomes
and the higher order chromatin structure itself. This histone is larger than
the core histones and binds to the nucleosome at the point of entry and exit
of the DNA that is wound around the core particle, in contact with both the
core histones and the DNA. The presence of H1 on nucleosomes facilitates the
compaction of chromatin into an organised structure that forms a condensed fibre
with a diameter of 30 nm (Robinson and Rhodes, 2006). This 30 nm fibre can
additionally form 300 nm loops which further package chromatin into a 250 nm
fibre, which itself can be coiled together to eventually form the highly condensed
structures of the chromatids which come together in pairs to form a mitotic
chromosome (Németh and Längst, 2004). Both the DNA and histones can serve
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as a platform for the binding of a variety of factors involved in various functions
such as remodelling of chromatin structure, regulation of gene expression, and
DNA replication and repair. The binding of these factors can be modulated by
the deposition of small molecular groups on either DNA or histones, by enzymes
known as chromatin modifiers. These modifications can also serve to change
the physical properties of the chromatin fibre and in this way influence gene
expression.
1.1.2 DNA and Histone Post-translational modifications
Although the chemical modification of all bases of DNA is theoretically possible,
the only modified bases that have been discovered to date are methylated cytosine
and adenine (Kumar et al., 2018). Of the two, methylated adenine, or 6-mA, is
the least well characterised. It was first discovered in bacteria and has recently
been suggested to also exist in eukaryotes, although study of the function of this
modification in these organisms remains in the early stages (Kumar et al., 2018).
Methylated cytosine, or 5-mC, on the other hand has been extensively studied
and has been known to exist for many years. 5-mC is most often found in a
CG DNA sequence context in animals, in fact around 80% of all CGs in the
mammalian genomes are known to be methylated (Jabbari and Bernardi, 2004).
The presence of this modification influences the accessibility of a given region to
the binding of factors involved in gene regulation and, if found around promoter or
enhancer regions, is usually associated with a silenced state of transcription (Dor
and Cedar, 2018; Kumar et al., 2018). DNA methylation is one of the few truly
epigenetic modes of regualtion as this mark is stably inherited throughout cell
divisions.
The addition of small molecular groups at specific residues is known as the post-
translational modification of histones. These post-translational modifications
(PTMs) are one of the most important factors governing chromatin state and one
of their main functions appears to be the regulation of gene expression. Their
influence on transcription is understood to be mainly conveyed by modulating
chromatin structure and recruiting or inhibiting the binding of effector proteins
(Bannister and Kouzarides, 2011; Taverna et al., 2007). These histone PTMs
have been identified at around 60 specific residues both on the globular domain
that is most tightly associated with the other histones of the nucleosome, as well
as on the more flexible and basic N-terminal tail which protrudes from the core of
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the nucleosome and is more readily accessible to interact with additional factors.
Several different molecular groups have been identified as being added to histones,
acetyl and mono-, di- and tri-methyl groups are perhaps the most extensively
studied, but additional residues have also been shown to be phosphorylated,
ubiquitylated or sumoylated (Kouzarides, 2007).
Many of these chemical modifications of the chromatin have been shown to be
associated with specific genomic regions, often correlating with the transcriptional
state. For instance, euchromatic loci are associated with active marks such
as mono-, di-, and tri-methylation of histone H3 lysine 4 (H3K4me1/2/3),
H3K36me3, acetylation of H3K9 (H3K9ac) and H3K27 (H3K27ac). An example
of this is the enrichment of H3K27ac and H3K4me1 that is found across enhancers
of active genes (Zentner et al., 2011). Heterochromatic loci are characterised by
repressive marks such as H3K9me2/3, H3K27me3, H4K20me2/3 and monoubiq-
uitination of H2A lysine 119 (H2AK119ub) (Bannister and Kouzarides, 2011;
Kouzarides, 2007). This type of chromatin can be further sub-categorised into
facultative and constitutive heterochromatin, each bearing a different set of these
histone modifications with H3K27me3 and H2AK119ub marking the former and
H3K9me2/3 the latter. Although we understand the genome-wide distribution
of many histone modifications and some of their functions, we are far from
uncovering all roles for these modifications individually and especially in the
different combinations that can be found at nucleosomes. As specific genomic
features were found to often bear a specific set of different histone PTMs, it was
proposed that they could combine to generate a “histone code”, such that the
chromatin state at a given locus is determined at least in part by the combination
of PTMs on the nucleosomes at this locus (Jenuwein and Allis, 2001). It should
be noted, however, that the term “histone code” has fallen out of use in recent
years as it conjures an overly simplistic image of how combinations of histone
modifications might function as part of the complex local chromatin landscape
(Rando, 2012).
1.1.3 Readers and Writers
The majority of histone PTMs are known to function through their interaction
with additional factors. These PTMs influence chromatin in an indirect fashion,
by facilitating or obstructing the binding of non-histone proteins. While
the complexes that place histone modifications can be termed writers, these
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proteins are the readers of histone PTMs. These readers all contain domains
that allow them to recognise histone modifications. Acetylation is recognised
by bromodomains, methylation by chromodomains and PHD domains, and
phosphorylation by 14-3-3 proteins (Kouzarides, 2007; Ruthenburg et al., 2007).
The recognition of these marks can lead to the recruitment of these effector
proteins which are then able to carry out further modifications of chromatin,
activate or repress transcription, or even act as platforms for the recruitment of
additional proteins. An example of this is the ING family of proteins, which once
bound to H3K4me3 are then able to recruit histone acetyltransferases or histone
deacetylases to chromatin (Champagne and Kutateladze, 2009). In contrast
to this, some proteins find their recruitment to be blocked by the presence of
certain histone modifications, which in turn will act to inhibit their activity on
chromatin. For instance the NURD complex associated with gene repression
is unable to be recruited to chromatin in the presence of H3K4me3 (Zegerman
et al., 2002). DNA methylation mediates its effect on gene regulation in a similar
way. Proteins containing methyl-CpG-binding domains (MBD) are able to bind
methylated DNA, whereas only unmethylated CpG islands can be bound by CxxC
domains (Long et al., 2013; Du et al., 2015). In line with the co-occurrence of
multiple different modifications in the same region, many of the reader proteins
are able to interact with more than one modification, which may allow for the
modulation of the activity of these proteins, either inhibiting or stimulating it
with the presence or absence of a specific set of modifications (Ruthenburg et al.,
2007; Kouzarides, 2007).
There is a subset of histone PTMs that are known to influence regulation by
physically altering chromatin. This type of histone modification functions by
creating changes in charge which can affect histone interactions with DNA and
disrupt contacts between nucleosomes. An example of this is lysine acetylation.
This modification neutralises the positive charge of the lysine, which in turn
affects the interaction of the nucleosome with the negatively charged DNA and
leads to destabilisation of this structure and a less compact state of chromatin
(Shogren-Knaak, 2006). Histone phosphorylation, on the other hand, has been
shown in one instance to lead to an increase in condensation of chromatin (Wei
et al., 1998).
The ”writers” of histone modifications fall into multiple families of protein
complexes, which are often themselves able to detect the presence or absence
of a certain number of histone marks, which in turn can either stimulate or
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attenuate their catalytic activity towards their target residue. Acetylation marks
are placed by proteins of the MYST, GNAT and CBP families, ubiquitiylation
is placed by RING finger proteins and methylation is placed by the large family
of proteins containing SET domains (Kouzarides, 2007). Two major groups of
the SET domain containing methyltransferases are the Trithorax and Polycomb
families of proteins.
1.2 Polycomb and Trithorax group proteins
Trithorax (TrxG) and Polycomb (PcG) group proteins are chromatin modifiers
that play antagonistic roles in gene regulation and have been found to play
important roles throughout development. Polycomb group proteins were first
discovered in Drosophila as regulators of homeotic (Hox) genes (Lewis, 1978).
The regulation of transcriptional silencing of these genes was found to play a
major role in the body patterning of these organisms by spatially and temporally
restricting the expression of key target genes throughout development (Zink and
Paro, 1989). PcG proteins assemble to form several complexes, of which there
are 2 main families found in mammals, PRC1 and PRC2. These complexes
are both chromatin binders and are responsible for placing post-translational
modifications on histones H3 and H2A, with PRC1 placing ubiquitylation on
lysine 119 of histone H2A, and PRC2 placing methylation on lysine 27 of histone
H3. Gene repression is thought to be mediated by these 2 complexes, often
in a cooperative manner. The Trithorax group proteins were discovered in
parallel with the Polycomb as antagonists to the regulatory functions carried
out by the PcG proteins. The main histone PTM associated with TrxG
proteins is H3K4me3 and in mammals the primary methyltransferase responsible
for its deposition is the SET1A/B complex (Shilatifard, 2012). H3K4me3 is
associated with active transcription and is most often found at promoters and
transcriptional start sites (TSS) of active genes. This mark is mostly known to
function through the recruitment of proteins that promote transcription, such
as initiation factor TFIID (Vermeulen et al., 2007; Lauberth et al., 2013), as
well as recruiting additional chromatin modifying complexes such as the SAGA
histone acetyltransferase complex (Ringel et al., 2015). As well as the SET1A/B
complexes, H3K4me3 can additionally be catalysed by the MLL1/2 group of
Trithorax proteins. Both these complexes contain CxxC domains that allow
them to recognise unmethylated CpG islands, many of which are found at gene
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promoters (Birke, 2002; Bach et al., 2009). The MLL3/4 complexes, which also
belong to the Trithorax group but do not possess CxxC domains, are responsible
for placing H3K4me1 which is mostly enriched at active enhancers (Herz et al.,
2012).
As mentioned above, these two families of complexes have mostly antagonistic
functions, however are both preferentially targeted to unmethylated CpG islands
and as such occasionally target the same domains. This co-localisation will be
discussed in a section below (see 1.4).
1.2.1 PRC2
Polycomb repressive complex 2 (PRC2) is conserved in all eukaryotes and
composed of 4 core subunits that together form a complex of around 250
kDa responsible for methylating lysine 27 of histone H3 (H3K27), a histone
modification associated with gene repression (Kuzmichev, 2002; Czermin et al.,
2002; Müller et al., 2002). Of these core subunits, the catalytic activity is
conveyed by the SET domain containing EZH1/2 protein which requires both
the EED and SUZ12 subunits to be enzymatically active (Cao et al., 2002; Yuan
et al., 2012), with further stimulation provided by the RbAp46/48 subunit (Pasini
et al., 2004; Ketel et al., 2005).
Non-catalytic core subunits
The Embryonic Ectoderm Development (EED) subunit contains a WD40 domain,
which forms an aromatic cage enabling it to bind the H3K27me3 mark placed
by PRC2 (Margueron et al., 2009; Poepsel et al., 2018). The binding of this
mark by EED leads to the stabilisation of the SRM domain of EZH2 triggering
a conformational change of the catalytic subunit to a more active state and thus
contributing to the propagation of the histone modification (Margueron et al.,
2009; Jiao and Liu, 2015; Justin et al., 2016; Poepsel et al., 2018). This positive
feedback loop not only allows for the propagation of H3K27me3 across the broad
domains typically observed at Polycomb targets, but can also contribute to the
maintenance of these domains through cell division as the mark is diluted by the
deposition of new nucleosomes after DNA replication.
Suppressor of Zeste (SUZ12) interacts with the catalytic subunit EZH2 or EZH1
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of PRC2 primarily through its C-terminal VEFS domain, an interaction that
aids in the stabilisation of the latter and is essential for enzymatic activity. This
same VEFS domain has also been shown to interact with EED (Jiao and Liu,
2015), while the N terminus of SUZ12 interacts with both the RbAp46/48 subunit
and several accessory factors involved in PRC2 recruitment and regulation. In
addition, SUZ12 has been shown to be involved in the ability of PRC2 to sense
the local chromatin state (see below, Recruitment of PRC2). The stimulation of
the histone methyltransferase (HMT) activity of PRC2 in the presence of densely
packed nucleosomes has been shown to involve SUZ12 and its interaction with
a portion of histone H3 (Yuan et al., 2012). Conversely SUZ12 and its VEFS
domain have also been suggested to be involved in the mechanism underlying
the inhibition of H3K27 methylation by the pre-existence of H3K4me3 on the
same histone tail (Schmitges et al., 2011), although the details of this mechanism
remain poorly understood. SUZ12 may also be involved in the regulation of PRC2
recruitment as it has been shown to bind to CpG islands independently of the
other core subunits (Højfeldt et al., 2018), but also binds to nascent RNA which
was found to be antagonistic to PRC2 binding to chromatin (Beltran et al., 2016).
The association of the Retinoblastoma-binding protein 46 and 48 (RbAp46/48)
subunit with PRC2 requires the presence of SUZ12, suggesting it only interacts
with this subunit (Pasini et al., 2004). This subunit is known to interact with
both histone H3 and H4 via its WD40 domain (Schmitges et al., 2011), possibly
contributing to the stabilisation of PRC2 binding to nucleosomes. Its interaction
with H3 has been shown to be prevented in the presence of H3K4me3, further
hinting at the mechanism of inhibition of PRC2 activity by this mark (Schmitges
et al., 2011).
Catalytic subunits Enhancer of zeste (EZH1/2)
By itself the EZH2 subunit assumes a catalytically inactive conformation and is
unable to methylate H3K27 unless it forms a complex with at least EED and
SUZ12. These interactions with EED and SUZ12 led to a change of state of
the SET domain from an auto-inhibitory conformation to an active conformation
in which the substrate binding site becomes accessible and the pocket which
accepts the methyl donor SAM is stabilised (Jiao and Liu, 2015; Wu et al., 2013;
Antonysamy et al., 2013; Justin et al., 2016).
All of these elements contribute to enabling the HMT activity of EZH2. This
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activity can be further stimulated by the binding of H3K27me3 by the EED
subunit, or inhibited by signals thought to be conferred by SUZ12 and RbAp46/48
in the presence of H3K4me3, as described above. The methyltransferase activity
of PRC2 has been shown to be favoured by a more densely packed nucleosomal
substrate (Yuan et al., 2012; Jiao and Liu, 2015). This is thought to be mediated
at least in part by the SUZ12 subunit interacting with the H3 tail.
The enzymatically active SET methyltransferase domain of EZH2 itself has
been extensively characterised and the crystal structure solved (Wu et al., 2013;
Antonysamy et al., 2013; Jiao and Liu, 2015). Essential amino acids have been
identified within or in proximity to the lysine binding pocket of the SET domain,
several of which have been found to be mutated in cancerous cells leading to gain
of function (Kipp et al., 2013; Ott et al., 2014; Wu et al., 2013; Antonysamy
et al., 2013). This gain of function was found to be due to a shift in substrate
preference of EZH2 to H3K27me2 leading to hypermethylation of H3K27 in these
cells.
Additionally loss of function mutations have also been associated with malig-
nancy, some of which include point mutations in the SET domain of EZH2
leading to abrogation of its catalytic activity while maintaining the integrity
of the complex (Ernst et al., 2010; Jankowska et al., 2011). Recent studies
have also achieved loss of function of EZH2 by the point mutation of a highly
conserved tyrosine in physical proximity to the lysine pocket and the S-adenosyl-
L-methionine, previously suggested to be essential to catalytic activity (Wu et al.,
2013; Antonysamy et al., 2013; Lavarone et al., 2019; Wang et al., 2019).
The catalytic subunit of PRC2 exists in mammals as 2 paralogues named EZH1
and EZH2, which can each assemble with the other core subunits to form EZH1-
PRC2 or EZH2-PRC2. The degree of conservation of these two proteins is
shown in Fig. 1.1. These 2 catalytic paralogues of PRC2, although similar
in sequence, are different from each other in several ways. Although both
subunits are able to deposit trimethylation on H3K27, EZH2 displays a much
higher HMT activity towards nucleosomes than EZH1 (Margueron et al., 2008).
Additionally, a difference in the SRM domain of EZH1 contributes to a much
reduced response in this subunit to the allosteric activation conferred by EED
upon binding of H3K27me3, as compared to EZH2 (Lee et al., 2018). EZH1
and 2 also interact differently with chromatin. EZH1 has a higher affinity for
chromatin than EZH2 (Son et al., 2013; Lee et al., 2018) due to nucleosome
binding domains in the former that are poorly conserved in the latter. Electron
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microscopy has also revealed a chromatin compaction activity of EZH1 that EZH2
does not possess (Margueron et al., 2008), although whether this ability is a
direct consequence of the higher nucleosome binding affinity of EZH1 is not
yet known. There is a suggestion that EZH1’s higher affinity for chromatin
may also contribute to the recruitment of EZH2 (Son et al., 2013). It has
been shown that the binding of EZH2 to mononucleosomes in vitro is greatly
enhanced by the addition of EZH1 and heterodimers of EZH1-PRC2 and EZH2-
PRC2 have been identified in vitro and in vivo (Son et al., 2013; Davidovich
et al., 2014). Lastly, the expression patterns displayed by EZH1 and EZH2 also
differ from one another. While EZH2 expression tracks with highly proliferating
cells (Bracken, 2003) and thus is the main subunit associated with PRC2 in
ESCs, EZH1 is expressed more ubiquitously. As cells differentiate and slow rates
of proliferation, EZH2 expression levels decrease whereas EZH1 is expressed in
both adult and undifferentiated cell types, dividing and nondividing (Laible et al.,
1997; Margueron et al., 2008). These differences between the 2 paralogues have
given rise to a hypothesis of specialisation of function of these subunits wherein
the more highly active EZH2 is required for the maintenance of H3K27me3 levels
in actively proliferating cells, while EZH1 is sufficient to maintain these already
established domains in more differentiated cells which are dividing much more
slowly.
Figure 1.1 Comparison of EZH1 and EZH2 protein domains. Adapted
from (Yu et al., 2019). Regions with the lowest sequence conservation between the
two paralogues are highlighted in purple and green. Single residue differences in
the SRM and SET domains that lead to the reduced activity of EZH1 are indicated
with an asterisk.
1.2.2 Accessory subunits of PRC2
Several additional proteins have been found to interact with PRC2, diversifying
the subtypes of the complex. These proteins are mostly involved in stabilising
the complex on chromatin and enhancing or moderating its catalytic activity, and
although many of them are involved in the localisation of PRC2 to its target sites,
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the model for the exact mechanism of PRC2 recruitment remains incomplete.
These accessory factors are not able to all interact with PRC2 at the same time
and are in fact, in some cases, mutually exclusive. This has led to the further
sub-classification of PRC2 into two types: PRC2.1 and PRC2.2 (Hauri et al.,
2016; Holoch and Margueron, 2017). A schematic representation of these two
distinct subtypes is shown in Fig. 1.2.
PRC2.1
PRC2.1 associates with a group of proteins referred to as PCL proteins. The
Drosophila Polycomblike protein has 3 mammalian orthologues, PCL1,2, and 3,
which area also named PHF1, MTF2 and PHF19, respectively. These proteins
are all able to interact with SUZ12, however this binding occurs in a mutually
exclusive manner and is also in competition with AEBP2 (Hauri et al., 2016;
Grijzenhout et al., 2016). The Tudor domain and PHD fingers contained in all
PCLs suggests a histone binding activity of these proteins that led to speculation
that they could be involved in recruitment and chromatin binding of PRC2.
For PCL2 an aspect of this function has been shown in its ability to facilitate
recruitment of PCR2 to the inactive X chromosome (Casanova et al., 2011). This
subunit has also been shown to contribute to the recruitment of PRC2 to CpG
islands (Li et al., 2017; Perino et al., 2018).
Additionally, all 3 PCLs are able to recognise H3K36me3 through their N-terminal
Tudor domain (Ballaré et al., 2012; Brien et al., 2012; Musselman et al., 2012), a
mark associated with active genes which has been shown to be mutually exclusive
with H3K27me3 on the same histone tail (Schmitges et al., 2011). The binding of
an active mark by factors associated with a repressive complex such as PRC2 may
seem contradictory, however it has been shown that for PCL1 and PCL3, this
may serve as a way to target Polycomb repression to active genes (Cai et al., 2013;
Brien et al., 2012). PCL3 specifically has been shown to enable the recruitment of
PRC2 to these H3K36me3 associated genes while also recruiting NO66, a H3K36
demethylase, which would allow for clearing of the active mark and deposition
of H3K27me3. Finally, PCL1 has been shown to be important for efficient tri-
methylation of H3K27, as was also found to be the case for the Drosophila Pcl
(Sarma et al., 2008; Nekrasov et al., 2007).
Recent studies have revealed the presence of an additional accessory factor of
PRC2.1 whose function remains to be fully elucidated. EPOP or C17orf96 is
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mostly unstructured and was found to interact with PRC2 via its C terminus
(Liefke and Shi, 2015). The N terminus of this protein interacts with elongin
BC (ELOBC) and it is thought that EPOP may function as a mediator between
PRC2 and ELOBC, recruiting the latter to Polycomb genes in order to promote
their transcription (Beringer et al., 2016; Liefke et al., 2016). It has been theorised
that this may be a way to attenuate PRC2 activity and by maintaining low levels
of transcription, allow for rapid activation in the event of the removal of Polycomb
silencing. Another recently discovered interactor with PRC2.1 is Pali1/2. Found
only in vertebrates, this protein was shown to stimulate the activity of PRC2 in
vitro and associates with co-repressors in cells (Conway et al., 2018).
PRC2.2
Jumonji AT-rich interactive domain 2 (JARID2) is a member of the JMJC
histone demethylases which are active towards methylated lysines. However,
JARID2 lacks essential residues in the catalytic domain rendering it enzymatically
inactive (Cloos et al., 2008). It has been shown by multiple studies to interact
with PRC2 (Peng et al., 2009; Li et al., 2010; Pasini et al., 2010; Shen et al.,
2009) and more recently this has been shown to involve its binding to the N-
terminal ZnB-Zn domain of SUZ12 (Chen et al., 2018). JARID2 has been
shown in vitro to stimulate the activity of PRC2 (Son et al., 2013), and its
knockdown in vivo has been shown to lead to a reduction in PRC2 binding (Li
et al., 2010; Pasini et al., 2010; Peng et al., 2009; Shen et al., 2009). Although
the C terminus of JARID2 does have some DNA binding properties and has
a preference for GC-rich sequences similar to those found at PRC2 occupied
sites (Li et al., 2010), it is not yet known whether this activity contributes to
PRC2 recruitment in vivo. JARID2 is also known to be involved in mediating
feedback between PRC1 and PRC2, as it is able to bind the H2AK119ub mark
placed by PRC1 through its N-terminal ubiquitin-interacting motif, which may
also facilitate PRC2 recruitment (Kalb et al., 2014; Cooper et al., 2016). JARID2
has also been shown more recently to contribute to the stimulation of PRC2
activity. A residue in the N terminus of the protein, K116, was found to be
a target for methylation by EZH2 (Sanulli et al., 2015). This lysine, once
methylated, is able to stimulate the activity of PRC2 through its binding to the
WD40 domain of EED, essentially mimicking the binding of a methylated H3K27
and possibly aiding in the establishment of H3K27me3 domains at previously
unmethylated sites (Sanulli et al., 2015; Kasinath et al., 2018). JARID2 does
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appear to have a preference for EZH2-PRC2 over EZH1-PRC2 in vivo (Pasini
et al., 2010), and indeed its expression pattern closely mirrors that of EZH2,
being highly expressed in undifferentiated, actively dividing cells and decreasing
through differentiation (Mikkelsen et al., 2007; Walker et al., 2010). This reduced
association with EZH1 correlates with this subunit’s increased innate stability on
chromatin and relative lack of response to stimulation by EED.
A protein with functions complimentary to JARID2 is the zinc-finger protein
Adipocyte enhancer-binding protein 2 (AEBP2). This accessory factor was found
to increase the stability of the complex when associated with PRC2 (Cao et al.,
2002; Ciferri et al., 2012). This interaction occurs primarily through contacts
between the C terminus of AEBP2 and the C2 domain of SUZ12 (Chen et al.,
2018) but also involves other members of PRC2 (Cao and Zhang, 2004; Ciferri
et al., 2012). Although AEBP2 possesses DNA binding activity through its zinc-
finger domain, there is little sequence specificity which, as with JARID2, does
not provide strong evidence for the contribution of this activity to site-specific
PRC2 recruitment but might aid in increasing general chromatin affinity of the
complex (Kim et al., 2009). AEBP2 has also been shown to bind to RbAP46/48,
mimicking its interaction with the unmodified H3 tail. This interaction further
contributes to stability of the complex, which in turn enhances stimulation by
JARID2 (Son et al., 2013; Kasinath et al., 2018).
Figure 1.2 Schematic representation of the PRC2.1 and PRC2.2
complexes. The association of the PRC2 core complex (EZH1/2, EED, SUZ12
and RBAP46/48) with its accessory subunits are divided into two subcomplexes,
PRC2.1 and PRC2.2.
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1.2.3 Catalytic products of PRC2 and their functions
Although the principle histone modification associated with PRC2 is H3K27me3,
it is also responsible for the deposition of mono and di-methylation at this
residue. Each of these 3 methylation states of H3K27 has a distinct profile
of distribution and abundance throughout the genome. In ESCs around 70%
of all histone H3 carries H3K27me2 while H3K27me1 and H3K27me3 occupy
a further 10% and 5% of H3 respectively (Peters et al., 2003; Ferrari et al.,
2014). Perhaps the most poorly understood of the 3 methylation states of H3K27,
H3K27me1 is paradoxically enriched in the gene bodies of actively transcribed
genes and correlates with H3K36me3 (Ferrari et al., 2014). In some studies it
has been found to persist in PRC2 deficient cells which gave rise to speculation
of an additional pathway of deposition of this mark (Schoeftner et al., 2006;
Pasini et al., 2007), although it has since been shown is that it relies solely on
PRC2 (Ferrari et al., 2014). H3K27me2 is the most abundant of all forms of
H3K27 methylation, is found in much broader regions and is associated with a
more transcriptionally inactive state (Ferrari et al., 2014). This mark also covers
the flanking regions surrounding H3K27me3 enriched domains and its enrichment
accumulates at these sites before the catalysis of trimethylation (Oksuz et al.,
2018). The enrichment of H3K27me3 broadly mirrors that of PRC2 being found
mostly around the TSS of unmethylated CGI promoters, although in some cases
can cover broader domains such as at the Hox gene clusters where it can spread
over more than 100 kb (Boyer et al., 2006; Zhao et al., 2007). As mentioned
above, PRC2 is able to bind to this histone modification via the EED subunit,
in a manner that is thought to aid in the propagation of H3K27me3 (Margueron
et al., 2009; Oksuz et al., 2018; Poepsel et al., 2018). This mark also acts as one
mode of recruitment of PRC1 via the CBX subunit, as will be further explained
below. The depostion of H3K27me2 does not require stable binding of PRC2 to
chromatin and this mark is deposited rapidly following DNA synthesis (Sneeringer
et al., 2010). However, PRC2 has a higher activity towards unmethylated H3K27
than towards H3K27me2 and thus the deposition of H3K27me3 is much less
efficient and mostly co-localised with the binding of PRC2 itself (Tie et al.,
2009). This suggests that H3K27me3 is only able to be catalysed in regions
where there are additional factors stabilising the binding of PRC2, and in this
way the deposition of this mark can be more specific and fine-tuned as compared
to the broad regions of mono and dimethylation of H3K27. This in turn also leads
to a more site specific recruitment of PRC1 via its binding to H3K27me3. The
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dimethylation of H3K27 appears to not play an important role in gene silencing,
however it is possible that this mark may not exist solely as an intermediate to
H3K27me3, but also as a way to inhibit the deposition of the active H3K27ac
mark which is antagonistic to Polycomb gene repression (Trojer and Reinberg,
2007).
Additional non-histone targets of PRC2 methyltransferase activity have also
been discovered. As previously mentioned the accessory protein JARID2 can
be methylated on its lysine 116 (Sanulli et al., 2015). Other examples include
GATA4, the methylation of which reduced the transcriptional activity of this
protein (He et al., 2012), and STAT3, for which the activity is stimulated following
methlyation (Kim et al., 2013). Recently, an additional non-histone target of
PRC2 methylation was identified as Elongin A (Ardehali et al., 2017). The
methylation of this transcription elongation factor is thought to contribute to the
maintenance of a repressed state at a subset of Polycomb genes.
1.2.4 PRC1
The PRC1 complex is one of the main binders of H3K27me3 and is implicated
in mediating a significant portion of its function. PRC1 encompasses a larger
collection of subunits than have been identified for PRC2, and as such this
complex can assemble in a number of different combinations leading to a diverse
set of variants.
Core subunits and variant complexes
Although the PRC1 complex is subdivided into multiple variants, there are 2
core subunits that are common to all versions of the PRC1 complex. The
first of these is RING1A/B, and the second is PCGF, of which there are 6
paralogues in mammals. Together these two subunits, function as an E3 ubiquitin
ligase and are responsible for the ubiquitylation of lysine 119 on histone H2A
(H2AK119ub) (Wang et al., 2004; McGinty et al., 2014). The PRC1 complexes
that assemble around this core heterodimer are defined as canonical or non-
canonical based on the subset of additional proteins that they contain, as well
as which of the PCGF subunits is included (Gao et al., 2012). The canonical
complex contains one of the 5 CBX proteins CBX2,4,6,7, or 8, all of which contain
a chromodomain which is able to bind to H3K27me3, as well as a PHC subunit
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which contributes to gene repression by oligomerisation of its SAM domain leading
to chromatin compaction (Fischle, 2003; Bernstein et al., 2006b; Isono et al.,
2013). This compaction activity is discussed in more detail in section 1.5. The
non-canonical PRC1 contains the RYBP/YAF2 subunit which binds to the core
heterodimer in a mutually exclusive manner with the chromobox (CBX) proteins.
The non-canonical complex can also include H3K36 demethylase KDM2B which
is able to bind to CGIs via its zinc-finger CxxC domain (Farcas et al., 2012),
as well as DCAF7 and WDR5 both of which contain WD40 domains and act as
scaffold proteins (Hauri et al., 2016). There are several different proteins that can
additionally associate with non-canonical PRC1, further diversifying the subsets
of this variant and fine-tuning its activity (Gao et al., 2012). These variants
often depend on the subunits expressed in different cell types (O’Loghlen et al.,
2012). Although both canonical and non-canonical PRC1 are able to ubiquitylate
H2AK119, it has been shown both in vivo and in vitro that of the two, the non-
canonical complex has the higher catalytic activity (Blackledge et al., 2014; Gao
et al., 2012). This mark has been suggested to mediate gene repression in part
by inhibiting transcriptional elongation (Zhou et al., 2008; Stock et al., 2007).
However, H2AK119ub is not essential for Polycomb mediated silencing as its
depletion does not lead to upregulation of target genes in Drosophila (Pengelly
et al., 2015), and it is thought that the chromatin compaction activity of PRC1
plays a more substantial role in repression (Isono et al., 2013; Lau et al., 2017).
1.3 Polycomb target genes and recruitment
As previously mentioned, PcG proteins were first discovered as chromatin binding
proteins that were responsible for the timely regulation of Hox genes during the
embryonic development of Drosophila (Lewis, 1978). Since their discovery this
association with the regulation of developmental genes has persisted and been
shown to be critical in mammalian development (O’Carroll et al., 2001; Pasini
et al., 2004; Bernstein et al., 2006a). PcG proteins occupy a highly conserved
set of genes (Schuettengruber et al., 2007) which in mammals is highly enriched
for transcription factors involved in the regulation of developmental pathways,
as well as other factors involved in cell fate decisions and differentiation (Boyer
et al., 2006; Bracken, 2006; Lee et al., 2006). A well as their role as regulators of
developmental genes, PcG protiens have additionally been found to have functions
in X chromosome inactivation and silencing of imprinted genes (Zhao et al., 2008;
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da Rocha et al., 2014; Inoue et al., 2017).
In line with their binding to developmental genes, many Polycomb mutants cause
severe developmental abnormalities. The mutants generated in Drosophila led
to striking defects in body patterning and limb development (Lewis, 1978). In
ESCs, depletion of PcG proteins has little effect on gene expression, nor on the
self-renewal capacity or viability of the cells (Chamberlain et al., 2008; Shen et al.,
2008; Riising et al., 2014). These deficient cells are however unable to differentiate
correctly in many cases (Chamberlain et al., 2008; Shen et al., 2008; Pasini et al.,
2007). In mice, null mutations of PcG proteins lead to defects early in embryonic
development. Knockout mutants of core proteins of the PRC2 complex result in
developmental defects that become evident at the post implantation stage and
are usually embryonic lethal around the stage of gastrulation (Faust et al., 1995;
O’Carroll et al., 2001; Pasini et al., 2004) with the knockout of RING1B leading to
a similar lethality at a slightly later stage (Voncken et al., 2003). Null mutants of
PRC2 accessory factors, and all other PRC1 subunits however, have mostly been
found to produce viable mice, although with varying degrees of abnormalities and
growth defects (Coré et al., 1997; Motoyama et al., 1997; Takihara et al., 1997;
del Mar Lorente et al., 2000; Walker et al., 2010).
1.3.1 Role of CpG islands in Polycomb recruitment
One of the key features of Polycomb bound genes is the presence of unmethylated
CpG islands in proximity to the transcriptional start sites (TSS) at promoters
(Boyer et al., 2006; Tanay et al., 2007; Mendenhall et al., 2010). It has even
been shown that the introduction of ectopic, unmethylated CG rich DNA was
sufficient to induce recruitment of PcG proteins in ESCs (Mendenhall et al., 2010;
Jermann et al., 2014; Riising et al., 2014; Wachter et al., 2014). This discovery
led to the hypothesis that CGIs may serve as the mammalian equivalent of the
Polycomb response elements (PREs) found in Drosophila which serve to recruit
PRC2 in this organism. However there is little evidence that direct binding
to CGIs is responsible for all Polycomb recruitment. Both JARID2 and PCL2
possess low affinity DNA-binding activity with a preference for CG-rich sequences,
and it has recently been shown that a knockout of both these proteins leads to a
massive loss of PRC2 binding to chromatin (Oksuz et al., 2018). However, there
was evidence that PRC2 could still access some of its targets in this context,
hinting at additional factors involved in its recruitment (Oksuz et al., 2018). One
17
such alternative recruitment method to CG-rich sequences is through the PRC1
associated protein KDM2B which can be included as part of the noncanonical
complex (Lagarou et al., 2008; Farcas et al., 2012). Although this protein is a
demethylase of H3K36, it also possesses a zinc-finger CxxC domain which binds
to CGIs allowing the recruitment of PRC1 to these sites (He et al., 2013). Despite
this activity and its near ubiquitous binding of CGIs however, KDM2B has only
been shown to be essential for the recruitment of Polycomb to around one third of
all mammalian CGIs (Bernstein et al., 2006b; Ku et al., 2008) but could act as the
starting point for the PRC1 dependent recruitment of PRC2 in some instances. A
few additional DNA binding factors such as REST and SNAIL have been found to
interact with PcG proteins and contribute to recruitment, however each of these
have only proven to be involved at specific loci and not essential for Polycomb
recruitment as a whole (Herranz et al., 2008; Dietrich et al., 2012; Yu et al., 2012).
As is suggested by the preference of both PRC1 and PRC2 for unmethylated
CGIs, DNA methylation is an important factor in defining the borders of
Polycomb domains. Hypomethylation induced by the depletion of the Dnmts has
been shown to lead to spreading of H3K27me3 into regions not normally occupied
by this mark (Brinkman et al., 2012). This antagonism of Polycomb activity by
DNA methylation appears to lie in its ability to obstruct the binding of PRC2
to chromatin (Bartke et al., 2010). Methylated DNA is not however the only
factor restricting the spreading of Polycomb domains, as hypomethylation of the
genome does not lead to the deposition of H3K27me3 at all newly demethylated
sites (Brinkman et al., 2012). Indeed, there is some evidence that PRC2
may not even be directly affected by DNA methylation. In in vitro assays of
PRC2 methyltransferase activity methylated DNA appeared to have no effect on
catalysis (Cooper et al., 2014). Furthermore recruitment of PRC2 to a methylated
region was achieved by artificial deposition of H2AK119ub, as was methylation of
H3K27 (Cooper et al., 2014), indicating that methylated DNA is not as inimicable
to PRC2 binding as was suggested by their lack of overlap on chromatin.
1.3.2 Role of RNA in PRC2 activity
The interaction of Polycomb with RNA has become apparent in recent years and
although the role of lncRNAs in the recruitment of PcGs to specific loci has been
established, expansion of this model of recruitment to include other RNAs in a
more general Polycomb targeting strategy remains elusive. The first instance of
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lncRNA involvement in PRC2 recruitment was shown with the interaction of Xist
(X inactive specific transcript) with PRC2 in its localisation to the inactive X
chromosome (Silva et al., 2003). This process requires the presence of JARID2
and may not be a direct interaction but rather may involve an additional Xist
binding protein known as SHARP (da Rocha et al., 2014; Cerase et al., 2014;
McHugh et al., 2015). A further example of Polycomb recruitment by lncRNA
involves HOTAIR. This transcript originates from the Hox C locus and its direct
interaction with PRC2 serves to recruit the complex in trans to the HoxD locus
(Rinn et al., 2007).
In addition to its interactions with specific lncRNAs, PRC2 has been show
in recent years to interact with RNA in general with low sequence specificity
(Davidovich et al., 2015; Beltran et al., 2016) and indeed is even able to bind
to L-RNA, the enantiomer of naturally occurring RNA molecules (Deckard
and Sczepanski, 2018). Despite the evidence of these many interactions, their
involvement in PRC2 function is still unclear and appears to vary based on the
genomic context. In particular, the association of PRC2 with nascent transcripts
at active genes has been a point of debate (Kaneko et al., 2013; Kaneko et al.,
2014). Two schools of thought exist on this subject, one argues that the binding
to nascent RNAs sequesters PRC2 away from chromatin at active genes in order
to inhibit any repressive effects of PRC2 on transcription (Beltran et al., 2016).
The second theory views this binding of nascent transcripts as a method of
localisation of PRC2 in proximity to the promoter region of active genes for
timely recruitment to chromatin in the event of transcriptional repression of these
genes (Kaneko et al., 2014). In the case of transcriptionally repressed genes it
is thought that the binding of PRC2 to short, non-elongating RNAs is able to
stabilise the association of the complex and repress any further aberrant initiation
of transcription (Kanhere et al., 2010). It should be noted that RNA has been
shown to inhibit the catalytic activity of PRC2 in vitro (Cifuentes-Rojas et al.,
2014; Kaneko et al., 2014) which further hints at its role being to attenuate the
catalytic activity of PRC2 towards its chromatin substrate.
It has recently been shown that the formation of a DNA-RNA hybrid structure
called R-loops over a subset of Polycomb genes contributes to both gene repression
at these sites, and the recruitment of PcG proteins (Skourti-Stathaki et al., 2019).
R-loops are formed by the interaction of nascent RNA with the template DNA
strand which leaves the opposite DNA strand single-stranded over this region and
have been shown to mediate transcriptional repression (Skourti-Stathaki et al.,
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2011). The resolution of these R-loops in mESCs led to a decrease in RING1B
recruitment and derepression of genes that appeared to be independent of PRC2
activity (Skourti-Stathaki et al., 2019).
1.3.3 Chromatin features involved in Polycomb occupancy
Mutual recruitment of Polycomb group proteins
PRC1 and PRC2 co-occupy many of their target genes, which in turn leads to the
co-occurrence of the H3K27me3 and H2AK119ub marks on chromatin. There is
an interaction of these 2 complexes based on the mutual recognition of the histone
mark placed by the other complex, for PRC1 through the binding of the CBX
subunit to H3K27me3 and for PRC2 through the interaction of JARID2 and
AEBP2 with H2AK119ub. This first interaction of CBX containing PRC1 with
H3K27me3 has been shown to increase its affinity for chromatin (Fischle, 2003).
This is known as the hierarchical model of Polycomb recruitment and involves
initial recruitment of PRC2 which then deposits H3K27me3 which in turn leads
to the recruitment of a canonical PRC1 through its CBX subunit, and subsequent
ubiquitilation of H2AK119 (Wang et al., 2004). In this model PRC2 serves as the
initial marker of genes to be silenced and mediates the recruitment of PRC1 which
is more directly responsible for gene repression by the deposition of H2AK119ub
and the formation of compact Polycomb bodies.
Although this method of PRC1 recruitment makes sense for the canonical form
of the complex, this H3K27me3 dependent model does not work with the non-
canonical PRC1 complex which does not possess the H2K27me3 binding CBX
subunit. Recruitment of PRC1 to chromatin independently of PRC2 has since
been observed (Tavares et al., 2012). An alternative model for recruitment of PcG
proteins was put forth following a study involving tethering PRC1 to a region
not normally occupied by PcG proteins. This tethering of PRC1 and resulting
H2AK119ub were found to lead to the recruitment of PRC2 and deposition of
H3K27me3 at this locus (Blackledge et al., 2014; Cooper et al., 2014). The
recruitment of PRC2 to PRC1 bound loci is thought to involve the interaction
of a JARID2 and AEBP2 associated PRC2 with the H2AK119ub catalysed by
PRC1 (Kalb et al., 2014) and is thought to predominantly involve the more
catalytically active noncanonical form of PRC1 (Blackledge et al., 2014; Tavares
et al., 2012). In this model gene repression is still thought to be mainly mediated
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by canonical PRC1 which can be recruited via the hierarchical mechanism once
PRC2 has been recruited by the noncanonical PRC1.
Influence of additional histone modifications and role of transcriptional
state
As mentioned above, both PRC1 and PRC2 are able to sense the histone mark
placed by the other complex and this aids in their recruitment. This mutual
recruitment of the 2 complexes gives rise to the co-occupation of most Polycomb
bound genes by both complexes, however this is not the case at all of the target
sites (Ku et al., 2008). The methylation of H3K36 may also contribute to the
recruitment of PRC2 in some cases both through its interaction with the tudor
domains of the PCL proteins (as mentioned above), facilitating the establishment
of Polycomb silenced domains at previously active genes (Ballaré et al., 2012).
There is also a suggestion that H3K9me3 may influence PRC2 occupancy on
chromatin as this mark can be bound by EED (Margueron et al., 2009) and the
enzymes that place it can interact with the PRC2 complex (Mozzetta et al., 2014)
although this histone modification is associated with constitutive heterochromatin
rather than the facultative heterochromatin of Polycomb domains.
Several elements of active gene transcription have been shown to be antagonistic
to Polycomb activity. Indeed transcription inhibits the deposition of H3K27me3
in mESCS (Jermann et al., 2014). Conversely, global inhibition of transcription
has been shown to be sufficient to recruit PRC2 to many newly inactive sites
(Riising et al., 2014). As previously discussed, the nascent transcripts from active
genes are thought to sequester PRC2 from chromatin and histone modifications
associated with active marks also contribute to obstructing Polycomb activity at
these sites. Marks such as H3K4me3 and H3K36me3 have been shown to exclude
the deposition of H3K27me3 on the same histone tail, potentially through a
mechanism involving SUZ12 and RbAp46/48 (Schmitges et al., 2011). In the case
of H3K27ac, another mark associated with active genes, its presence physically
excludes the deposition of methylation on H3K27. However all of these active
marks can coexist in the same nucleosome as H3K27me3 if residing on separate
H3 tails (Voigt et al., 2012). This finding, along with the fact that complexes that
place active marks such as the SET1A/B and MLL1/2 complexes have a similar
preference for unmethylated CGIs as Polycomb, goes some way to explaining why
active H3K4me3 and repressive H3K27me3 have been found to co-occur in many
21
instances, despite there apparent opposite functions.
1.4 Bivalency
1.4.1 Discovery in ESCs
It was discovered that in ESCs virtually all Polycomb genes display a co-
localisation of both active and repressive marks. These sites were first discovered
in 2006 by mapping H3K4 and H3K27 methylation across highly conserved non-
coding elements such as promoters and enhancers by chromatin immunoprecipita-
tion (ChIP) and microarray analysis (Bernstein et al., 2006a). These experiments
found that at the promoters of some genes there is an overlap of the repressive
H3K27me3 and the active H3K4me3 marks. These loci, which are mainly found
at developmental genes in ESCs, were dubbed bivalent domains. These studies
were confirmed by genome-wide ChIP and next generation sequencing (ChIP-seq)
studies in ESCs but also, to lesser extent, other cell types (Mikkelsen et al., 2007;
Pan et al., 2007; Mohn et al., 2008). A bivalent state was later also found to
exist at enhancers of some developmental genes, again in ESCs. In the case of
enhancers the bivalent or poised state is defined by a co-localisation of H3K27me3
and H3K4me1 (Creyghton et al., 2010; Rada-Iglesias et al., 2011).
1.4.2 Mechanism
As mentioned above, H3K4me3 can be placed both by the SET1A/B complexes
and the MLL1/2 complexes, although it is thought that at bivalent promoters
this mark is preferentially catalysed by the MLL2 complex (Clouaire et al., 2012;
Denissov et al., 2014; Hu et al., 2013). Both the SET1A/B and MLL1/2 proteins
belong to the Trithorax family and either themselves (MLL1/2) or indirectly
(CFP1 subunit of SET1 complexes) contain CxxC domains that allow them
to recognise unmethylated CpG islands (Birke, 2002; Bach et al., 2009), found
at high density at the vast majority of mammalian promoters and frequently
targeted by Polycomb.
The bivalent state of chromatin at Polycomb bound enhancers is mediated by a
slightly different set of complexes. H3K4me1 is placed by the MLL3/4 complexes
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and is mostly enriched at active enhancers (Herz et al., 2012). This mark also
has a broad distribution across gene bodies however, this is likely a by-product of
SET1A/B-dependent catalysis of H3K4me3 at promoters. Despite also belonging
to the Trithorax family, MLL3/4 do not possess a CxxC domain, which may
explain why they are not enriched at promoters. However, it remains unclear how
MLL3/4 are specifically targeted to enhancers. Presence of H3K4me1 has been
shown to often precede and indeed stimulate, at least in Drosophila, deposition
of the H3K27ac mark by the CBP/p300 co-activator proteins and subsequent
activation of enhancers (Tie et al., 2014). CBP/p300 has been found to be
in physical contact with the H3K27 demethylase UTX. A subset of MLL3/4
complexes are known to contain UTX, suggesting a process by which MLL3/4
in mono-methylating H3K4 could allow the removal of methylation at H3K27 by
UTX, after which it is then accessible to acetylation by CBP/p300 (Herz et al.,
2012).
As has been discussed previously, the presence of active histone modifications is
known to be antagonistic to PRC2 activity, however the presence of these active
marks on one H3 histone within the nucleosome does not preclude the deposition
of H3K27me3 on the other H3. Indeed it was shown that nucleosomes at bivalent
domains are largely in an asymmetric conformation, with one copy of H3 carrying
the active mark and the other the repressive one (Voigt et al., 2012; Shema et al.,
2016). Nucleosomes at bivalent domains could also be symmetrically modified
with active or repressive PTMs and bivalency conferred by positioning of active
and repressive nucleosomes adjacent to one another. Recent genome wide reChIP
studies have further confirmed this co-occurrence of H3K4me3 and H3K27me3 on
the same nucleosomes (Kinkley et al., 2016; Sen et al., 2016; Shema et al., 2016;
Weiner et al., 2016; Mas et al., 2018).
1.4.3 Hypotheses of function
The purpose of bivalent domains is thought to be to keep genes in a poised state
in ES cells, keeping transcription largely repressed but ready to be activated
or fully repressed rapidly upon cell differentiation, simply by the removal of
one or the other of the opposing PTMs. Indeed, the bivalency at these loci
is mostly resolved upon cell differentiation as H3K27me3 is lost and genes are
expressed or H3K4me1/3 is lost and genes are silenced (Mikkelsen et al., 2007;
Pan et al., 2007). The subset of genes that become silenced or expressed by the
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resolution of these bivalent domains depends largely on which cell type results
from the differentiation process. It appears that the bivalent state is at least
dispensable for viability and the maintenance of self renewal in ESCs as these
are largely unaffected by the loss of bivalent chromatin in EED-/- or SUZ12-
/- cells (Pasini et al., 2007; Chamberlain et al., 2008; Shen et al., 2008). One
function that H3K4me3 may have at these domains is to keep the Polycomb genes
in a more permissive state than they would otherwise be. In mESCs, depletion of
MLL2 was found to lead to greater compaction and reduced transcription of many
bivalent genes following an increase in binding of PcG proteins (Mas et al., 2018).
Depletion of MLL2 in these cells also leads to impaired differentiation (Lubitz
et al., 2007; Denissov et al., 2014) and in mice is lethal by E11.5, slightly later
than seen in many Polycomb knockouts (Glaser et al., 2006).
Although Polycomb genes are not actively transcribed, there is still evidence
of RNA polymerase II bound at their promoters. This Pol II is not in an
active state, as demonstrated by its phosphorylation signature, however there
are still detectable levels of RNA transcribed from these genes (Brookes et al.,
2012; Stock et al., 2007). This low level of transcription only generates short,
immature RNAs as there is no elongation following initiation. Nevertheless, this
is a further element arguing for the function of Polycomb regulation being to
maintain a poised state of gene expression rather than a fully silenced state.
Another characteristic of Polycomb genes is an enrichment of the histone variant
H2Az (Creyghton et al., 2008). This histone is mostly associated with active
genes and has also been shown to be mutually exclusive with DNA methylation,
which is consistent with the state observed at bivalent genes.
Although we have some insights into how these different PTMs such as H3K27me3
and H3K4me3 work individually, there is little known about how they function
together, particularly in combinations such as those found at bivalent domains.
It remains unclear how this bivalency is established and maintained in ESCs,
particularly given that the enzymes that place the opposing marks are mutually
antagonistic. It is also unclear whether these complexes have non-catalytic roles
in addition to their histone modifying activity, for instance by occupying binding
sites they could block access to other factors, or they could be involved in nuclear
organisation, mediating interactions between different sites.
The exact function of these bivalent domains in regulating gene expression and
cell differentiation also remains to be explicitly defined. Poised enhancers in
particular have not been extensively studied and much about their regulation,
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interactions and specific function in determining cell fate are still unknown.
1.5 Involvement of Polycomb in chromatin or-
ganisation
A significant branch of epigenetic regulation is the modulation of chromatin
state into more ”open” or ”closed” conformations which are thought to affect
transcription by controlling the accessibility of DNA to binding factors. It has
been established for some years that Polycomb domains are in a more condensed
state than that of actively transcribed genes (Shao et al., 1999; Francis et al.,
2004).
Of the PcG proteins, those most associated so far with changes to chromatin
structure are members of the PRC1 complex. While the non-canonical form of
PRC1 is responsible for the majority of H2AK119ub, the canonical form of the
complex is able to influence chromatin structure, both on a local and a more distal
scale. Polycomb domains are characterised by a more condensed chromatin state,
nucleosome density is increased at the promoters of Polycomb bound genes with
a slower turnover of histones. However, the incorporation of the more mobile
histone variant H2Az in these nucleosome may counteract, to a certain extent,
the decrease in accessibility that would be generated by the condensation of
chromatin at theses sites. As PRC2 has been shown to be more active towards
more densely packed nucleosomes (Yuan et al., 2012), this system may function
as a way to enhance the Polycomb signature at these sites, while maintaining
the more open state of chromatin typical of Polycomb domains, that is more
permissive to transcription than constitutive heterochromatin. The mechanism
by which this local condensation of chromatin occurs involves the CBX2 subunit
of the canonical PRC1. The intrinsically disorganised region (IDR) of this protein
has been shown to be essential for this compaction (Lau et al., 2017).
In regions where multiple Polycomb targets are localised in close proximity along
the chromosome, such as at the Hox gene clusters, this chromatin compaction
occurs on a much larger scale. Across these broad domains the PHC subunits
become more important for the condensing activity of PRC1. The SAM domains
of this subunit are able to oligomerise to bring into contact multiple Polycomb
targets whilst also omitting any non-Polycomb genes that may exist in the same
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region (Isono et al., 2013; Kundu et al., 2017). This activity has also been
observed on a much larger scale, with chromatin looping between distal Polycomb
domains, even between separate chromosomes. Many of these contacts have
been shown to dissociate upon cell differentiation as the genes involved become
expressed, and indeed in some studies the loss of condensing activity of PRC1
has been shown to lead to derepression of Polycomb targets. Whether on a
local scale or involving much more distal contacts, this chromatin compaction
activity of PRC1 has been shown to function in a manner that is independent
of its catalytic activity (Eskeland et al., 2010). Indeed, depletion of H2AK119ub
was found to have little effect on gene repression or on chromatin compaction in
mESCs (Illingworth et al., 2015; Kundu et al., 2017).
While the majority of studies of Polycomb involvement in chromatin structure
have focused on PRC1, there is also evidence of PRC2 influencing these processes.
PRC2 has been associated with the formation of long-range chromatin contacts
in multiple studies. The depletion of PRC2 has been shown to disrupt structures
formed both in the clustering together of multiple Polycomb targeted regions,
within a single chromosome and between chromosomes (Denholtz et al., 2013;
Vieux-Rochas et al., 2015; Tiwari et al., 2008a), as well as those involving
chromatin looping to bring into contact specific loci (Tiwari et al., 2008b; Joshi
et al., 2015).
Although in general the chromatin contacts and compaction mediated by
Polycomb have mostly been associated with repression of transcription, in some
instances it has been suggested to function to mediate the contact between
genes and regulatory elements in preparation for their activation upon cell
differentiation. In ESCs, poised enhancers have been found to already be in
contact with the promoters of some Polycomb bound genes, although in contrast
to active enhancers, this contact does not trigger active transcription of these
genes (Cruz-Molina et al., 2017; Kondo et al., 2014; Gentile et al., 2019). How
this looping is established is not fully understood but it has been suggested that
it may be in part mediated by PRC2 as the loss of this complex leads to the
dissociation of these contacts. The looping of these enhancers and promoters,
while not resulting in active transcription in undifferentiated cells was found to be
essential for the expression of these genes at the correct time during development.
Although it is thought that many of the contacts that have been shown to be
PRC2 dependent may only be so insofar as PRC2 is required for the recruitment
of PRC1, which then is directly responsible for the chromatin compaction, it has
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yet to be fully proven that PRC2 plays no role in this independently of PRC1.
Furthermore, it has not been definitively proven whether the catalytic activity of
PRC2 is a critical factor in the establishment of condensed chromatin.
1.6 Aims of the project
As discussed above, the PRC1 complex, although responsible for placing a histone
modification, also has functions that are independent of this catalytic activity.
A recent study involving the H3K4 methyltransferases MLL3/4 has shown that
the catalytic activity of these complexes is not required for the maintenance of
enhancer RNA transcription and Pol II occupancy of their target genes (Dorighi
et al., 2017). However, a similar study on these complexes found that the loss
of catalytic activity led to a destabilisation of the MLL4 protein (Jang et al.,
2017). Given these findings concerning complexes involved in similar chromatin
modifying activities, and the complexity of the PRC2 interactome, it seems
reasonable to hypothesise that PRC2 may perform functions that do not rely
entirely upon its catalysis of the H3K27me3 mark. In this project I aimed to
further our knowledge on H3K27me3’s role in the execution of PRC2 function.
To achieve this, I generated knockout mutant mESCs that lead to a depletion of
both the PRC2 complex and H3K27me3 as well as catalytically inactive PRC2
mutant mESCs in which only the H3K27me3 was lost. I compared these two
PRC2 mutants in order to address the following points: First, how does the loss
of catalytic activity of PRC2 affect its binding to Polycomb target sites and how
does this influence H3K4me3 levels at bivalent genes? Second, how crucial is
the H3K27me3 mark for the maintenance of 3D chromatin structures at specific
Polycomb targets? Third, how does the loss of H3K27me3 alone affect gene
expression as compared to the loss of both the PRC2 complex and the histone
mark it places? Finally, I aimed to clarify whether the catalytic activity of PRC2






2.1.1 mESC culture conditions
E14 male Mouse embryonic stem cells (mESCs) were grown at 37◦C in 5%
CO2 on 10 cm plates coated with 0.1% gelatin (Sigma) in ESC media: DMEM
containing 4.5 g/l glucose (Gibco) with 15% fetal bovine serum (FBS, Life
Technologies, South American, A3160802), 2 mM l-glutamine, 1 mM pyruvate, 1x
MEM nonessential amino acids, 50 units/ml penicillin and 50 µg/ml streptomycin
(all Gibco), 0.2 mM -mercaptoethanol (Sigma), and heterologously expressed
recombinant LIF (made in-house and batch-tested for maintenance of self-
renewal).
2.1.2 Cell passaging
mESCs were passaged every 2 days at a ratio of around 1:15. Media was removed
and cells were briefly washed in around 5 ml of warm PBS (Gibco) before adding
2.5 ml 0.25% trypsin-EDTA (Gibco) and incubating cells at 37◦C for 5 min.
Trypsin was then quenched by adding 7.5 ml of ESC media and cells were gently
resuspended using a 5 ml serological pipette (Sarstedt) before being centrifuged
at 500 x g for 5 min at room temperature. The cell pellet was then resuspended
in ESC media and plated at required density onto fresh gelatinised plates.
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2.1.3 Cryo-preservation of cells
Cells that were to be frozen for storage in liquid nitrogen were cultured as
described above and grown on the required number of 15 cm plates before
being trypsinised for 5 mins at 37◦C. Trypsin was quenched and resuspended
as described above before cells were counted and centrifuged at 500xg for 5 mins
at room temperature. The cell pellet was then resuspended in the appropriate
volume of serum free freezing medium Bambanker (Lymphotec) for a density of 4
million cells per ml. Cells were then aliquoted into cryogenic vials (Corning) with
2 million cells per vial before being added to a freezing container (Nalgene) which
was then placed in a -80◦C freezer. The next day, they were then transferred to
liquid nitrogen storage.
2.2 Generation of mutant cell lines: CRISPR
design, transfection, and validation
The approach taken for the CRISPR/Cas9 genome editing followed the protocol
laid out by the Zhang lab in 2013 (Ran et al., 2013).
2.2.1 gRNA and ultramer design
Optimal gRNA sequences were chosen from those suggested by the Zhang lab
CRISPR design tool (crispr.mit.edu url now defunct). This tool uses an algorithm
to score gRNAs for a given target sequence based on the likelihood of off-
target binding (Hsu et al., 2013; Ran et al., 2013). Single stranded donor
oligodeoxynucleotides (ssODN, ordered from IDT) of around 200 bp were designed
to act as donors for homologous repair of targeted sites. These ssODNs contained
the desired mutations for each genoytpe with additional point mutations in
the gRNA hybridisation site and/or in the PAM to prevent cleavage of the
donor and repeated cleavage events by Cas9 after repair of the target sequence.
ssODNs were designed with at least 70 bp of homology flanking each side of
the targeted site to enable efficient homologous repair. Single strand oligos for
gRNA expression were annealed and phosphorylated before being ligated into
linearised into pSpCas9(BB)-2A-GFP (pX458) Cas9 expression vector following
the protocol described in Ran et al. (Ran et al., 2013). This vector enables the
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expression of the S. pyrogenes Cas9 endonuclease as well as GFP, and contains the
cloning backbone for the gRNA. Ligated plasmids were then used to transform
chemically competent XL-10 gold strain E.coli. Individual colonies were picked
and expanded in 5 ml LB medium (10 g/l tryptone, 5 g/l yeast extract, 10 g/l
NaCl) for small-scale plasmid preparation (EZNA plasmid mini kit, Omega).
sgRNA inserts in purified plasmids were sequenced using a primer annealing to the
the U6 promoter and bigdye sequencing technology (Thermofisher)according to
the manufacturer’s instructions. Sequencing runs were carried out by Edinburgh
Genomics. The detail of sgRNA sequence and ssODN design for each cell line
can be found in chapters 3 and 5.
2.2.2 Generation, transfection, cell sorting and colony
picking/Genotyping
Co-transfection of the sgRNA and Cas9 in pX458 and donor ssODN was
performed using Optimem and Lipofectamine 2000 on low passage E14 ES cells.
400,000 cells were used per transfection and were grown in 6-well plates for 24 h
post-transfection without antibiotics and for another 24 h with antibiotics. For
FACS sorting, cells were trypsinised and passed through a 70 µm cell strainer.
FACS sorting of GFP+ cells (co-expressed with Cas9 from pX458 as a 2A fusion)
was performed and 10,000-15,000 cells were then plated onto a 15 cm plate. After
7-10 days, single colonies were picked by hand, broken up with trypsin, and plated
in duplicate into two 96-well plates, one for genotyping and one for maintaining
the cell lines, and grown for 2-3 days. DNA was extracted from one plate using
the QuickExtract DNA extraction solution (Epicentre) and an initial genotyping
PCR was performed using primers of which one specifically recognised mutated
sequences introduced by the homology repair template and the other annealed
to a genomic sequence adjacent to the area targeted for repair. Cell lines that
appeared positive for the desired mutations from the genotyping PCR were then
sequenced across the entire target site and its borders to confirm the presence of
the correct mutation only.
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2.3 Neural differentiation
Neural differentiation was carried out following a protocol adapted from that
developed by Bibel et al. (Bibel et al., 2007). Embryoid body (EB) formation
was induced by removal of LIF, on day 0 ESCs were plated onto non-adherent
bacterial plates (Greiner) in 10 ml EB medium: DMEM containing 4.5 g/l glucose
(Gibco) with 10% FBS (Life Technologies, South American, A3160802), 2 mM
l-glutamine, 1 mM pyruvate, 1x MEM nonessential amino acids, 50 units/ml
penicillin and 50 µg/ml streptomycin (all Gibco), and 0.2 mM -mercaptoethanol
(Sigma), at a density of 4x106 cells per 10 cm plate. Embryoid bodies began to
form after one day. On day 2 the media was changed and increased to 13 ml by
transferring cells to a 15 ml falcon tube, allowing EBs to settle at the bottom, and
carefully aspirating the supernatant, and then adding fresh media before gently
resuspending EBs and transferring to a fresh plate. On day 4 media was changed
in the same manner to 15 ml of EB medium with 10 µM all trans retinoic acid
(Sigma). On day 6 media was changed again maintaining the same volume of
EB medium + retinoic acid. On day 8 the EBs were washed 3x in 20 ml PBS,
trypsinised for approximately 3 min at 37◦C with agitation and then quenched in
10 ml EB medium. Cells were then centrifuged for 5 min at 300 x g, resuspended
in 10 ml EB medium and passed through a 40 µm cell sieve to remove clumped
cells and undigested EBs. Cells were then counted, centrifuged again at 300 x
g for 5 min and plated onto poly-D-lysine (Sigma) and laminin (Sigma) coated
6 cm dishes in 3 ml Advanced DMEM/F12 (Gibco) containing 1x N2 supplement
(Gibco) at a density of 1x106 cells/ml. On day 9 half the medium was replaced
with Neurobasal medium (Gibco) containing 1x B27 supplement (Gibco), this
was repeated on day 12 and day 15.
2.4 Gene expression analysis methods
2.4.1 RNA purification
RNA was extracted from cells by first resuspending in 1 ml TriPure RNA isolation
reagent (Roche) and leaving samples at room temperature for 5 min. Samples
were then centrifuged at 12,000 x g for 10 min at 4◦C and the supernatant
transferred to a fresh tube. 200 µl of chloroform was added to samples and mixed
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by shaking before centrifuging samples again at 12,000 x g for 15 min at 4◦C.
The aqueous phase was transferred to a fresh tube along with an equal volume
of isopropanol and 1 µl of glycoblue (Ambion). Samples were then centrifuged
at 20,000 x g for 20 min at 4◦C and the supernatant discarded. The pellet was
then washed in 1 ml 70% ethanol then 1 ml 80% ethanol, centrifuging samples
for 5 min at 20,000 x g at 4◦C between washes. Supernatant was discarded and
pellets allowed to air dry before resuspending in BTE (10 mM bis-tris pH6.7, 1 mM
EDTA). Samples were treated with 2 units of Turbo DNAse (Ambion) for 30 min
at 37◦C before adding 1 ml of TriPure and 200 µl of chloroform. Protocol was
then repeated up to the air drying of the RNA pellets which were resuspended
in 50 µl BTE and concentration measured on Nanodrop. Quality of the RNA
samples was further assessed on an Agilent bioanalyser using an RNA 6000 Nano
chip. Samples were stored at -80◦C.
2.4.2 cDNA synthesis and qPCR
cDNA samples were prepared from starting material of 1 µg RNA to which was
added a final concentration of 2.5 µM oligodT and 0.5 mM dNTP mix. Samples
were incubated at 65◦C for 5 mins to anneal primer to RNA then returned to ice.
To the annealed RNA/primer solution was added 1 µl, or 200 units of SuperScript
IV reverse transcriptase and 4 µl 5X Superscript IV buffer with RNAase inhibitor
and 100 mM DTT. Samples were transferred to thermocycler for 10 minutes each
at 42◦C, 50◦C, 55◦C and 80◦C in succession. The resulting cDNA samples were
then diluted at least 1/30 in water before being used in qRT-qPCR experiments
and stored at -20◦C. qRT-PCR experiments were carried out on a Lightycler
480 (Roche) using a 10 µl reaction volume with 2 µl of cDNA, 5 µM primers and
1x SyGreen Blue Mix (PCRBiosystems). Results were analysed using the 2-
ΔΔCT method with Gapdh as the reference gene. Statistical analysis of the
data generated was performed using a one-way ANOVA test followed by a Tukey
Honest Significant Difference test.
2.4.3 RNA library preparation and quality control
RNA libraries were prepared from 1 µg of starting material as measured by
Qubit (Invitrogen), using the NEBNext rRNA depletion kit and NEB Ultra II
Directional RNA library prep kit for Illumina. All samples were first run on
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Agilent bioanalyser RNA Nano 6000 chips to verify that all starting material had
an RNA integrity number (RIN) of 8 or higher. Samples were then processed
following directions provided with the kits. Briefly, rRNA depletion was carried
out first by hybridising ssDNA probes to rRNA then treating with RNAse H
which specifically degrades DNA/RNA hybrids. Samples were then treated
with DNAse I to remove residual ssDNA probes before RNA was purified using
Agencourt RNAClean XP beads (Beckman Coulter). Fragmentation of RNA was
then performed for 15 mins at 94◦C before first and second strand synthesis of
cDNA were carried out. The double stranded cDNA was then purified using
SPRIselect beads. End prep of the cDNA was then performed before ligation of
adaptors and excision of the uracil by treatment with USER enzyme, breaking
the hairpin structure formed by the adaptors. SPRIselect beads were then used
to clean up the ligation reaction before proceeding to the PCR enrichment of
the adaptor ligated cDNA using the universal PCR primer and a unique index
primer for each separate library (NEBNEXT multiplex oligos for Illumina were
used). Amplification was performed for 7 PCR cycles and samples purified
with SPRIselect beads (Beckman Coulter). Quality and size distribution of the
libraries was verified on Agilent bioanalyser DNA HS chips. Quantification of
libraries was performed by qubit measurement and qPCR using the NEBNext
Quant Kit for Illumina. Appropriate volumes of each samples were pooled to
achieve a similar concentration of each library in the final pool, then submitted
to the Edinburgh genomics facility for Next-Generation sequencing on an Illumina
NovaSeq using an S2 flowcell and a 50 pair end read setup.
2.4.4 RNA-seq analysis
Once the raw data was received from the Edinburgh genomics sequencing facility,
analysis was performed under my direction by Shaun Webb using the following
methods.
Read processing and alignment
Preprocessing of reads was performed using Trimmomatic version 0.36 to trim
low quality bases and adapter sequences from the ends of 50 bp, paired-end
reads. Reads were then aligned to the mouse mm10 reference genome with
STAR version v2.5.3.a. Properly paired primary alignments were selected for
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downstream analysis and further filtering was performed to remove alignments to
mm10 blacklisted regions. Unique alignments were obtained by selecting those
with a mapping quality ≥20 using Samtools v1.9. Read coverage profiles for both
strands were generated using bedTools v2.27 genomeCoverageBed to produce
visualisation tracks.
Gene level quantification and differential expression analysis
Pseudo alignment of reads to transcripts was performed using Salmon v0.13.1 and
transcript annotation, including non-coding RNA, from the Ensembl GRCm38.78
release. Read counts at the gene level were aggregated using the R package
tximport and differential expression analysis was performed between multiple
samples using DESeq2.
Gene ontology and transcription factor motif analysis
The GProfiler tool (biit.cs.ut.ee/gprofiler) was used for gene ontology analysis.
Genes found to be significantly differentially expressed were grouped by cell line,
timepoint and direction of change of expression (up or down). These groups were
then analysed by GProfiler for the enrichment of terms associated with gene IDs
using the Gene Ontology database which is subdivided into molecular function,
cellular component and biological process. This tool was also used to interrogate
the Kegg database which gives information on the biological pathways enriched
amongst the genes of each group, as well as the TRANSFAC database which
provides the regulatory motifs enriched in these genes. The transcription factor
motifs were restricted to a +/- 1kb region around the TSS of genes.
2.5 DNA gel electrophoresis
All DNA samples were run at 100V on 1-2% agarose gels in TBE (100 mM Tris-
HCl, 100 mM boric acid, 2 mM EDTA pH8) stained with SYBR safe (Invitrogen




Protein samples were prepared by boiling whole cell pellets at 95◦C for 5 min
in SDS sample buffer (190 mM Tris-HCl, 30% glycerol, 6% SDS, 150 mM DTT,
0.3% bromophenol blue) using a ratio of 50 µl buffer per 1 million cells. Samples
were then stored at -20◦C. Proteins were separated by SDS-PAGE. Samples were
loaded onto a1.5 mm mini acryalamide gel of appropriate percentage (15% for
histone modifications, 8.5% for PRC2 subunits) and run at a voltage of 120 V for
the stacking and 200 V for the separation gel. Cassettes used to cast gels and
electrophoresis tanks from Novex by LifeTech. Proteins were then transferred to
nitro-cellulose membrane using the semi-dry Trans-Blot turbo transfer system
by Bio-Rad. Membranes were then blocked for 1 hour in a solution of 5%
dry skimmed milk (Premier Foods) in TBS-t (20 mM Tris-HCL, 137 mM NaCl,
0.1% (v/v) Tween). Membranes were then washed 3x 5 min in TBS-t before
adding primary antibodies, diluted appropriately in 5% BSA in TBS-t. This was
incubated overnight with shaking at 4◦C. Primary antibodies were then removed
and membranes washed again 3x 5 min in TBS-t before adding corresponding
HRP-conjugated secondary antibodies diluted 1:5000 in 5% BSA in TBS-t.
This was incubated for 1 h with shaking at room temperature before removing
secondary antibodies, washing 3x 5 min in TBS-t and developing membranes
using the Clarity Western ECL substrate (Bio-Rad) and the Chemidoc touch
imaging system (Bio-Rad).
2.7 Immunofluorescence staining of cells
2.7.1 Plating and fixation of cells
In preparation for plating 16 mm coverslips were soaked overnight in ethanol
before being air dried then washed twice in PBS before coating. Cells were
plated onto coverslips, coated with 0.1% gelatin (for ESCs) or with PDL and
laminin (for NPCs) in 12 well plates. Cells were fixed either one day after being
plated (for ESCs) or at different days of differentiation (for NPCs) by washing
once in PBS and adding 4% paraformaldehyde for 20 mins at room temperature.
Coverslips were then washed 3x 10 mins in PBS then stored in PBS at 4◦C and
used within 2 months of fixing.
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2.7.2 Staining
Coverslips were washed once with PBS and blocked with 10% donkey serum in
PBS with 0.1% Triton X-100 and incubated with primary antibodies overnight
at 4◦C. The following day, coverslips were washed 3x with PBS for 10 min, then
incubated with Alexa fluor secondary antibodies (Invitrogen) at a dilution of
1:1000 in 1% donkey serum in 0.1% Triton X-100 for 1 h at room temperature
in the dark. The coverslips were then washed 3x with PBS for 10 min. Nuclei
were counterstained with 50 nM DAPI for 5 min, and washed 2x 10 min with PBS
before being mounted on slides using vectashield.
2.7.3 Acquisition and processing of images
Imaging was carried out using a Zeiss Axio imager with 40x objective using
standard filter sets. The microscope was equipped with a Hamamatsu Flash
sCMOS camera. Micro-manager software (version 1.4) was used to capture images
(Edelstein et al., 2014).
2.8 Chromatin immuno-precipitation
2.8.1 Chromatin preparation and quality control
Media was removed by aspiration from cells cultured on 15 cm plates and 15 ml
fixation buffer (DMEM with 1% formaldehyde, 10 mM HEPES pH 7.6, 15 mM
NaCl, 0.15 mM EDTA, 0.075 mM EGTA) was added. Crosslinking was carried
out for 10 min at room temperature on a rocker. The formaldehyde was then
quenched with 750 µl of 2.5 M glycine. The fixation buffer was then removed
and cells were rinsed in 15 ml of cold PBS, resuspended in 2.5 ml cold PBS and
pelleted at 2500 x g for 5 min at 4◦C. The supernatant was then removed and
the cell pellet weighed. The cells were resuspended in lysis buffer 1 (50 mM
HEPES pH 7.6, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% Igepal, 0.25%
Triton-X) to a concentration of 75 mg cells/ml. This was then placed on an end-
over-end rotator for 10 min at 4◦C and pelleted at 3000 x g for 5 min at 4◦C. The
supernatant was removed and the pellet resuspended in the same volume of lysis
buffer 2 (10 mM Tris-HCl pH 8.0,200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA)
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and again rotated at 4◦C for 10 min before being pelleting at 3000 x g for 5 min
at 4◦C. The supernatant was removed and the pellet resuspended in the same
volume of lysis buffer 3 (10 mM Tris-HCl, 1 mM EDTA, 0.5 mM EGTA, 0.5%
N-lauryl sarcosine). Chromatin was sheared in a Bioruptor (Diagenode) for 17
cycles (30 s on, 30 s off) at the highest setting. The samples were centrifuged at
20,000 x g for 10 min at 4◦C then the supernatant was aliquoted and frozen at
-80◦C. Size of chromatin fragments was verified on a 1% agarose gel and on a high
sensitivity DNA chip in a 2100 Agilent bioanalyser after decrosslinking overnight
at 65◦C with shaking in elution buffer (100 mM NaHCO3, 1% SDS, 200 mM NaCl,
0.4 mg/ml each proteinase K and RNAse A).
2.8.2 Immuno-precipitations
Chromatin was incubated overnight with antibodies in IP buffer (2% Triton X100,
200 mM NaCl, 1 mM PMSF, 1 mM EDTA, 10 mM Tris-HCl pH 8.0) rotating at
4◦C, at this stage 10% input sample was taken from each IP. 50 µl per sample
magnetic protein A or G DYNA bead suspension (Invitrogen) were washed twice
using a magnetic rack (Invitrogen), then blocked overnight with PBS + 0.5%
(w/v) BSA overnight at 4◦C with rotation. On day 2 the beads were washed 5
times in TE buffer (10 mM Tris pH8, 1 mM EDTA) then aliquoted in protein
low-bind tubes. IPs were spun at 20,000 x g for 10 min at 4◦C to remove
any precipitate that may have formed overnight. The supernatants were then
transferred to the aliquoted DYNA beads and incubated at 4◦C for 2-3 h rotating.
Beads were then washed 5 times in cold RIPA buffer (10 mM HEPES pH 7.6,
1 mM EDTA, 0.5 M LiCl, 1% Igepal NP-40, 0.1% N-Lauryl Sarcosine, 0.2 mM
PMSF) with 1-2 min rotating incubation for each wash. Beads were then washed
once in TEN buffer (TE with 50 mM NaCl) without incubation. 200 µl elution
buffer (100 mM NaHCO3, 1% SDS, 200 mM NaCl, 0.4 mg/ml each proteinase K
and RNAse A) was then added to beads and to samples corresponding to 10%
of the input chromatin used per IP before incubating at room temperature for
15 min then at 65◦C overnight with shaking to reverse crosslinking. The next
day samples were purified using NEB Monarch columns and eluted using 50 µl
kit elution buffer then stored at -20◦C.
When using Drosophila S2 chromatin spike-ins in the preparation of samples
for ChIP-seq, 100 ng of S2 chromatin (generated in house using the protocol
outlined above) was added to each sample. During the immuno-precipitation
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stage, an additional antibody for H2Av (Active Motif), a Drosophila specific
histone variant, was included.
2.8.3 ChIP-qPCR
Eluted DNA was used in qPCR reactions on a Lightcycler 480 (Roche) in the
same manner as described above. Enrichments were calculated as percentage of
Input. Statistical analysis of the data generated was performed using a one-way
ANOVA test followed by a Tukey Honest Significant Difference test.
2.8.4 ChIP library preparation and quality control
All ChIP samples were measured using qubit then 2-3 ng were used as starting
material for library prep. Libraries were generated using the NEBNext Ultra II
DNA library prep kit for Illumina following instructions provided with the kit.
Briefly, end prep of DNA fragments was performed before ligation of adaptors,
treatment with USER enzyme and 8 cycle PCR enrichment of libraries. Again,
NEBNEXT multiplex oligos were used for index primers. Quality and fragment
length of resulting libraries was assessed by bioanalyser using Agilent DNA HS
chips. Concentration of each library was then determined by qPCR and by qubit
measurements. Libraries were then pooled and submitted to Edinburgh genomics
for Next-Generation sequencing on a HiSeq S1 flow cell using 50 paired end reads.
2.8.5 ChIP-seq analysis
Once the raw data was received from the Edinburgh genomics facility the analysis
was performed under my direction by Shaun Webb using the following methods.
Read processing and alignment
Preprocessing of reads was performed using Trimmomatic version 0.36 to trim
low quality bases and adapter sequences from the ends of 50 bp, paired-end
reads. Reads were then aligned to a reference sequence containing the mouse
mm10 and Drosophila dm6 assemblies, with bwa mem version 0.7.5.a using the
-M option. Properly paired primary alignments were selected for downstream
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analysis and further filtering was performed to remove alignments to mm10
blacklisted regions. Unique alignments were obtained by selecting those with
a mapping quality ≥20 using Samtools v1.9, and duplicate reads were removed
with Picard MarkDuplicates v2.20.3. Alignments were next split into mm10
and dm6 files to perform quantification and to calculate normalisation scaling
factors. Spike in normalisation was performed following the protocol described
at activemotif.com/documents/1977.pdf. This protocol is briefly described as
follows: Uniquely aligning Drosophila sequencing tags were counted and the
sample with the fewest tags was identified. By comparing this sample with each
other sample a normalisation factor was generated for each sample. Final counts
were acquired by multiplying each sample by its normalisation factor.
Read coverage and visualisation
Read coverage profiles as bigWig files were generated using Deeptools v3.13
bamCoverage and bamCompare.
2.9 Fluorescence in situ hybridisation
2.9.1 Probe preparation
Fosmid probes were selected from the WIBR-1: Mouse Fosmid Library (White-
head Institute/MIT). Probes were prepared from glycerol stocks stored at -
80◦C. Probes are listed in Fig.2.1. Probes were prepared by small scale DNA
plasmid preparation (Omgea) and stored at -20◦C. Probes were directly labelled
with fluorescent nucleotides by nick translation, using the following reaction mix
(20 µl): 2 µl Nick translation salts, 2.5 µl 0.5 mM dATP, 2.5 µl 0.5 mM dCTP, 2.5 µl
0.5 mM dGTP, either 2.5 µl 1 mM ChromaTide Alexa 594-5-dUTP (Invitrogen) or
2.5 µl 1 mM 5(6)-Carboxyrhodamine Green dUTP (Enzo), 6 µl fosmid miniprep
DNA (estimated 0.5-1ug), 1 µl DNase I (1:10 dilution) and 1 µl DNA polymerase
I (Invitrogen). This reaction was incubated for 90 mins at 16◦C. The reaction was
stopped by adding 3 µl 0.5M EDTA (pH 8) and 2 µl 20% SDS. 65 µl of TE buffer
was then added to the sample, before successfully labelled DNA was purified
using a Quick spin column (Pharmacia) per manufacturers instructions. Labelled
fosmid DNA was then stored at -20◦C.
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Figure 2.1 FISH probe location and size
2.9.2 Preparation of cells
Superfrost plus slides (Thermo Scientific) were prepared by soaking overnight
in 70% ethanol then air drying and washing in PBS before plating cells at
approximately 1-2x106 cells per slide. The following day, slides were washed 3x
in PBS before being fixed in 4% paraformaldehyde for 10 min. Slides were then
washed 3x in PBS and treated with 0.5% Triton X-100 for 10 min to permeabilise
cells before being washed again 3x in PBS. Slides were finally allowed to air dry
before storing at -80◦C.
2.9.3 Probe hybridisation
Slides were briefly washed in 2x saline-sodium citrate (SSC) buffer, then incubated
for 1 hour in 2x SSC with 100 µg/ml RNaseA at 37◦C. Slides were then washed
in 2x SSC before cells were dehydrated using a series of ethanol washes (2 min
each 70%, 90% then 100% ethanol). Slides were air dried and then heated to
70◦C in an oven for 5 min before denaturation in 2x SSC with 70% formamide
(Honeywell), pH 7.5 at 80◦C for 30 min. A second dehydration step was then
performed (2 min each 70% ice cold, 90% room temp, 100% room temp ethanol).
Slides were air dried then incubated at 37◦C while probes were prepared.
For each slide 10 µl of directly-labelled probe was used as well as 8 µg of mouse
Cot1 DNA (Invitrogen) and 5 µg sonicated salmon sperm DNA, used to prevent
non-specific binding during hybridisation steps. 2x volumes of 100% ethanol were
used to precipitate probes which were then vacuum dried then 15 µl hybridisation
solution (50% deionised formamide, 10% dextran sulphate, 1% Tween-20 in 2x
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SSC) was added to the precipitated probes, and allowed to dissolve for 1 h at
30◦C. Denaturation of the probes was then carried out at 80◦ for 5 min followed
by pre-annealing at 37◦C for 15 min. Probes were then added to a 22 mm × 22 mm
coverslip at 37◦C before the slides that had been pre-warmed at 37◦C were placed
face down on coverslips. A rubber solution was used to seal the coverslips and
slides which were then left to hybridise overnight at 37◦C. Following hybridisation,
the rubber seal was removed and slides were washed 4x in 2x SSC for 3 min at
45◦C and then 4x in 0.1x SSC for 3 min at 60◦C. Slides were then washed once in
4x SSC with 0.1% Tween-20 before adding 50 µg/ml DAPI in 4x SSC with 0.1%
Tween-20 for 3 min. A 22 mm × 40 mm coverslip is then added with Vectasheild
mounting medium (Vector labs) and sealed with nail varnish.
2.9.4 Acquisition and analysis of images
FISH images were acquired using a Zeiss Axio imager with 100x objective using
standard filter sets. The microscope was equipped with a Hamamatsu Flash
sCMOS camera and a Marzhauser 8 slide motorised stage. Images were taken
with a 0.2 µm z-step. Micro-manager software (version 1.4) was used to capture
images (Edelstein et al., 2014).
The 3D captured images were then deconvolved using Autoquant X3 software
with blind 3D deconvolution settings. Imaris 8.0 was used for image analysis,
where the Spots function was used to mark hybridised probe signals, and the XYZ
coordinates of the centre of each probe was recorded. The 3D distances between
each red probe and its closest green pair were calculated using an automated
javascript written by Dr David Kelly. The results were then manually assessed
to select only the true probe pairs, and to discard any aberrant signals and
ensure data was reliable. Measurements were made for at least 80 cells per
genotype across at least 2 slides. Statistical significance of the differences between





of EZH2 knockout and knockin
cell lines
3.1 Introduction and aims
In order to address the main question of my project I first aimed to establish
a system in which I could compare the absence of both PRC2 and H3K27me3
from chromatin to the loss of H3K27me3 alone while maintaining an intact PRC2
complex. By using mESCs I was able to examine the effects of a catalytically
inactive PRC2 on the chromatin state and gene regulation of its target genes not
only in a steady state but also in the dynamic transition through differentiation.
Bivalency was also first identified in mESCs in 2006 and this cell type has been
used extensively for the study of Polycomb group proteins. In this way, any
findings from this project will be directly comparable to many published studies,
facilitating the positioning of my work in the context of the broader field of
Polycomb research. In light of this we chose to generate mESC lines with either
a catalytically inactive PRC2 or a PRC2 KO. The gene editing method we
chose for introducing these mutations was CRISPR Cas9 genome editing, due
to its simplicity in design, ease of implementation, and high specificity. In order
to obtain all PRC2 mutants in the same genetic background and to minimise
differences between the lines due to varied time in culture and gene editing
methods, I opted to generate all cell lines myself rather than using pre-existing
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lines with different backgrounds, for which it would be difficult to control.
Many previously generated EZH2 KO cell lines have used C-terminal truncations
which, while indeed leading to loss of the catalytic function of the protein, does
not necessarily lead to complete removal of the EZH2 protein, dissociation of the
complex and thus loss of its binding to chromatin, nor would it ensure the loss
of any potential activity of EZH2 that is distinct from the enzymatically active
C terminus (Shen et al., 2008; Højfeldt et al., 2018). In this project I aimed to
block the production of the entire protein in order to not only lose the methylation
activity of PRC2 but also to disrupt potential other functions located within the N
terminus as well as the assembly of the EZH2-PRC2 complex and consequently
its binding to chromatin. Moreover, I also chose to target EZH2 itself rather
than one of the other core subunits to minimise the differences between the KO
mutant and the catalytic mutant to ensure that any differences that I may observe
between the two lines are not a consequence of secondary effects due to the loss
of the SUZ12 or EED subunits. This strategy also allowed me to study EZH1 in
the absence of EZH2 with the aim of gaining further insight into their distinct
functions.
To generate a catalytically inactive form of EZH2 I aimed to introduce as few
mutations as possible to selectively target the active site of the SET domain
without unintentionally disrupting other functions of the protein. It has been
shown that within the SET domain of all protein lysine methyltransferases there
are 2 conserved tyrosines, the mutation of one of which has been shown to
completely abrogate methyltransferase activity (Kwon, 2003). In EZH2 this
corresponds to tyrosine 726, one of several aromatic residues located in the
methyl-lysine binding pocket of the protein (Kipp et al., 2013). We chose to
mutate this highly conserved residue in order to achieve robust inactivation of
the catalytic activity of EZH2.
In this chapter I will describe in detail how we designed and carried out the gene
editing of the mESCs as well as the validation methods used to confirm that the
cell lines were indeed mutated at the desired sites and produced the expected
effect on EZH2 and H3K27me3 levels.
The work in this chapter was performed with the help of several members of the
Voigt lab under my direction. Genotyping and passaging of the EZH2 Y726A
and EZH2 KO cell lines was done with the help of Elana Bryan and the cloning
of the pX458 plasmid targeting EZH1 was done by Viktória Major, while Katy
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McLaughlin and Giulia Bartolomucci helped with the genotyping of these cell
lines.
3.2 EZH2 single mutants
I initially chose to target the EZH2 subunit of PRC2 as its expression is associated
with highly proliferating cells and thus is much more highly expressed in ESCs
than EZH1 (Laible et al., 1997; Bracken, 2003). It has also been shown that
EZH2 is more enzymatically active than its paralogue and responsible for the vast
majority of H3K27me3 in ESCs (Margueron et al., 2008). I therefore targeted
the EZH2 subunit in order to achieve the strongest reduction in H3K27me3 levels
in ESCs, expecting the remaining H3K27me3 levels due to EZH1 activity to be
negligible.
3.2.1 Design of EZH2 CRISPR targeting strategies
Each genotype was generated using a similar CRISPR targeting strategy. gRNAs
were generated by the CRISPR design tool created by the Zhang lab at MIT
(crispr.mit.edu now defunct) and a suitable gRNA was chosen based on proximity
to the bases to be altered in the genomic sequence. Once optimal gRNAs for
the target locus were identified, a 200-bp ultramer to be used for homologous
repair of the target site was designed. This single-strand donor oligonucleotide
(ssODN) DNA fragment included the desired mutations as well as additional
mutations within the PAM and/or gRNA hybridisation site to prevent cleavage
of the repair template and the repaired target sites by the Cas9 endonuclease.
For the KO of EZH2 we aimed to introduce premature in-frame stop codons
into an early exon that would result in a truncated and presumably unstable
protein fragment. Alternatively, the stop codons could induce non-sense mediated
decay of the transcripts generated from the gene and in turn lead to a loss of
protein expression. We initially attempted this at exon 2 and exon 3 of the EZH2
gene. Although in both cases clones with correctly mutated DNA sequences were
obtained, the mutations did not result in loss of protein expression. We found
that with both targeting strategies EZH2 was still detectable by Western blot but
appeared to be migrating at a slightly smaller size than expected, indicating that
the mutations introduced by CRISPR may have caused these exons to be skipped
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resulting in a N-terminally truncated EZH2 protein. Finally, our third attempt
targeting exon 7 was successful in producing a KO of EZH2. The ultramer
designed for this targeting approach contained the mutations shown in Fig. 3.1.
To generate a catalytically inactive form of EZH2 we targeted the SET domain
located in part in exon 19. Here we designed the ultramer to replace tyrosine 726
with an alanine (Y726A), while also introducing silent mutations in the gRNA
hybridisation site to prevent spurious cleavage, as shown in Fig. 3.2.
Figure 3.1 Design of EZH2 KO CRISPR targeting strategy. Alignment
of E14 Wild-type sequence of exon 7 of Ezh2 gene with the ssODN designed to
induce EZH2 KO mutations (uppercase is exonic sequence, lowercase is intronic).
gRNA hybridisation site and PAM sequence are labelled, Cas9 cut site is indicated
with scissors. Point mutations in ssODN are indicated by red asterisks (lowercase
in red), in frame stop codons are labelled.
Figure 3.2 Design of EZH2 Y726A CRISPR targeting strategy.
Alignment of E14 Wild-type sequence of exon 19 of Ezh2 gene with the ssODN
designed to induce EZH2 Y726A mutations (uppercase is exonic sequence,
lowercase is intronic). gRNA hybridisation site and PAM sequence are labelled,
Cas9 cut site is indicated with scissors. Point mutations in ssODN are indicated by
red asterisks (lowercase in red), critical Y726A mutation is highlighted. Wild-type
protein sequence is displayed above corresponding codons.
3.2.2 Screening and validation of successful targeting
Low passage E14 mESCs were first transfected with the repair ssODN and the
pX458 plasmid from which the gRNA and Cas9 protein are expressed. Cas9 is
expressed as a 2A peptide-cleavable fusion with GFP, which serves as a reporter
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of cells that have been successfully transfected and are expressing Cas9. 48 hours
after transfection, cells were sorted by FACS and single GFP positive cells were
plated sparsely and grown before being harvested as single colonies onto 96-well
plates for expansion and genotyping. The strategy used for genotyping (shown in
Fig. 3.3) was a PCR screen using a mutation-specific primer along with a primer
situated outside of the mutation site and the sequence covered by the ssODN. In
untargeted ESCs these primer pairs did not allow for correct amplification and a
PCR product for the predicted size could only be observed in the presence of the
correct mutated sequence at the target site. From this mutation-specific PCR
potentially positive clones were chosen for a secondary PCR screen using primers
situated in flanking regions of the mutation site allowing amplification of a DNA
fragment spanning the entire ssODN-targeted region. This PCR product was
then sequenced using both the forward and reverse genotyping primers to ensure
coverage across the target site. An example of this screening process is shown in
Fig. 3.4, with an example of a successfully homozygously targeted EZH2 Y726A
clone shown in Fig. 3.5. Using this strategy, we were able to identify several
clones of each genotype with the correct mutations both in a heterozygous and
homozygous state.
Figure 3.3 Schematic representation of genotyping PCR strategy. In
blue, forward and reverse genotyping primers annealing to flanking regions are
labelled FG and RG. In red, the mutation specific reverse primer is labelled RM.
Induced mutations in targeted sequence are represented by red asterisks.
Figure 3.4 Example of CRISPR genotyping PCR. Mutation specific
genotyping PCR of EZH2 Y726A clones generates a PCR product of around 70 bp
when the correct mutations are present at target site. Outside genotyping primers
amplify a fragment of around 500 bp to be extracted and sequenced.
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Figure 3.5 Sequence of a homozygous EZH2 Y726A clone. Example of
a sequencing chromatogram for EZH2 Y726A showing the correct mutation of the
nucleotides within the codon for the catalytic tyrosine of the EZH2 SET domain.
3.2.3 Phenotypic validation of successfully targeted cell lines
Once all potential positive clones were validated by sequencing each cell line was
expanded and subjected to cryo-preservation before performing further screening
at the protein level. First, I performed Western blot on whole cell extracts to
establish the presence or absence of EZH2 in the mutant cell lines (see Fig. 3.6).
In the EZH2 KO cell lines I confirmed that the protein was no longer detectable in
the homozygous clones, whereas in the heterozygous clones I observed a reduction
of EZH2 as compared to control E14 mESCs. Next I analysed whether the Y726A
mutation affected the expression of EZH2 in either heterozygous or homozygous
cells. I found that the expression levels of EZH2 appeared to be slightly reduced
in some clones but not others, as can be seen in Fig. 3.6. In the following chapters
I chose to use only clones for which the level of EZH2 expression in the Y726A
mutants was the closest to that of the E14 control mESCs.
Once I had confirmed the expected expression profiles of EZH2 I then wanted to
verify that both EZH2 KO and EZH2 Y726A mutations resulted in comparable
losses of H3K27me3. Both EZH2 Y726A and EZH2 KO clones were found to have
diminished, although still detectable levels of H3K27me3 as compared to control
E14 mESCs (see Fig. 3.7). An EED KO cell line (Chamberlain et al., 2008)
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Figure 3.6 EZH2 expression in EZH2 KO and EZH2 Y726A cells.
Western blot using an antibody against EZH2 on whole cell extracts of EZH2 KO
and EZH2 Y726A clones confirmed by sequencing to have integrated the desired
mutations. Lamin A/C was used as a loading control.
was used as a control in these blots as it has been shown that the knockout of
this PRC2 subunit results in the complete loss of H3K27 methylation. Although
the reduction of H3K27me3 observed in both EZH2 Y726A and EZH2 KO was
similar, it was significantly higher than the levels detected in the EED KO.
Figure 3.7 H3K27me3 levels in EZH2 KO and EZH2 Y726A cells.
Western blot using an antibody against H3K27me3 on whole cell extracts of EZH2
Y726A (CI) and EZH2 KO clones. Lamin A/C was used as a loading control.
3.3 Generation of EZH1/2 double mutants
The reduction of H3K27me3 in these first cell lines was not as complete as I had
predicted from the loss of EZH2 activity in light of the expected lower expression
and activity of EZH1. I hypothesised that any role of EZH2-PRC2 that relies on
H3K27me3 may still function even with the low level of residual tri-methylation
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catalysed by EZH1. For this reason, I decided to also combine the knockout of
EZH2 as well as the EZH2 Y726A mutation with the knockout of the less active,
less abundant EZH1 subunit in these cells, in order to obtain a more complete loss
of the H3K27me3 mark. In this way any potential catalysis-independent functions
of EZH2-PRC2 can be assessed without confounding residual H3K27me3. In the
following chapters work was carried out using both the EZH2 single mutant cell
lines as well as the EZH1/2 double mutant cell lines.
3.3.1 Design of EZH1 CRISPR targeting strategy
The EZH1 KO targeting strategy was analogous to that used for the knockout
of EZH2 within exon 7. As can be seen in Fig. 3.8, several point mutations
were introduced in an early exon (exon 8) to produce in-frame stop codons.
Additional point mutations were introduced in the gRNA hybridisation site to
prevent repeated cleavage of the target.
Figure 3.8 Design of EZH1 KO CRISPR targeting strategy. Alignment
of E14 Wild-type sequence of exon 8 of Ezh1 gene with the ssODN designed to
induce EZH1 KO mutations (uppercase is exonic sequence, lowercase is intronic).
gRNA hybridisation site and PAM sequence are labelled, Cas9 cut site is indicated
with scissors. Point mutations in ssODN are indicated by red asterisks (lowercase
in red), in frame stop codons are labelled.
3.3.2 Screening and validation of successful targeting of
EZH1
For the double mutants I initially attempted to introduce mutations targeting
both Ezh1 and Ezh2 simultaneously in E14 mESCs. This would have allowed me
to generate clones that were independent of the initial EZH2 single mutant clones
that I had already created. However, this strategy resulted in high amounts of
cell death and low levels of successful transfection (as measured by percentage of
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GFP expressing cells detected by FACS), perhaps due to the increased amount
of lipofectamine and DNA present in the transfection reaction. Ultimately, we
were unable to obtain any correctly targeted EZH1/2 double mutants from this
attempt. We were however able to obtain EZH1 single KO and additional,
independent EZH2 KO and Y726A clones from this round of transfections. After
this initial failed attempt to obtain the EZH1/2 double mutants we changed
strategy and instead used two clones each of the EZH2 KO and EZH2 Y726A
cell lines and transfected each of them with the EZH1 KO constructs. The
screening was performed in the same way as the previous mutants by performing
a genotyping PCR using a mutation-specific primer to identify the mutated clones
before sequencing these clones across the target site to confirm the presence of
the desired mutations in the Ezh1 gene.
3.3.3 Phenotypic validation of successfully targeted cell lines
As previously described for the single mutants, once all clones were verified by
sequencing the knockout of EZH1 was then further verified by Western blot (see
Fig. 3.9). In both the EZH1/2 KO/Y726A and EZH1/2 dKO, EZH1 was at least
strongly reduced in expression if not completely absent from each clone. Levels
of H3K27me3 were also assessed by Western blot and all EZH1/2 double mutants
were found to have levels of H3K27me3 that were no longer detectable.
Figure 3.9 EZH2 and H3K27me3 levels in EZH1/2 KO/Y726A and
EZH1/2 dKO cells.Western blot using antibodies against EZH2 and H3K27me3
on whole cell extracts of E14 control (WT ESC), EZH1/2 KO/Y726A (KO/CI)
and EZH1/2 dKO clones confirmed by sequencing to have integrated the desired
mutations. Lamin A/C was used as a loading control.
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3.3.4 Effects of EZH1/2 mutations on overall PRC2
expression
Once the mutations generated in EZH1 and EZH2 were validated, I then verified
by RT-qPCR whether these mutants had any effect on the mRNA expression
of PRC2 complex members. As shown in Fig. 3.10, this experiment further
confirmed the loss of expression of EZH2 in the EZH2 single KO and EZH1/2
dKO cell lines and of EZH1 in both of the EZH1/2 double mutant cell lines,
whereas the EZH2 Y726A mutation did not affect the expression of EZH2 at the
mRNA level compared to the E14 control. The mRNA expression of EZH1 was
found to be largely unchanged following mutations of EZH2, however there did
appear to be a slight upregulation of this gene in the EZH2 single Y726A cell
lines. The EED subunit was slightly decreased in expression in the EZH2 single
mutant cells, and even more so in the EZH1/2 dKO cells whereas it was largely
unaffected in the EZH1/2 KO/Y726A cells. SUZ12 was expressed close to wild-
type levels in the EZH2 single mutant cells but was expressed at lower levels in
the EZH1/2 double mutant cell lines (see Fig. 3.10).
Figure 3.10 Expression of PRC2 subunits in EZH2 single and EZH1/2
double mutant mESCs. Bar chart showing expression of PRC2 subunits in
EZH2 Y726A (CI), EZH2 KO, EZH1/2 KO/Y726A (KO/CI) and EZH1/2 dKO
cell lines relative to E14 control. Data was generated by RT-qPCR and normalised
to Gapdh. Error bars represent standard error of the mean across 3 independent
clones, * denotes a significant difference to WT with a p value of less than 0.01.
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3.4 Conclusions
I successfully generated all required PRC2 mutant cell lines using CRISPR Cas9
genome editing. I found that while the KO of EZH2 alone was successful in
knocking out any detectable levels of the EZH2 protein and strongly reducing the
mRNA expression of the gene, low but detectable levels of H3K27me3 persisted
in these cell lines. The amount of H3K27me3 remaining also appeared to vary
slightly between clones. In the EZH1/2 double mutants, although I found by
Western blot that the EZH1 protein was not completely lost in most clones, by
RT-qPCR I observed a complete loss of expression of the gene. These seemingly
conflicting findings might be due to unspecific reaction of the EZH1 antibody with
a protein of similar size to EZH1 itself. I further observed that the KO of EZH1
in addition to the mutations of EZH2 led to the complete loss of H3K27me3. I did
not find any strong effects of the mutation of these two subunits of PRC2 on the
expression of any of the other core subunits of the complex, although increased
clonal variability in the expression of these subunits was observed in the EZH1/2
double mutants. Importantly the catalytically inactive form of EZH2 was found
to still be able to associate as expected with the other subunits enabling the
assembly of the full PRC2 complex.
In the following experiments in this project I used 3 independent clones of each
genotype as biological replicates in order to minimise clonal effects due to the
selection of individual single cell clones. In addition to heterogeneity between
individual E14 mESCs, such clonal effects could arise from off-target activity
during genome editing, which is known to be low with CRISPR Cas9 but not
completely unavoidable. Each clone was confirmed to have the same sequence at




Characterisation of chromatin state
in PRC2 mutant cell lines
4.1 Introduction and aims
After successfully generating all the mutant PRC2 cell lines I next aimed to
investigate how the chromatin state of Polycomb-bound genes was affected. PRC2
is able to bind to chromatin through multiple interactions with the nucleosome
involving each of the core subunits of the complex. EZH1 and EZH2 themselves
are able to bind to the H3 tail by the interaction of lysine 27 with the binding
pocket of the SET domain. PRC2 is also able to read its own mark by the
recognition of H3K27me3 by the EED subunit. The remaining core subunits
SUZ12 and Rbap46/48 have also been shown to interact with histone H3, an
interaction which has been shown to be markedly weaker in the presence of
H3K4me3 (Schmitges et al., 2011; Yuan et al., 2012). PRC2 is known to bind
to promoters of its target genes, most of which in ES cells are involved in
development, and has a distinct preference for genes whose promoters contain
CpG islands devoid of DNA methylation (Boyer et al., 2006; Mikkelsen et al.,
2007; Mendenhall et al., 2010). The pattern of PRC2 binding to these loci mostly
follows a similar profile with relatively broad peaks centred around the TSS of
the gene. The profile of H3K27me3 at these genes tends to closely mirror that
of PRC2 binding. The allosteric activation of the PRC2 complex through the
interaction with the EED subunit is thought to be responsible for these broad
profiles across these genes. It has recently been suggested that PRC2 may initially
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be recruited to its targets through ”nucleation” sites from which the complex, and
thus the histone PTM it places are then able to spread (Oksuz et al., 2018). It has
also been proposed that this spreading could even happen in trans to secondary
target genes through chromatin looping and not just in cis around the initial
nucleation site within the same chromosome. In line with this discovery I was
curious to find out whether the catalytically inactive EZH2 would have a binding
pattern similar to that seen in this study. If the spreading of the PRC2 complex
indeed occurs solely via the recognition of its own mark through the EED subunit,
it is to be expected that the loss of catalytic activity would lead to a disruption
of this spreading.
After successfully generating the mutant PRC2 cell lines, I next aimed to
investigate how the chromatin state of Polycomb bound genes was affected. This
chapter describes ChIP-qPCR experiments that were performed to characterise
the chromatin state of the PRC2 mutant cell lines. With these experiments, I
aimed to address the following questions: To verify that the catalytically inactive
PRC2 complex was a suitable model to explore catalysis-independent actions of
PRC2, I sought to determine whether it was still able to bind to chromatin in
absence of H3K27me3 and in the presence and absence of EZH1. I also sought
to determine the distribution of H3K27me3 that is maintained by EZH1. It has
also been shown that while H3K4me3 and H3K27me3 coexist at bivalent genes,
these two marks are mutually exclusive on the same histone tail and it has been
shown in vitro that PRC2 is not able to modify histone tails already carrying
H3K4me3 (Schmitges et al., 2011; Voigt et al., 2012). In light of this I also
sought to determine whether the loss of H3K27me3 alone or along with PRC2
would have a considerable effect on the abundance of H3K4me3 at bivalent genes.
4.1.1 Changes in global histone PTMs
Before investigating the chromatin state at specific loci and genome-wide, I first
assessed global levels of certain histone modifications to determine whether any
of the mutations of PRC2 caused striking changes in modification levels. I also
examined the expression of a selection of Polycomb group proteins to verify
that the abundance of these components remained unchanged. Overall levels
of histone modifications relevant to the PcG proteins and bivalent genes were
determined by Western blot of whole cell extracts of the single EZH2 mutants
(Fig. 4.1). In both EZH2 Y726A and EZH2 KO cell lines the H3K27me3 histone
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mark was strongly reduced although not completely lost, as was seen in the
EED KO cells, used here as a control. This was in line with the loss of EZH2
catalytic activity in both cell lines, either by mutation of the SET domain in the
EZH2 Y726A lines, or by loss of the protein itself in the EZH2 KO lines. As
described in the previous chapter, remaining H3K27me3 observed in these cell
lines is likely to come from EZH1 which is known to be able to carry out the
same catalytic functions as EZH2 but with much lower activity. Accordingly, the
H3K27ac mark, which is mutually exclusive with H3K27me3, increased slightly
in the EZH2 mutant cell lines to an extent that was inversely proportional to the
loss of H3K27me3. The active histone mark H3K4me3 which co-occupies bivalent
genes with H3K27me3, did not exhibit any strong global changes in abundance in
the EZH2 single mutants although there was a subtle increase seen in the EZH2
Y726A cell lines. Surprisingly, there seemed to be an increase in the H3K27me1
levels in the EZH2 KO and one of the EZH2 Y726A cell lines. With regard to
Polycomb group proteins, EZH2 was detected in EZH2 Y726A cells but not in
EZH2 KO cells (Fig. 4.1, see also Fig. 3.7). Levels of the PRC2 subunit SUZ12
remained largely unchanged in all EZH2 mutant cell lines. Nor did I observe
any striking changes in the PRC1 complex (Fig. 4.1). Neither RING1B nor
CBX7, the PRC1 subunits responsible for placing H2AK119ub and binding to
H3K27me3 respectively, exhibited altered abundance following the mutation of
EZH1 or EZH2.
Figure 4.1 Global levels of histone PTMS and PcG proteins in EZH2
single mutant mESCs. Western blots analysis of histone PTMs and PcG
proteins using whole cell extracts and indicated antibodies. Histone H3 and Lamin
A/C were used as loading controls.
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4.2 Analysis of chromatin state at bivalent genes
by ChIP-qPCR
I next sought to determine the levels of binding of EZH2 to its target genes in
the mutant cell lines and to asses the abundance of H3K27me3 and H3K4me3 at
these genes by performing ChIP-qPCR. To determine whether the catalytically
inactive form of EZH2 retained its chromatin binding activity I performed ChIP
for EZH2 with each of the PRC2 mutant cell lines. I then probed for binding to
regions that corresponded to the promoters of active genes (Gapdh, Oct4 ) and
of known Polycomb bound genes (Hoxc5, Hoxc11, HoxB13, Gata4, Bcor, Olig1,
Pax3 ) as well as to the gene body of a Polycomb bound gene (Fabp7 ). I also
performed ChIP-qPCR in all PRC2 mutant cell lines for levels of H3K27me3
and H3K4me3 at the same sites to determine how their abundance is affected at
bivalent genes in the absence of PRC2 activity.
4.2.1 Analysis of H3K27me3 levels at bivalent genes
I first assessed the levels of H3K27me3 at active and Polycomb target genes in
E14 control and PRC2 mutant cell lines. In the E14 control H3K27me3 was
found to be enriched to varying degrees at all Polycomb target genes as expected,
while there was no significant enrichment at either of the active genes (Fig. 4.2).
Interestingly, H3K27me3 was still detectable within the gene body of Fabp7,
suggesting a degree of spreading of the mark from the promoter region of this
gene. In both EZH2 single mutants there was a strong reduction of H3K27me3 at
all Polycomb target genes. While it was depleted to a similar degree in both the
EZH2 KO and EZH2 Y726A, I found that most Polycomb target genes retained
low but detectable levels of H3K27me3 at their promoters. In the Fabp7 gene
body however, I found there to be no enrichment of H3K27me3 in either EZH2
single mutant. In the case of the EZH1/2 double mutants I found that H3K27me3
was completely depleted from all of the Polycomb target genes with no residual
enrichments detected for any of the genes probed. The levels of H3K27me3
detected in this assay in both the EZH2 single and EZH1/2 double mutants
reflected the global levels of this histone modification that I had previously
detected by Western blot. This further confirmed that the EZH2 Y726A mutant
was indeed devoid of catalytic activity and that the residual methylation of lysine
27 detected in the EZH2 single mutants was abolished by the knockout of EZH1.
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Figure 4.2 H3K27me3 enrichment in E14 control and PRC2 mutant
mESCs. ChIP-qPCR for H3K27me3 in E14 control (WT), EZH2 Y726A (CI),
EZH2 KO, EZH1/2 KO/Y726A (KO/CI) and EZH1/2 dKO cells. Enrichments
were normalised to input, with error bars representing standard error of the mean
across three biological replicates. * denotes a significant difference to WT with a
p value of less than 0.01 and ∆ a p value of less than 0.05.
4.2.2 Analysis of EZH2 binding to bivalent genes
I next sought to determine how the distribution of EZH2 was altered in the mutant
cell lines. In the E14 control cells EZH2 was found to be enriched at Polycomb
target genes, but was absent from the active genes (Fig. 4.3). The enrichment
of EZH2 was found to broadly mirror the levels of H3K27me3 detected at all
genes in the E14 control with the exception of the Fabp7 gene body. Though
this gene was found to be enriched for H3K27me3 in the E14 control, this was
not the case for EZH2, indicating that while EZH2 may be more restricted to
promoter regions, its mark can spread further into the gene body. In the EZH2
single and EZH1/2 double mutants the levels of EZH2 detected at active genes
and the Fabp7 gene body were comparable to that seen in the E14 control. At
Polycomb target genes the catalytically inactive EZH2 Y726A was found to bind
to varying levels, at some genes such as Hoxc11 and Bcor this level was similar
to that observed in the E14 control whereas at others such as Gata4 and Olig1
this enrichment was reduced by more than twofold. At the Fabp7 gene body, as
in the E14 control, EZH2 Y726A was not found to be enriched. In the EZH2
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KO cell line EZH2 binding was found to be strongly reduced at all Polycomb
target genes, although this depletion was not quite as complete as expected given
that this protein was undetectable by Western blot. In the EZH1/2 KO/Y726A
cells, though EZH2 binding was found to be reduced as compared to the E14
control, there was still an enrichment of this protein detected at all Polycomb
target genes. Finally, in the EZH1/2 dKO cells, I found that EZH2 was virtually
undetectable both at the active genes and the Polycomb target genes. Together
the results of this assay showed that the catalytically inactive EZH2 was able to
bind to its target genes in vivo both in the presence and absence of EZH1, if at
slightly reduced levels.
Figure 4.3 EZH2 enrichment in E14 control and PRC2 mutant mESCs.
ChIP-qPCR for EZH2 in E14 control (WT), EZH2 Y726A (CI), EZH2 KO,
EZH1/2 KO/Y726A (KO/CI) and EZH1/2 dKO cells. Enrichments were
normalised to input, with error bars representing standard error of the mean across
three biological replicates. * denotes a significant difference to WT with a p value
of less than 0.01, and ∆ a p value of less than 0.05. Significant differences between
the mutants are indicated using brackets.
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4.2.3 Analysis of H3K4me3 levels at bivalent genes
I next aimed to determine the consequences of the altered EZH2 recruitment
and H3K27me3 deposition in the PRC2 mutant cell lines on H3K4me3. This
histone modification is found at the vast majority of Polycomb target genes in
mESCs, resulting in a bivalent chromatin state. As expected in the E14 control
cells, H3K4me3 was most highly enriched at active genes (Fig. 4.4). Lower, but
still reliably detectable levels of this mark were found at the Polycomb target
genes with the lowest enrichments of H3K4me3 found at Hoxc11 and Hoxb13.
As expected, there was no enrichment of this mark detected at the gene body of
Fabp7.
In the EZH2 single mutants levels of H3K4me3 at the active genes were largely
unchanged except for a slight increase at Gapdh in the EZH2 KO cells. At
the Polycomb target genes the enrichment of H3K4me3 was similar in the EZH2
Y726A cells to the E14 control, with a slight increase at some genes such as Gata4
and Hoxb13. In the EZH2 KO cells there was an increase of the enrichment
of H3K4me3 found at all Polycomb target genes apart from Hoxc11. This
increase was found to be more pronounced than that seen in EZH2 Y726A
cells, apart from at Hoxb13 and Gata4. Levels of H3K4me3 detected at the
Fabp7 gene body remained negligible. Whereas the levels of H3K4me3 at active
genes remained unchanged in the EZH1/2 double mutants, the enrichment of this
histone modification was increased at the three Hox genes and Gata4 for both
EZH1/2 dKO and EZH1/2 KO/Y726A, with the biggest increases consistently
found for the EZH1/2 KO/Y726A. At the other 3 Polycomb bound genes assayed
there was also found to be an increase of H3K4me3 in both double mutants but
this increase was more modest for the EZH1/2 dKO cells at these genes. As with
the EZH2 single mutants, there was no increase in the level of H3K4me3 detected
at the Fabp7 gene body.
Overall I found that the EZH2 single mutants only underwent a small increase in
H3K4me3 deposition at Polycomb target genes, the least of which was detected
in the EZH2 Y726A with a slightly larger increase found in the EZH2 KO cells.
The EZH1/2 double mutants had a much stronger effect on levels of H3K4me3,
particularly at the Polycomb target genes which had the lowest enrichments in
the E14 control cells. While both double mutants induced an increase in this
histone modification at all the Polycomb target genes in this assay, the highest
enrichments were consistently found in the EZH1/2 KO/Y726A.
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Figure 4.4 H3K4me3 enrichment in E14 control and PRC2 mutant
mESCs. ChIP-qPCR for H3K4me3 in E14 control (WT), EZH2 Y726A (CI),
EZH2 KO, EZH1/2 KO/Y726A (KO/CI) and EZH1/2 dKO cells. Enrichments
were normalised to input, with error bars representing standard error of the mean
across three biological replicates. * denotes a significant difference to WT with a
p value of less than 0.01, and ∆ a p value of less than 0.05. Significant differences
between the mutants are indicated using brackets.
ChIP-seq experiments were additionally carried out for EZH2, H3K27me3 and
H3K4me3 in E14 control cells and all the PRC2 mutant cell lines generated in
this thesis, however time constraints have not allowed for the full analysis of the
data at this time. As such, I was not able to include any of the data from these
experiments as of August 31st 2019.
4.2.4 Analysis of RING1B binding to bivalent genes
To assess the binding of PRC1 to the Polycomb target genes in the PRC2 mutant
cell lines, I performed ChIP-qPCR using an antibody against RING1B, a subunit
of the complex that is found both in canonical and non-canonical PRC1. In the
E14 control there was a strong enrichment of RING1B at the all the Polycomb
target genes, while there was no RING1B detected at either the Fabp7 gene body
or the active genes (Fig. 4.5). In the EZH2 single mutants, RING1B enrichment
was reduced to a similar extent at all the Polycomb target genes in both EZH2
Y726A and EZH2 KO. There was however a large variation in the reduction of
RING1B by gene, from more than half lost at Hoxb13 and Gata4 to around a
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third lost at Hoxc5 and Pax3. This variation did not seem to correlate with
the variations in loss of H3K27me3 or the levels of EZH2 binding in these cell
lines. In both EZH1/2 double mutants the Polycomb target genes were completely
depleted for RING1B with the levels detected close to the background levels found
at the active genes and the gene body of Fabp7 and very little difference between
the two double mutants. This depletion of RING1B in these cell lines closely
mirrors that seen in the H3K27me3 ChIP. This experiment showed that the loss
of EZH2 alone had a modest effect on the binding of RING1B to its target genes.
This effect was greatly increased with the additional knockout of EZH1 in which
case the enrichment of RING1B at these genes was completely lost. It appeared
that the presence of a catalytically inactive form of PRC2 at these genes did not
mitigate this effect at all indicating RING1B, and thus PRC1 binding to these
sites must rely heavily on H3K27me3.
Figure 4.5 RING1B enrichment in E14 control and PRC2 mutant
mESCs. ChIP-qPCR for RING1B in E14 control (WT), EZH2 Y726A (CI),
EZH2 KO, EZH1/2 KO/Y726A (KO/CI), and EZH1/2 dKO cells. Enrichments
were normalised to input, with error bars representing standard error of the mean
across three biological replicates. * denotes a significant difference to WT with a
p value of less than 0.01, and ∆ a p value of less than 0.05. Significant differences
between the mutants are indicated using brackets.
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4.3 Conclusions
Overall the experiments in this chapter gave me a more detailed picture of
how PRC1 and PRC2 behave at Polycomb target genes and how bivalency is
maintained at these genes in mESCs. Although I found that H3K27me3 was
strongly reduced in the EZH2 single mutant cells, it was still present at some
Polycomb targets with varying abundance. This residual H3K27me3 was placed
by EZH1 and the reduced levels detected highlighted the inability of EZH1 to
compensate for the absence of EZH2 due to the reduced catalytic activity of
this subunit as compared to EZH2. The lack of H3K27me3 detected in the
EZh2 single mutants at the Fabp7 gene body may be reflective of the lower
overall catalytic activity of EZH1 as compared to EZH2, but also the much lower
sensitivity of this subunit to allosteric activation mediated by Jarid2 and EED,
which for the EZH2 subunit allows for spreading of H3K27me3 from the initial
site of deposition (Margueron et al., 2008; Margueron et al., 2009; Son et al.,
2013; Lee et al., 2018; Oksuz et al., 2018). The complete loss of H3K27me3 that
was observed in the EZH1/2 double mutants further confirmed that the residual
H3K27me3 detected in the EZH2 single mutants is the work of EZH1 as the
additional loss of this abolished all signal for H3K27me3.
The levels of EZH2 binding at Polycomb target genes detected in the EZH2
Y726A and EZH1/2 KO/Y726A showed that, although H3K27me3 did appear to
increase the affinity of EZH2 for its targets, EZH2-PRC2 was still able to bind
to chromatin even in the total absence of the histone mark. This has recently
been confirmed by another study in which the same residue is mutated in the set
domain of EZH2 as in our EZH2 Y726A (Lavarone et al., 2019).
Interestingly although both the EZH2 KO and EZH1/2 dKO cell lines had
undetectable levels of EZH2 by Western blot there was a difference in the levels
of EZH2 detected by ChIP in these cell lines. Although it was much reduced as
compared to the E14 control, the binding of EZH2 found in the EZH2 single KO
was higher than that found in the EZH1/2 dKO in almost every gene assayed.
It is possible that there may be some cross-reactivity between EZH2 and EZH1
for this antibody that could explain the low residual signal detected in the EZH2
single KO. The peptide used to produce the antibody used in this experiment was
stated as being a fragment around Arg354 of EZH2. Although there are many
differences in the protein sequence between EZH1 and EZH2 around this amino
acid it is not the most divergent part of the protein and so does not exclude the
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possibility of some cross-reactivity between the two paralogues.
I found that in all PRC2 mutants assayed in this chapter, there was an increase
in the abundance of H3K4me3 at Polycomb target genes irrespective of the level
of H3K4me3 at these genes in the E14 control. The increase in H3K4me3 was
found to be much more substantial in the EZH1/2 double mutant cells than
the EZH2 single mutants, indicating that residual H3K27me3 at the Polycomb
target genes is required for the inhibition of the deposition of tri-methylation
at H3K4. Interestingly the increase in H3K4me3 seen in the EZH1/2 double
mutants seems to be stronger in the EZH1/2 KO/Y726A even though PRC2
is still bound to these genes. This might indicate a stimulatory effect on the
deposition of H3K4me3 by the presence of PRC2. This effect could contribute
to the establishment of bivalent domains, allowing H3K4me3 to be deposited on
chromatin that carries a repressive signature.
The low enrichments of RING1B at Polycomb genes in the EZH1/2 double
mutants was surprising given that it is known to be able to be recruited
independently of PRC2 as part of variant PRC1 complexes. It appears that
at the Polycomb bound genes assayed in these experiments, the main mode of
recruitment for PRC1 is via its binding to the H3K27me3 deposited by PRC2,





Role of Polycomb in the 3D organ-
isation of the Lhx5 gene
5.1 Introduction and aims
Polycomb repressive complexes have been shown in many studies to be involved
in long range chromatin contacts. Polycomb targeted genes are known to cluster
together in the nucleus, both in Drosophila (Bantignies et al., 2003; Bantignies
et al., 2011; Tolhuis et al., 2011), and in mammalian ESCs (Denholtz et al., 2013;
Vieux-Rochas et al., 2015), with a higher enrichment of H3K27me3 increasing
the frequency of long-range contacts detected (Vieux-Rochas et al., 2015). These
contacts between Polycomb target genes were found to be dependent on the
PRC2 complex in mESCs, as the knockout of the EED subunit led to their
dissociation (Denholtz et al., 2013; Joshi et al., 2015). This depletion of the PRC2
complex did not affect TAD structure in these cells suggesting that Polycomb
mediated contacts and TADs are established independently from each other (Nora
et al., 2012). In embryonic carcinoma cells, the Gata4 gene, a Polycomb target,
was found to have interactions with several distal regions through a multi-loop
chromatin structure that kept this gene in a transcriptionally inactive state, and
this chromatin structure was dependent on the presence of EZH2 (Tiwari et al.,
2008b). It was recently found that PRC2 is involved in additional chromatin
looping events that mediate the contact of enhancers and promoters of poised
genes, and are lost in the absence of the EED subunit (Rada-Iglesias et al.,
2011; Cruz-Molina et al., 2017). This looping occurs in ESCs at a stage when
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these genes are not yet expressed. Upon differentiation of these cells towards
the neural lineage, it was found that the PRC2-dependent contact of enhancers
and promoters in ESCs was required for the timely expression of certain genes
necessary for the transition of pluripotent cells into neural progenitors.
It has been shown in vitro that PRC2 is able to form a dimeric structure by
associating with itself (Wu et al., 2013; Davidovich et al., 2014). These structures
have been found to be able to take the form of homodimers containing either 2
copies of EZH1 or of EZH2, or heterodimers containing one copy each of both
EZH1 and EZH2. It has been suggested that this dimeric state may be involved
in recruiting PRC2 to its targets as well as serving as an additional layer of
regulation that would depend on the relative levels of EZH1 and EZH2 in cells.
It is also conceivable that this dimerisation may play a role in mediating the
PRC2 dependent contacts formed at Polycomb domains.
Although the existence of PRC2-dependent contacts has now been demonstrated
in several studies, it remains unclear whether they are directly mediated by PRC2
itself. As PRC1 has been shown to mediate the majority of local and long-
range contacts between Polycomb targets (Shao et al., 1999; Francis et al., 2004;
Eskeland et al., 2010; Kondo et al., 2014; Schoenfelder et al., 2015), it is likely
that this is also the case at these sites that were found to be PRC2 dependent. In
this case, the essential role played by PRC2 in the establishment of these contacts
would be to enable the recruitment of PRC1.
I aimed to determine what effect the PRC2 mutants generated for this thesis
might have on the contacts in which PRC2 is involved. I hypothesised that
the catalytically inactive EZH2 may be able to retain some of PRC2’s roles in
mediating chromatin contacts, perhaps through its dimerisation or interaction
with other proteins, which would then be lost when this protein is knocked out.
To address this question, I probed the state of contacts at a gene that is known
to be a Polycomb target. For this I made use of all of the PRC2 mutant cell
lines as well as two PRC1 mutant cell lines and an EED KO cell line. The
approach I used in this chapter was fluorescence in situ hybridisation, or FISH.
This method allows for the marking of two or more loci in a cell by hybridisation
with fluorescently labelled probes, which in turn allows the distance between the
loci to be measured. Through this technique it is possible to determine whether
two loci are co-localising or not.
To assess the role played by PRC2 in mediating chromatin contacts I decided to
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focus on a contact that has already been shown to depend on the presence of
PRC2. For this purpose I chose the Lhx5 gene. This is a developmental gene
involved in differentiation towards the neural lineage and is a bivalent Polycomb
target in mESCs. The enhancer of this gene also carries a bivalent signature and
in mESCs, is in physical contact with its promoter (Cruz-Molina et al., 2017).
The contact of these two elements was shown to be dependent on the PRC2
complex, however this study did not discern between the presence of the complex
itself and the presence of the trimethylated H3K27.
By comparing the distances between the enhancer and promoter of this gene in
the E14 control cells against those measured in the PRC2 mutant as well as PRC1
mutant cells, I sought to begin elucidating the mechanism by which the PRC2
complex mediates these chromatin contacts.
The ChIP-qPCR and FISH experiments in this chapter were performed with
the help of Giulia Bartolomucci under my direction with advice from Katy
McLaughlin.
5.2 Generation and initial characterisation of
mESCs expressing a H3K27me3-binding de-
ficient CBX7
In addition to the PRC2 mutant cell lines described in the preceding chapters,
I also used two PRC1 mutant cell lines for the experiments in this chapter.
The RING1B KO cells were generated in the Bickmore lab in 2015 (Illingworth
et al., 2015). The CBX7 F11A mutant was generated in the Voigt lab using
CRISPR Cas9 (see Fig. 5.1 for CRISPR targeting strategy used). The mutations
incorporated in this cell line aimed to block the ability of this protein to bind to
the H3K27me3 mark deposited by PRC2.
This CBX subunit was chosen in particular as it has been shown to be the
most highly expressed of all CBX proteins in mESCs and is entirely dependent
on H3K27me3 for its recruitment to chromatin (Morey et al., 2012). The
phenylalanine 11 residue resides within the highly conserved chromodomain of
CBX7 and its mutation to an alanine has been shown to disrupt its binding to
chromatin (Li et al., 2010).
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Figure 5.1 Design of CBX7 F11A CRISPR targeting strategy.
Alignment of E14 Wild-type sequence of exon 1 of Cbx7 gene with the ssODN
designed to induce CBX7 F11A mutations (uppercase is exonic sequence, lowercase
is intronic). gRNA hybridisation site and PAM sequence are labelled, Cas9 cut
site is indicated with scissors. Point mutations in ssODN are indicated by red
asterisks (lowercase in red), in frame stop codons are labelled.
Before using these cell lines in the FISH experiments I first sought to assess their
effect on the levels of H3K27me3 and PRC1 at Polycomb targets. As can be
seen in Fig. 5.2A, there was an enrichment of H3K27me3 detected at Polycomb
targets Hoxc5 and Fzd1, as well as at both the enhancer and promoter of the Lhx5
gene. Neither the RING1B KO nor the mutation of the CBX7 protein altered the
enrichment of the H3K27me3 mark at the control Polycomb target genes Hoxc5
and Fzd1, nor was there any change at the enhancer or promoter of Lhx5. I next
sought to determine how the binding of RING1B was affected at these loci. As
shown in Fig. 5.2B, I found that although RING1B was enriched at both Hoxc5
and Fzd1, it was only detected at the promoter of Lhx5 but not its enhancer in
the E14 control cells. This enrichment of RING1B was strongly depleted in both
the RING1B KO and CBX7 F11A cell lines. These ChIP experiments showed
that although the mutations in both the RING1B KO and the CBX7 F11A cells
led to a massive loss of PRC1 binding to the genes assayed, this did not have a
great effect on the activity of PRC2 at these sites, as evidenced by the unaffected
levels of H3K27me3 detected. These results also demonstrated that H3K27me3
binding by CBX7 appears to be the major determinant of PRC1 recruitment to
these sites.
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Figure 5.2 H3K27me3 and RING1B enrichments in E14 control and
PRC1 mutant mESCs. A. ChIP-qPCR for H3K27me3 in E14 control (E14
WT), RING1B KO and CBX7 F11A cells. B. ChIP-qPCR for RING1B in
E14 control(E14 WT), RING1B KO and CBX7 F11A cells. Enrichments were
normalised to input. Results from one experiment shown.
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5.3 FISH experimental design
The fluorescently labelled probes used for the experiments in this chapter were
designed to hybridise to the enhancer and the promoter of the Lhx5 gene.
These sites also corresponded to regions that were marked by an enrichment
of H3K27me3 as was observed by ChIP-seq (see Fig. 5.3 and Cruz-Molina et
al., 2017). A control probe was designed to hybridise to a region downstream of
Lhx5 that was an equal distance from the promoter probe as the enhancer probe.
This region has no Polycomb enrichment and therefore its position relative to the
promoter, although the same distance from the promoter as the enhancer, was
not expected to be affected in the Polycomb mutant cell lines.
Figure 5.3 Position of probes used in Lhx5 FISH experiments.
Schematic showing the position of probes corresponding to enhancer and promoter
of Lhx5 as well as equidistant control probe, relative to Lhx5 location. Lower track
shows H3K27me3 enrichments across this region (ENCODE)
5.4 Analysis of a PRC2 dependent enhancer-
promoter contact - Lhx5 locus
The results of the FISH analysis are shown in Fig. 5.5. In the EZH2 single mutant
cell lines there was not an increased distance between the probes corresponding to
the enhancer and the promoter of the Lhx5 gene as compared to the E14 control
cells. For the EZH2 KO cells however there even appeared to be a decrease in
the interprobe distance as compared to the control. An additional observation
that was made for the EZH2 single mutant cell lines was the broader variation of
individual values for the measured interprobe distances.
In the EZH1/2 dKO cells the average interprobe distance was significantly
increased as compared to the E14 control, indicating a reduced propensity for
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contacts between the enhancer and promoter of Lhx5 to form in these cells. A
comparable increase in the interprobe distance was also observed in the EED KO
cell line (Fig. 5.5A). This increased spacing between the enhancer and promoter
of Lhx5 in these two cell lines further confirmed the findings from the Cruz-Molina
2017 paper that this contact at this locus in mESCs is disrupted upon depletion
of PRC2.
I next assessed the enhancer-promoter contact at this same locus in two
PRC1 mutant cell lines. In the RING1B KO there was an increase in the
interprobe distance as compared to the E14 control cells (although just below the
threshold for significance), suggesting that the PRC1 complex was also involved
in establishing the contact between these elements. An increase in the interprobe
distance was also observed in the CBX7 F11A cells (Fig. 5.5A). This result
showed that H3K27me3 was essential for the recruitment of canonical PRC1 to
this locus and the formation of the enhancer-promoter contact.
There was no significant difference observed in the distance between the promoter
and control probes in any of the cell lines analysed as compared to the E14
control (Fig. 5.5B). Overall these experiments suggest that the contact between
the poised enhancer and promoter of the Lhx5 gene required the contribution of
both the PRC2 and PRC1 complexes.
Figure 5.4 Lhx5 enhancer and promoter probe hybridisation in
mESCs. Representative images of probe hybridisation signal (shown in green
and red) for the Lhx5 locus in E14 control and EED KO cells. DAPI counterstain
is shown in blue.
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Figure 5.5 FISH analysis of Lhx5 enhancer-promoter contact in E14
control and PRC1 and PRC2 mutant mESCs. A. Boxplot showing
the distribution of distances between Lhx5 promoter and Lhx5 enhancer probe
hybridisation signals in E14 control, EZH2 Y726A, EZH2 KO, EZH1/2 dKO,
EED KO, CBX7 F11A and RING1B KO cell lines. Significant differences (p
value ≤0.05) as determined by a Kruskal-Wallis test followed by a Mann-Whitney
test, are marked by an asterisk. B. Boxplot showing average distance measured
between probes corresponding to Lhx5 promoter and control locus in E14 control
(E14 WT), EZH2 Y726A, EZH2 KO, EZH1/2 dKO, CBX7 F11A and RING1B
KO cell lines.
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5.5 Lhx5 expression in mESCs
As will be described in detail in chapter 6, I performed RNA-seq on both the
E14 control and the EZH2 single and EZH1/2 double mutant cell lines. I used
this data to further investigate the state of the Lhx5 locus. As can be seen in
Fig. 5.6, very little transcription was detected across the Lhx5 gene in the E14
control cells, as is expected of a gene involved in neuronal development in this
undifferentiated cell type. In the EZH2 Y726A cells the levels of transcription
appeared similar to those detected in the E14 control cells, while in the EZH2
KO cells, there seemed to be a slight decrease in the level of transcripts detected
across Lhx5. For both of the EZH1/2 double mutant cell lines there was a marked
increase in transcription of this gene, with this increase being marginally larger
in the EZH1/2 dKO cells, indicating derepression of the gene in complete absence
of PRC2 activity.
Figure 5.6 RNA-seq reads detected across the Lhx5 gene in E14
control and PRC2 mutant cell lines. Screenshot of the IGV genome browser
tool. RNA-seq tracks for E14 control (E14 WT), EZH2 Y726A, EZH2 KO, EZH1/2
KO/Y726A and EZH1/2 dKO were aligned with the mm10 version of the mouse
genome assembly to display reads detected for the Lhx5 gene. Tracks shown are
representative of one of three replicates.
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5.6 Conclusions
Taken together, the preliminary results in this chapter indicate that the enhancer-
promoter contact at the Lhx5 gene, although dependent on the presence of PRC2,
appears to require this complex in order to recruit the PRC1 complex which is
likely to be the direct mediator of compaction. The loss of PRC2 from cells in
the EZH1/2 dKO and EED KO backgrounds, as well as the loss of PRC1 binding
seen in the RING1B KO and CBX7 F11A cells, both led to an increase in the
distance between the Lhx5 enhancer and promoter probes, demonstrating that
both complexes were required for the maintenance of this contact. Furthermore,
the depletion of PRC2 in the EZH1/2 dKO cells led to a loss of PRC1 binding to
Polycomb targets (see chapter 4), but the depletion of PRC1 from its targets in
the RING1B KO and CBX7 F11A cells did not result in a loss of H3K27me3 from
these sites. We can presume that PRC2 was also maintained at these loci in the
absence of PRC1, but further ChIP experiments probing for EZH2 or other core
subunits of PRC2 would be required. We can then conclude from this that, while
PRC2 is required for the contact between the Lhx5 enhancer and promoter, this
complex alone cannot directly enable it, but rather acts through the recruitment
of PRC1, via the H3K27me3 mark, to this site. PRC1 is then itself able to mediate
the contact, likely through the action of its PHC subunit which can enable this
type of interaction through the oligomerisation of its SAM domain (Isono et al.,
2013; Kundu et al., 2017). This is in accord with the finding of Tiwari et al. that
the losses of contacts between two given sites observed following the depletion
of EZH2 correlated more strongly with the degree of H3K27me3 depletion than
with the loss of EZH2 at these same sites (Tiwari et al., 2008b). The results from
the CBX7 F11A cells indicated that CBX7 plays a major role in the recruitment
of PRC1 to these sites and further stressed the importance of H3K27me3 in this
recruitment. It remains to be determined whether the presence of H3K27me3 is
sufficient for the establishment of the contact between the enhancer and promoter
of Lhx5, or whether the additional presence of the PRC2 complex itself at these
sites is also required.
I found that the presence of EZH1 alone appears to be sufficient to maintain
the enhancer-promoter contact. This correlates with the results from chapter
4 in which I observed that in the EZH2 single mutant cell lines, the majority
of RING1B was maintained at Polycomb genes as opposed to the complete loss
that occurred in the EZH1/2 double mutant cells. Together these results further
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demonstrate that in mESCs, very low levels of H3K27me3 appear to be sufficient
to maintain the majority of PRC2 function.
Surprisingly, in the EZH2 KO cells I found that the interprobe distance was
actually decreased as compared to the E14 control. This may be due to the
presence of EZH1 which is known to have a chromatin compaction activity that
EZH2 does not possess (Margueron et al., 2008). In the EZH2 KO cells, as there
is no EZH2-PRC2 present, there may be an increased binding of EZH1 as this site
which could then lead to an even more condensed state than was observed in the
E14 control. This may not have been observed in the EZH2 Y726A cells as the
EZH2-PRC2 species is maintained and bound to Polycomb targets, preventing an
increase in the binding of EZH1. As was shown by the RNA-seq data across the
Lhx5 locus, there was a derepression of this gene only in the case of the EZH1/2
double mutant cells. In the EZH2 KO there was a slight decrease in the level of
transcription detected, which could be a reflection of the more condensed state
that was found at this locus in the FISH experiment. This suggests that EZH2
may play a role in prohibiting an overly compact state of the genes it binds.
As previously stated, the work in this chapter is preliminary and experiments such
as the ChIP-qPCR for H3K27me3 and RING1B need to be repeated and the FISH
experiments performed in additional clones as well as in the EZH1/2 KO/Y726A
cells. In the longer term additional individual contacts will be analysed by FISH




Gene expression in PRC2 mutant
mESCs
6.1 Introduction and aims
In previous studies it has been shown that although a knockout of EZH2 results in
massive loss of H3K27me3 from all PRC2 targets and depletion of PRC2 binding
to chromatin, this does not result in a strong phenotype at the level of gene
expression (Chamberlain et al., 2008; Riising et al., 2014; Shen et al., 2008).
Although it might be expected that the loss of this repressive chromatin signature
at Polycomb target genes would lead to their upregulation, that appears not to be
the case for the vast majority of genes. Derepression of these genes has only been
found to occur in a situation where the PRC2 complex is completely disrupted,
for instance by knockout of the core subunits EED or SUZ12 (Pasini et al., 2007;
Chamberlain et al., 2008; Shen et al., 2008). Perhaps reflecting these moderate
changes in gene expression, neither EZH2 knockout nor SUZ12 or EED knockout
leads to any defects in self-renewal or viability in mESCs (Pasini et al., 2007;
Chamberlain et al., 2008; Shen et al., 2008).
Although EZH1 and EZH2 have quite different expression profiles and have
differing enzymatic activity towards H3K27 (Bracken, 2003; Margueron et al.,
2008), it has been shown that there is a certain redundancy between these two
subunits at least in ESCs. As has been shown in previous studies (in agreement
with the ChIP-seq experiments from chapter 4) in the absence of EZH2, EZH1 is
able to place H3K27me3 at most PRC2 targets albeit at a much lower level and
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a narrower distribution across the target sites.
The aim of the work described in this chapter was to obtain a comprehensive
view of how the different mutations of PRC2 affect gene expression in mESCs and
to determine how these changes relate to Polycomb occupancy and abundance
of H3K27me3 and H3K3me3 at these genes by comparison to ChIP-seq data.
Although we expected only minor changes in gene expression in the EZH2
single mutants compared to E14 control cells based on previous work, there
may be differences between the EZH2 KO and EZH2 Y726A. The greatest
changes in expression should be observed in the EZH1/2 double mutants as it
has been shown previously that complete loss of PRC2 and H3K27me3 leads
to significant upregulation of Polycomb genes (Pasini et al., 2007; Chamberlain
et al., 2008; Shen et al., 2008). Here, I was interested to see if the maintenance
of a catalytically inactive PRC2 bound to genes could maintain some extent of
repression of Polycomb genes, either genome-wide or on a subset of genes affected.
The immunofluorescence staining of cells in this chapter was performed with the
help of Katy McLaughlin. The quality control and processing of RNA-seq raw
data was performed under my direction by Shaun Webb.
6.1.1 Expression of pluripotency factors
I first aimed to determine the expression patterns of a known pluripotency factor
in the PRC2 mutant cell lines to provide some insight into the ”stemness” of these
cell lines. The intention was to verify that any changes in gene expression observed
in the following experiments were not caused by cells exiting pluripotency and
exhibiting characteristics of early stages of differentiation. All mutant cell lines
were stained for OCT4 as well as expression of TUJ1, a neuron-specific beta-
tubulin, often used as a neuronal marker gene and not expected to be expressed
in undifferentiated ESCs. As can be seen in Fig. 6.1, there were no striking
changes in the expression pattern of Oct4 in any of the mutants as compared
to the E14 control. Similarly, there was no obvious increase in the expression of
Tuj1. RT-qPCR analysis of the expression of Oct4 and Nanog in all cell lines,
as seen in Fig. 6.2, similarly showed that there was no strong downregulation of
either of these genes in any of the PRC2 mutants relative to the E14 control. This
is consistent with previous studies in which similar mutations of PRC2 did not
have a significant effect on the expression of pluripotency factors (Pasini et al.,
2007; Shen et al., 2008).
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Figure 6.1 Immunofluorescence analysis of Oct4 and Tuj1 expression
in E14 control, EZH2 single and EZH1/2 double mutant mESCs. DAPI
(far left) OCT4 (left) and TUJ1 (right) staining of E14 control, EZH2 Y726A,
EZH2 KO, EZH1/2 KO/Y726A and EZH1/2 dKO ESCs. Merge is shown in
panels on far right, DAPI in cyan, OCT4 in green and TUJ1 in magenta. Scale
bar corresponds to 100 µm.
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Figure 6.2 Expression of pluripotency factors Oct4 and Nanog in
EZH2 single and EZH1/2 double mutants. Bar chart showing expression of
Oct4 and Nanog relative to E14 control. Data was generated by RT-qPCR and
normalised to expression of Gapdh. Plotted are the mean and standard error of
the mean (SEM) across 3 biological replicates.
6.1.2 Expression of select Polycomb genes
To assess the expression of a selection of known Polycomb target genes I
performed RT-qPCR on cDNA samples from E14 control ESCs and both EZH2
single and EZH1/2 double mutants. As can be seen in Fig. 6.3 for all but one
genes tested there was a modest but detectable increase in expression for every
mutant cell line. This increase was of a similar amount at each gene for the
EZH2 single mutants, with little consistent difference detected between EZH2
KO and EZH2 Y726A. Overall, the increase in expression of the genes analysed
was stronger for the EZH1/2 double mutants than for the EZH2 single mutants.
This increase was also more variable gene to gene in the double mutants with the
foldchange in expression of Hoxb13 found to be nearly 4 times higher than that of
Meis2. Interestingly, the EZH1/2 KO/Y726A mutant was found to express all of
the genes assayed (with the exception of HoxB13 ) to a much higher level than the
EZH1/2 dKO which displayed a gene expression pattern much closer to that of
the EZH2 single mutants. Overall, these results showed that the EZH1/2 double
mutants exhibited stronger derepression of the Polycomb target genes tested than
the EZH2 single mutants, with the EZH1/2 KO/Y726A mutant appearing to
induce the strongest upregulation of these genes. Interestingly however, I found
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that not all Polycomb target genes were derepressed in the double mutants, as
silencing of Pax6 was maintained in all cell lines tested.
Figure 6.3 Expression of Polycomb target genes in EZH2 single and
EZH1/2 double mutants. Bar chart showing expression of known Polycomb
target genes in EZH2 Y726A (CI), EZH2 KO, EZH1/2 KO/Y726A (KO/CI) and
EZH1/2 dKO cells relative to E14 control. Data was generated by RT-qPCR
and normalised to expression of Gapdh. Plotted are the mean and SEM across 3
biological replicates. * denotes a significant difference to WT with a p value of
less than 0.01, and ∆ a p value of less than 0.05.
6.1.3 RNA-seq analysis of gene expression in Polycomb
mutants
After having established that the EZH2 and EZH1 mutation affect expression
for Polycomb target genes, I performed RNA-seq to assess genome-wide effects
on gene expression of the EZH1 and EZH2 mutations. I chose to use three
independent clones of each genotype as replicates for these experiments in order
to account for any clonal variation in gene expression. Before I was able to move
forward with the analysis, a rigorous quality control was performed on the raw
data. All samples were found to have between 20 and 40 million unique reads and
were tested for, among others, GC bias, overall base composition, read length,
and adaptor contamination. Once each sample was confirmed to be of acceptable
quality based on each of these criteria, the reads were mapped to the mouse
genome. For all samples the percentage of uniquely mapped reads was between
60 and 85% and these were again, screened for the same set of criteria as the raw
83
data. With the quality control complete and all samples passing the threshold
that was set, I was confident in moving onto the analysis of gene expression in
each cell line.
6.1.4 Global changes in gene expression
As can be seen in Fig. 6.4 and 6.5, the trends in gene expression changes between
E14 control and EZH1/2 mutant ESCs that I observed by RT-qPCR were reflected
in the gene expression patterns genome wide. Very few genes were differentially
expressed in either of the EZH2 single mutant cells, with approximately 0.3% of all
protein coding genes found to be significantly up- or downregulated as compared
to the E14 control. Of these 70 or so differentially expressed genes in the EZH2
single mutants, surprisingly, the majority were downregulated relative to the E14
control. In the EZH1/2 double mutants, as expected, a much higher proportion
of genes was differentially expressed. Expression of around 10% of all protein
coding genes was misregulated in EZH1/2 KO/Y726A cells, slightly fewer than
in the EZH1/2 dKO cells in which this rose to 13%. In EZH1/2 KO/Y726A cells
a greater number of genes was upregulated than downregulated. This was also
true for the EZH1/2 dKO cell lines, although in these cells there were around 300
more genes misregulated than in the EZH1/2 KO/Y726A. In addition, I found
that EZH1/2 dKO cell lines had nearly 1.5 times as many genes upregulated by
more than a log(2) foldchange of 1 (i.e. upregulated by more than 2 fold) than
the EZH1/2 KO/Y726A.
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Figure 6.4 Differential gene expression in EZH2 single mutant mESCs.
Pie charts representing expression of all protein coding genes in EZH2 Y726A and
EZH2 KO cell lines relative to E14 control. Genes significantly upregulated are
shown in shades of yellow, genes significantly downregulated are shown in shade
of blue. Darker shades correspond to genes differentially expressed by more than
a log(2) foldchange of 1 or -1 over E14 control. For this and all subsequent figures
presenting RNA-seq data, data is derived from analysis of three independent cell
lines per genotype.
Figure 6.5 Differential gene expression in EZH1/2 double mutant
mESCs. Pie charts representing expression of all protein coding genes in EZH1/2
KO/Y726A and EZH1/2 dKO cell lines relative to E14 control. Genes significantly
upregulated are shown in shades of yellow, genes significantly downregulated are
shown in shade of blue. Darker shades correspond to genes differentially expressed
by more than a log(2) foldchange of 1 or -1 over E14 control.
6.1.5 Gene expression changes in EZH2 Y726A and EZH2
KO cell lines
As was shown in Fig. 6.4, both EZH2 Y726A and EZH2 KO cell lines misregulated
a similar number of genes as compared to the E14 control. I found however, that
of these genes, only around half were common to both cell lines (Fig. 6.7A). These
35 genes were found to be expressed in a very similar manner in both EZH2 KO
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and EZH2 Y726A cell lines, being either up- or downregulated by approximately
the same factor in each mutant cell line relative to the E14 control. For the
genes that were found to only be significantly differentially expressed in one or
the other cell line, changes in gene expression still followed the same trend and
were comparable between the two mutants when this was plotted according to
log(2) foldchange relative to the E14 control, but only satisfying the criteria for
significance in one but not the other genetic background (Fig. 6.6).
Figure 6.6 Comparison of differentially expressed genes in EZH2 single
mutant mESCs. Log(2) foldchange in expression over E14 control in both EZH2
single mutant cell lines of genes for which the threshold of significance was only
reached in one of the mutants.
To shed some light on the function of the genes that were found to be differentially
expressed in the mutant cell lines I performed gene ontology (GO) analysis (Fig.
6.7B). In line with only a small number of genes being significantly upregulated
in the EZH2 single mutant cell lines, very few GO terms were found to be
significantly enriched amongst these genes. Only the Sgk3 homodimer complex
was found to be enriched amongst the genes upregulated in both single mutants.
This is a protein kinase activated by phosphorylation by 3-phosphoinositide-
dependent protein kinase-1 (PDK1) (Kobayashi et al., 1999), and has been
associated with cell proliferation and cancer cell survival (Basnet et al., 2018).
However it should be noted that the tumour suppressor gene Cdkn2a which is
associated with senescence, was also upregulated in both cell lines as has been
previously described both in EED KO and SUZ12 KO cell lines (Bracken et al.,
2007; Shen et al., 2008; Lowe and Sherr, 2003).
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Figure 6.7 Gene ontology of differentially expressed genes in EZH2
single mutant mESCs. A. Venn diagram of genes differentially expressed in
EZH2 Y726A and EZH2 KO cells. B. GO terms enriched in genes significantly
upregulated (yellow) and downregulated (blue) in EZH2 Y726A and EZH2 KO
mESCs relative to E14 control.
Amongst the genes that were found to be downregulated there was little overlap
between GO terms enriched for EZH2 Y726A and EZH2 KO cell lines. In the
EZH2 Y726A cell line there was an enrichment of genes with binding motifs for a
few different transcription factors (TF), which were not significantly enriched in
the EZH2 KO. Both EZH2 single mutants did however significantly downregulate
genes associated with the lateral element and synaptonemal complex, a protein
structure present between sister chromatids during prophase of meiosis (Heyting,
1996). The EZH2 KO was found to additionally downregulate genes associated
with morphological abnormalities and defects in growth of certain body parts
such as abnormality of the ribs and of the abdominal wall. Genes which were
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common to all of these GO terms to do with body abnormalities were Col1a1
and Col1a2, both encoding alpha chains of type I collagen. Taken together, these
results did not suggest a great difference in the effects on gene expression between
the catalytically inactive form of EZH2 and the EZH2 KO.
6.1.6 Gene expression changes in EZH1/2 KO/Y726A and
EZH1/2 dKO cell lines
Similarly to what I observed in the EZH2 single mutant cell lines, I found that a
considerable number of the differentially expressed genes in the EZH1/2 double
mutant cell lines were shared between both genotypes. In the EZH1/2 KO/Y726A
cells about two thirds of all differentially expressed genes were also affected in
EZH1/2 dKO (Fig. 6.11A). In the EZH1/2 dKO cells, however, more than half
of the genes differentially expressed were not significantly affected in the EZH1/2
KO/Y726A.
As with the EZH2 single mutant cell lines, I performed GO term analysis to
gain some insight into the function of the deferentially expressed genes (Fig. 6.8
and Fig. 6.9). Analysis of the transcription factor motifs enriched amongst the
differentially expressed genes was also performed to provide further information
on their regulation, for instance to clarify whether any transcription factors that
are direct PRC2 targets could be responsible for the changes in expression of a
significant portion of the genes misregulated. This analysis could also be helpful
in identifying common traits in the regulatory regions of the genes affected, and
possibly shed light on major regulatory pathways influencing the expression of
these genes.
In both double mutant backgrounds, there was a strong enrichment in the
upregulated genes for terms related to embryo development, body patterning and
cell fate commitment, all terms that are also strongly enriched amongst known
Polycomb target genes. In addition, I found that in the EZH1/2 dKO many of
the genes upregulated contained TF binding motifs that were often quite CG
rich (Fig. 6.10), a well-known hallmark of Polycomb bound genes. As for the
downregulated genes, there were fewer enriched GO terms identified in EZH1/2
KO/Y726A than in EZH1/2 dKO cells (Fig. 6.8 and Fig. 6.9). No specific
biological processes were found to be downregulated in the EZH1/2 KO/Y726A,
and only a few TF binding motifs that had little sequence homology were
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Figure 6.8 Gene ontology of differentially expressed genes in EZH1/2
KO/Y726A mESCs. GO terms enriched in genes significantly upregulated
(yellow) and downregulated (blue) in EZH1/2 KO/Y726A mESCs relative to E14
control.
Figure 6.9 Gene ontology of differentially expressed genes in EZH1/2
dKO mESCs. GO terms enriched in genes significantly upregulated (yellow) and
downregulated (blue) in EZH1/2 dKO mESCs relative to E14 control.
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identified, some of which were also found in the single EZH2 Y726A background.
In the EZH1/2 dKO cells, however, there was an enrichment of downregulated
genes associated with gene expression and the metabolism of RNA and several
other biological compounds. There were also many transcription factor binding
motifs associated with the downregulated genes in EZH1/2 dKO cells, notably
motifs for the binding of YY1, a transcription factor which had initially been
associated with PRC2 recruitment (O’Carroll et al., 2001), but has since been
shown to have no direct interaction with PRC2 (Sarma et al., 2008).
Figure 6.10 Enrichment of transcription factor binding sites in
differentially expressed genes in EZH1/2 dKO mESCs. Transcription
factor binding motifs enriched in genes significantly upregulated (yellow) and down
regulated (blue) in EZH1/2 dKO mESCs relative to E14 control.
Although I found that a significant number of genes were uniquely differentially
expressed in one or the other double mutant cell line when compared to
control E14 ESCs, only a small number of genes was significantly differentially
expressed when directly comparing gene expression between the two double
mutant backgrounds (Fig. 6.11B). Of this group an equivalent number were
upregulated and downregulated in the EZH1/2 dKO as compared to the EZH1/2
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KO/Y726A, however a greater number of genes were found to be upregulated by
a factor of more than 1 than were downregulated by this same factor. The GO
term analysis of these genes only revealed a downregulation of genes enriched
for binding motifs of the YY1 transcription factor in the EZH1/2 dKO over the
EZH1/2 KO/Y726A cells (Fig. 6.11C). The expression of YY1 however was
not found to be significantly different between the 2 double mutant cell lines,
suggesting that the effects on genes which have a binding site for this factor may
be down to changes in the recruitment of this factor rather than a decrease in its
abundance.
Figure 6.11 Comparison of gene expression between EZH1/2
KO/Y726A and EZH1/2 dKO mESCs. (A.) Venn diagram representing
overlap of genes differentially expressed in EZH1/2 KO/Y726A and EZH1/2
dKO mESCs. (B.) Pie chart representing expression of all protein coding genes
in EZH1/2 dKO relative to EZH1/2 KO/Y726A mESCs. Genes significantly
upregulated in dKO cells are shown in shades of yellow, genes significantly
downregulated are shown in shade of blue. Darker shades correspond to genes
differentially expressed by more than a log(2) foldchange of 1 or -1 over EZH1/2
KO/Y726A cells. (C.) GO terms enriched in genes significantly downregulated in
EZH1/2 dKO relative to EZH1/2 KO/Y726A mESCs.
I next analysed the expression profiles of selected known Polycomb targets,
initially focusing on the Hox genes. Hox genes are developmental genes that
play roles at several different stages of development both in Drosophila and in
vertebrates, and have been shown to be very strongly enriched for H3K27me3
and Polycomb group proteins across broad domains in ESCs (Duboule and
Dollé, 1989; Boyer et al., 2006; Zhao et al., 2007). In both EZH1/2 double
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mutant backgrounds I found that the vast majority of Hox genes was significantly
upregulated compared to the E14 control (Fig. 6.12). The derepression observed
was very similar between EZH1/2 KO/Y726A and EZH1/2 dKO cells for all
significantly differentially expressed Hox genes. In the EZH2 single mutant cells,
however, none of these genes were significantly upregulated, nor was there any
similar trends of gene expression to that seen in the double mutant cell lines (Fig.
6.13), suggesting that repression of Hox genes can be maintained in the absence
Figure 6.12 Upregulation of Hox genes in EZH1/2 double mutant
mESCs. Log(2) foldchange of expression of Hox genes in EZH1/2 KO/Y726A and
EZH1/2 dKO backgrounds relative to E14 control. Error bars represent standard
error of Log(2) foldchange. Genes significantly differentially expressed (p value
≤0.05) are marked by an asterisk, pink for EZH1/2 KO/Y726A and blue for
EZH1/2 dKO cells.
Figure 6.13 Upregulation of Hox genes in EZH2 single mutant mESCs.
Log(2) foldchange of expression of Hox genes in EZH2 Y726A and EZH2 KO
mESCs relative to E14 control. Error bars represent standard error of Log(2)
foldchange. Of these genes none were found to be significantly differentially
expressed in these cell lines.
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of EZH2 but not both EZH2 and EZH1.
A similar behaviour was observed in the double mutant cells when I analysed
differential expression of around 40 Polycomb target genes featuring CGIs of
varying lengths in proximity to their TSS and a range of levels of H3K27me3
enrichments (based on published data), shown in Fig. 6.14. As was seen with the
Hox genes, the log(2) foldchange of these genes generally correlated well between
the EZH1/2 KO/Y726A and the EZH1/2 dKO cell lines.
Figure 6.14 Upregulation of Polycomb target genes in EZH1/2 double
mutant mESCs. Log(2) foldchange of expression of Polycomb target genes in
EZH1/2 KO/Y726A and EZH1/2 dKO mESCs relative to E14 control. Error bars
represent standard error of Log(2) foldchange. Genes significantly differentially
expressed (p value ≤0.05) are marked by an asterisk, pink for EZH1/2 KO/Y726A
and blue for EZH1/2 dKO cells.
Figure 6.15 Upregulation of Polycomb target genes in EZH2 single
mutant mESCs. Log(2) foldchange of expression of Polycomb target genes in
EZH2 Y726A and EZH2 KO mESCs relative to E14 control. Error bars represent
standard error of Log(2) foldchange. Genes significantly differentially expressed
(p value ≤0.05) are marked by an asterisk.
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These results showed that, contrary to the what was suggested by the initial
RT-qPCR experiment, for the majority of overexpressed genes the two EZH1/2
double mutant cell lines induced similar levels of derepression. Again, in the EZH2
single mutants the vast majority of these genes were not found to be significantly
differentially expressed (Fig. 6.15). Despite most changes in expression for the
single mutants not being above the threshold of significance, I did notice that
the largest changes detected in the single mutant cells were mostly seen for genes
which were significantly upregulated in the double mutant cells. This trend was
perhaps more evident amongst the Hox genes than the other Polycomb genes.
6.2 Conclusions
Taken together, these results demonstrated that there was a substantial difference
in gene expression patterns between the EZH2 single mutant cells and the EZH1/2
double mutant cells, both with regards to the overall number of differentially
expressed genes, as well as the expression of specific Polycomb targets. This
further confirms, as has already been documented, that in mESCs, EZH1 is
able to compensate for the majority of EZH2 functions in the regulation of gene
expression. This compensation is able to occur despite the very low levels of
H3K27me3 that EZH1 is able to catalyse, suggesting that high levels of this
histone modification may be of minimal importance for Polycomb gene regulation
in mESCs.
As expected, the most significant changes in Polycomb gene expression were
observed in the EZH1/2 double mutant cell lines, with many of these genes being
upregulated as the repressive PcG proteins and H3K27me3 were lost. However
there were a significant number of genes that were downregulated in the EZH1/2
double mutant cell lines, which may, at first glance seem surprising. These genes
may be being indirectly affected, with their downregulation due to the action of
repressive factors that are direct Polycomb targets, which become expressed upon
depletion of PRC2.
The experiments in this chapter also provided some information about the
influence of a catalytically inactive PRC2 on gene expression. It would seem
that the catalytically inactive EZH2 was still able to maintain a minor degree
of gene repression as compared to the EZH2 KO, as evident from the larger
number of significantly upregulated genes seen in the EZH1/2 dKO than in the
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EZH1/2 KO/Y726A. Interestingly, although broadly the same genes were affected
in both the KO and catalytically inactive conditions, it would seem that EZH2
Y726A was also able to prevent the silencing of certain genes that were seen
to be downregulated in the EZH1/2 dKO conditions. Additionally, it appeared
that the catalytically inactive EZH2 may have been able to maintain the levels
of expression of genes that have a binding motif for transcription factor YY1. As
compared to the effect of a total loss of H3K27me3 versus a partial loss however,
the effect of maintaining a catalytically inactive EZH2 was minimal. This was
illustrated by the drastic difference in the number of misregulated genes in both
EZH1/2 double mutant cell lines as compared to both EZH2 single mutant cell
lines, indicating that globally the catalytically inactive EZH2 was not able to
contribute in a meaningful way to the silencing of its target genes.
Overall, these results point to the histone modifying activity of PRC2 as the most
important factor in the maintenance of PRC2-mediated Polycomb gene silencing.
It appeared that the presence of H3K27me3, even at a low level, at Polycomb
target genes was sufficient to maintain the correct level of expression for the vast
majority of these genes. One hypothesis to explain this is the strong decrease in
RING1B enrichment at Polycomb target genes observed in both EZH1/2 double
mutant but not the EZH2 single mutant backgrounds (see Chapter 4). This
depletion of the catalytic subunit of PRC1 from these genes could explain their
upregulation, as the this complex is thought to play an important role in gene
repression by condensing chromatin and reducing the accessibility of genes to the
transcription machinery (Stock et al., 2007; Zhou et al., 2008). However it has
also been shown that PRC1 is not present at appreciable levels at all PRC2 target
genes so it may not be the sole factor responsible for silencing of all Polycomb
targets (Ku et al., 2008). Another mechanism through which H3K27me3 may be
mediating repression is through inhibiting the recruitment of chromatin modifying
complexes responsible for placing histone modifications associated with active
genes. This could occur either through direct inhibition of the complex by the





Differentiation of PRC2 mutant
cell lines
7.1 Introduction and Aims
Although the loss of EZH2 alone is not sufficient to induce major defects in mESC
self-renewal, proliferation, or gene expression patterns (Chamberlain et al., 2008;
Shen et al., 2008; Riising et al., 2014) (see also previous chapter), it is known
to have a considerable effect on development and ESC differentiation. The loss
of EZH2 causes severe disruption of embryonic development in mice, specifically
an inability to progress past gastrulation and lethality around embryonic day
8 (O’Carroll et al., 2001). A similar phenotype has also been described for knock-
outs of EED and SUZ12 (Faust et al., 1998; Pasini et al., 2004). In cell culture
conditions, loss of EZH2 from mouse ESCs leads to defects in differentiation.
Typically these defects are characterised by a failure to repress pluripotency
factors, aberrant expression of genes involved in lineage specification, and failure
to upregulate genes involved in key pathways required for cell fate commitment
(Shen et al., 2008). As with embryo development, these differentiation defects
have also been observed in the absence of other PRC2 subunits (Chamberlain
et al., 2008; Pasini et al., 2007). In human cells the loss of EZH2 leads to a more
severe phenotype, as ESCs exhibit defects in differentiation similar to those seen
in mice, although in this case there is no failure to repress pluripotency factors,
but also have a reduced capacity for self-renewal (Collinson et al., 2016; Shan
et al., 2017).
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Although in undifferentiated ESCs I found there to be no discernible difference
between the EZH2 KO and EZH2 Y726A cell lines, with the following experiments
I aimed to ascertain whether the catalytically inactive EZH2 main have a
significant effect on gene expression throughout differentiation as compared to the
knockout. I also sought to gain some insight into which stages of differentiation
PRC2 may be the most vital for and whether its full catalytic activity is required
for all of its function in gene regulation during this process. I hypothesised
that although the catalytically inactive form of EZH2 was unlikely to restore full
differentiation capacity to the cells, it may allow the progression of differentiation
to a more mature state than that seen in the EZH2 KO cells.
The differentiation protocol used in this chapter is based on the protocol described
by Bibel et al. (Bibel et al., 2007) that generates a uniform population of
glutamatergic neurons. This protocol has been used in studies of Polycomb
proteins (Mohn et al., 2008; Schmitz et al., 2011) and is a straightforward,
well characterised procedure which allowed me to examine the requirements of
PRC2 throughout a multi-step differentiation process. As this protocol involves
a progression through several states of differentiation it allowed me to assess
the contribution of PRC2 not only to the early stages of differentiation during
the formation of embryoid bodies (EBs), but also to the later stages in the
transition of neural precursors to the terminally differentiated neurons. The
expression of several marker genes throughout the protocol has been described
in detail, allowing me to verify the differentiation process was working correctly
in my hands. These markers were also of use to begin to pinpoint the stages at
which the EZH2 deficiency becomes antagonistic to the correct regulation of gene
expression. It should be noted however, that although the expression patterns of
some specific markers are well characterised, there remains much to be learned
about the regulation of cell fate decisions from analysing global gene expression
throughout differentiation.
The immunofluorescence staining of cells in this chapter was performed with the
help of Katy McLaughlin. The quality control and processing of RNA-seq raw
data was performed under my direction by Shaun Webb.
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7.2 Overview of neuronal differentiation proto-
col
I performed neuronal differentiation assays with both the E14 control cells and the
PRC2 mutant cells to test whether presence alone or catalytic activity of EZH2
was required for this process. I followed the progression of differentiation first
by monitoring the morphology of cells as they went from ESCs to EB, neural
progenitor, and finally terminally differentiated neurons, before analysing gene
expression changes by RT-qPCR and RNA-seq. An outline of the differentiation
protocol along with expected expression behaviour of marker genes is shown in
Fig. 7.1. To determine how singular loss of EZH2 compares to loss of both EZH1
and EZH2, I performed differentiation experiments with both single and double
mutant cell lines.
Figure 7.1 Scheme of the neural differentiation protocol. Detail of media
changes and cell types at each stage of the differentiation.
7.3 Cell morphology of PRC2 mutant cell lines
throughout differentiation
Throughout the first stages of differentiation the PRC2 mutant cell lines behaved
similarly to the E14 control cells. The EBs were of a similar size and shape and
appeared to grow in size at a similar rate (data not shown). After the addition of
retinoic acid (RA), however, obvious differences in morphology became apparent,
between the E14 control and EZH1/2 double mutant cell lines in particular. As
can be seen in Fig. 7.2 where the E14 control line started to produce more smooth
and evenly shaped EBs by day 6, the EBs in the double mutant lines were smaller,
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more unevenly shaped with less defined outlines and even occasionally appeared
to be hollow. This phenotype was not as pronounced in the EZH2 single mutant
cell lines, for which the EBs formed were slightly smaller than the E14 control
and had a slightly less smooth edge (Fig. 7.2).
Figure 7.2 Embryoid bodies on day 6 of differentiation. Brightfield
imaging at 10x magnification of embryoid bodies on day 6 of differentiation. Two
representative images (upper an lower panels) of EB morphology of E14 control
(E14 WT) and EZH2 single and double mutant cell lines across at least 3 separate
differentiation experiments. Scale bar corresponds to 100 µm.
After trypsinisation on day 8, cells were counted and the same number in each line
plated onto PDL-laminin coated plates (see Fig. 7.1). A few hours after plating
cell morphology was similar for the EZH2 single mutants cell lines and the E14
control. However, in the double mutants there already appeared to be a greater
level of cell death, and the remaining live cells partially failed to properly adhere
to the plate. By day 9 the differences between E14 control and EZH2 single
mutant cell lines started to become evident (Fig. 7.3). Whereas the E14 control
cells were beginning to form the typical neurite structure seen in neuronal cells,
this was not apparent in either EZH2 single mutant background (Fig. 7.3 ), even
though a similar number of viable cells were present on the plate in the EZH2
single mutants as compared to the E14 control. In contrast, this was not the
case for the EZH1/2 double mutant cell lines, which not only failed to undergo
the morphological changes seen for E14 control cells, but were also subject to
significant rates of cell death by day 9. These low cell numbers meant that I was
unable to obtain RNA samples for the double mutant cell lines past day 8 of the
differentiation protocol.
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Figure 7.3 Cell morphology on day 9 of differentiation. Brightfield
imaging at 10x magnification of E14 control (E14 WT) and EZH2 single and double
mutant cell lines on day 9 of differentiation. Cells plated on PDL-laminin coated
plates. Two representative images (upper an lower panels) of cell morphology as
seen across at least 3 separate differentiation experiments. Scale bar corresponds
to 50 µm.
Throughout the next week of differentiation, the E14 control cells maintained
and further developed the network of neuronal cells, whereas both EZH2 single
mutants failed to form proper neuronal protrusions and networks. There were,
however, no obvious signs of significant cell death in these lines. Although they
did not appear neuronal from a morphological point of view, they were able to
grow and even proliferate in the neurobasal B27 supplemented media as evidenced
by the increase in cell density on the plates over time for these cell lines. Based
on their morphology, the EZH2 single mutant cells at this stage appeared to be
a mixed population of cell types (Fig. 7.4).
This morphological assessment of neuronal differentiation in each cell line revealed
that none of the PRC2 mutant cell lines were able to differentiate in the same
manner as the E14 control. Although the EZH2 single mutants were able to
survive throughout the entire course of differentiation, they never took on a
morphology resembling the network of neurites typically formed by neuronal cells,
as was seen in the E14 control cells. The EZH1/2 double mutants were even less
capable to carry out this neuronal differentiation, with very few of these cells
even surviving through to the later stages.
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Figure 7.4 Cell morphology on day 15 of differentiation. Brightfield
imaging at 10x magnification of E14 control (E14 WT) and EZH2 single and double
mutant cell lines on day 15 of differentiation. Cells plated on PDL-laminin coated
plates. Two representative images (upper an lower panels) of cell morphology as
seen across at least 3 separate differentiation experiments. Scale bar corresponds
to 50 µm.
7.4 Analysis of gene expression in PRC2 single
mutant cell lines throughout differentiation
7.4.1 RT-qPCR analysis of differentiation markers
RT-qPCR was performed at different time points throughout differentiation for
select marker genes for different stages of differentiation, including Pax6 and
Fapb7 which are two marker genes used to identify cells undergoing correct neural
differentiation following the protocol described by Bibel et al. 2007 (Bibel et al.,
2007).
As expected, Otx2, a TF induced early in EB formation was found to be
upregulated by day 2 in the E14 control cells and was later repressed by day
6, likely in response to the RA treatment (Fig. 7.5). This gene was upregulated
and silenced in a timely manner and to levels close to those observed in the E14
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control cells for both EZH2 single mutant cell lines, suggesting that early stages
of differentiation could be unaffected by both single mutations. The Pax6 gene,
a TF that serves as a marker of neural precursors, was found to be expressed
from day 6 onwards in the E14 control cells. Despite a slight upregulation of
this gene in the EZH2 single mutants that followed the temporal pattern of the
E14 control cells, expression failed to reach the levels seen in the E14 control
cells (Fig. 7.6 ), suggesting increasing defects in these cell lines as differentiation
progresses. The Fabp7 gene is a fatty acid binding-protein essential for early
brain development which is induced upon expression of Pax6 and marks more
terminally differentiated neurons (Arai, 2005). In the E14 control cells Fabp7 was
upregulated from day 8 of differentiation onwards, reaching very high levels of
induction by day 15. However it did not ever become expressed in either of the
EZH2 single mutants.
Figure 7.5 Expression of Otx2 throughout differentiation. Bar chart
showing expression of early differentiation marker Otx2 in E14 control (E14 WT) ,
EZH2 Y726A (EZH2 CI) and EZH2 KO cell lines throughout differentiation. Data
was generated by RT-qPCR and normalised to expression of Gapdh, expression was
then expressed as fold change relative to E14 control on day 0. Error bars represent
SEM across 3 biological replicates. * denotes a significant difference to WT with
a p value of less than 0.01, and ∆ a p value of less than 0.05.
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Figure 7.6 Expression of Pax6 throughout differentiation. Bar chart
showing expression of neural-progenitor marker Pax6 in E14 control (E14 WT),
EZH2 Y726A (EZH2 CI) and EZH2 KO throughout differentiation. Data was
generated by RT-qPCR and normalised to expression of Gapdh, expression was
then expressed as fold change relative to E14 control on day 0. Error bars represent
SEM across 3 biological replicates. * denotes a significant difference to WT with
a p value of less than 0.01, and ∆ a p value of less than 0.05.
Figure 7.7 Expression of Fabp7 throughout differentiation. Bar chart
showing expression of neuronal marker Fabp7 in E14 control (E14 WT), EZH2
Y726A (EZH2 CI) and EZH2 KO throughout differentiation. Data was generated
by RT-qPCR and normalised to expression of Gapdh, expression was then
expressed as fold change relative to E14 WT on day 8. Error bars represent
SEM across 3 biological replicates. * denotes a significant difference to WT with
a p value of less than 0.01
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As can be seen by immunofluorescence staining in Fig. 7.8, the E14 control cells
expressed high levels of neuronal marker Tuj1 throughout their cell body by day
15. As was shown by the brightfield images of cells on day 15, the EZH2 single
mutants did not form the neurite network characteristic of neuronal cells (Fig.
7.4). Immunofluorescence staining of cells on day 15 showed that, in addition
to not displaying a neuronal morphology, the EZH2 single mutants also failed to
express Tuj1. Furthermore, there appeared be a higher degree of Oct4 expression
in these cells than in the E14 control (Fig. 7.8).
These results indicated that although genes such as Otx2 were able to be up- and
subsequently downregulated in the earlier stages of differentiation in both EZH2
single mutant backgrounds, neither of them were able to initiate the expression
of neural lineage programmes at the EB stage, eventually leading to their failure
to produce mature neurons.
Figure 7.8 Immunofluorescence staining of OCT4 and TUJ1 on day
15 of differentiation. DAPI (far left), OCT4 (left), and TUJ1(right) staining
of E14 control, EZH2 Y726A and EZH2 KO cells on day 15 of differentiation.
Merge is shown in panels on far right, DAPI in cyan, OCT4 in green and TUJ1
in magenta. Scale bar corresponds to 100 µm
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7.5 Analysis of genome-wide gene expression
patterns during differentiation by RNA-seq
To further explore the gene expression dynamics throughout differentiation, RNA-
seq was performed at 3 time points throughout differentiation. Samples were
taken on day 2, day 8 and day 15 for E14 control, EZH2 Y726A, EZH2 KO
and EZH1/2 dKO cells using 3 separate clones of each genotype as replicates
for each time point. These time points were chosen with the aim to capture
gene expression profiles and dynamics across the full differentiation protocol in
order to encompass both early and late stage events. By comparing the EZH2
single mutant cell lines to each other I aimed to gain insight into any potential
catalysis-independent functions of EZH2 throughout differentiation. By including
the EZH1/2 dKO cells in this assay as a comparison to the EZH2 single mutant
cells I also aimed to shed some light on the functions that EZH1 is able to carry
out throughout differentiation in the absence of EZH2.
7.5.1 Gene expression dynamics throughout differentiation
I will first discuss the dynamics in gene expression that I observed in the E14
control cell line to establish what was expected at each stage of differentiation in
terms of pathways and families of genes that are up- and downregulated.
Day 2 EB stage
Although the samples for day 0 and day 2 of differentiation cluster together
very closely in principle component analysis (PCA) compared to the later days
of differentiation (see Fig. 7.20), a considerable number of genes nonetheless
changed their expression from day 0 to day 2. Approximately 12% of protein
coding genes were differentially expressed by day 2, with around 1100 genes
upregulated and 1570 downregulated. The analysis of GO terms of upregulated
genes identified an enrichment of genes involved in cell communication and
signalling as well as the metabolism of sterols, cholesterol and alcohol. Genes
downregulated at this time were found to be mostly involved in the regulation of
gene expression, as well as RNA metabolism and processing (Fig. 7.9).
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Figure 7.9 Differential gene expression in day 2 relative to
undifferentiated mESCs for E14 control. Upper panel - Pie chart
representing differential expression of all protein coding genes in day 2 E14
control (E14 WT) cells relative to undifferentiated mESCs. Genes significantly
upregulated are shown in shades of yellow, genes significantly downregulated are
shown in shades of blue. Darker shades correspond to genes differentially expressed
by more than a log(2) foldchange of 1 or -1 over E14 control. Lower panels - GO
term enrichment of significantly upregulated (yellow) and downregulated (blue)
genes.
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When analysing the association of these genes with specific TF families in order to
begin understanding how these genes might be regulated, I observed that genes
upregulated on day 2 were enriched for TF binding motifs that were GC rich,
many of which corresponded to the binding motifs for factors from the Sp family.
Amongst genes that were downregulated there was an enrichment of binding
motifs of several different transcription factors. Of these binding motifs many of
them had a CCGGAA motif in common (Fig. 7.10).
Figure 7.10 Enrichment of TF motifs in differentially expressed genes
in day 2 E14 control. TF binding motifs enriched in genes significantly
upregulated (yellow) and down regulated (blue) in day 2 E14 control cells (E14
WT) relative to undifferentiated mESCs.
I next assessed the expression of a selection of specific marker genes at this time
point. As expected from the findings of previous studies, the withdrawal of LIF at
this first stage of differentiation led to the downregulation of genes such as Klf4,
Stat3 and Tbx3 (Fig. 7.11), all genes involved in the maintenance of self-renewal
and an undifferentiated state in ESCs (Trouillas et al., 2009; Zhang et al., 2010;
Wang et al., 2017; Lu et al., 2011). This also led to an upregulation of genes
such as Otx2 and Fgf5 (Fig. 7.11), both markers of early ectoderm (Haub and
Goldfarb, 1991; Gammill and Sive, 2001).
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Figure 7.11 Expression of developmental genes in E14 control
throughout differentiation. Log(2) foldchange of expression of genes known
to be affected by withdrawal of LIF in E14 control cells at each timepoint relative
to undifferentiated ESCs. Significant changes in expression (p value ≤0.05) are
marked by an asterisk.
Pluripotency factors Oct4, Nanog, and Sox2 were found to still be expressed at
this stage of differentiation, albeit at reduced levels (Fig. 7.14) This was to be
expected as their expression is known to be at least partially maintained in the
first few days of EB formation (Trouillas et al., 2009).
Day 8 Transition to neural progenitor state
By day 8 approximately 40% of protein coding genes were differentially expressed
as compared to day 2, with a similar number of genes upregulated as downreg-
ulated. The gene expression pattern observed on day 8 appears to reflect the
treatment of cells with retinoic acid and their transition into the neural progenitor
state. As expected, amongst upregulated genes there was a strong enrichment of
genes involved in nervous system development and cell differentiation (Fig. 7.12).
There was a strong downregulation of genes involved in translation and peptide
biosynthesis, RNA processing and gene expression as well as several metabolism
pathways such as that of nitrogen compounds and RNA, indicating a switch from
a highly proliferative to a more neuronal phenotype (Fig. 7.12).
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Figure 7.12 Differential gene expression in day 8 E14 control cells
relative to day 2. Top panel - Pie chart representing expression of all protein
coding genes in day 8 E14 WT cells relative to day 2. Genes significantly
upregulated are shown in shades of yellow, genes significantly downregulated are
shown in shades of blue. Darker shades correspond to genes differentially expressed
by more than a log(2) foldchange of 1 or -1 over day 2 E14 control. Lower panels
- GO term enrichment of significantly upregulated (yellow) and downregulated
(blue) genes.
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As was seen on day 2, there was an enrichment of GC rich TF motifs amongst
the upregulated genes (Fig. 7.13). These binding motifs were however associated
with a wider variety of TFs than seen on day 2. Of the transcription factor
binding motifs enriched in the downregulated genes, many of those most enriched
contained a CACGTG motif. Of the upregulated genes there is an enrichment
of the binding motif for GKLF. This is another name for the Klf4 gene, and
though its expression decreases in early stage embryoid bodies, it is re-expressed
in neural progenitor cells (Qin and Zhang, 2012). Also enriched amongst
upregulated genes were binding motifs for Kaiso, RNF96, AP2 and ZF5. Kaiso
is a methyl-CpG binding protein that has been suggested to play a role in
neural development (Mart́ın Caballero et al., 2009). RNF96, otherwise known
as Trim28 is a transcriptional repressor, involved in the maintenance of stem cell
pluripotency (Fazzio et al., 2008). The AP2 transcription factors are expressed
in primitive ectoderm and are important for the development of the neural
crest (Eckert et al., 2005). ZF5, also known as Zbtb14, has been shown to act
both as a transcriptional repressor and activator and promotes the development of
neural tissues (Takebayashi-Suzuki et al., 2018). Amongst the TFs for which there
was an enrichment of the corresponding binding factors in the downregulated
genes c-Myc was identified, one of the Yamanaka reprogramming factors and a
major regulator of stem cell identity (Takahashi and Yamanaka, 2006). These
enrichments taken together again demonstrated a transition of cell state from
pluripotent stem cell to neural lineage at this stage of differentiation.
As expected at this time in the differentiation process there was a strong induction
of transcription factors and markers of neural progenitors such as Pax6, shown in
Fig. 7.15. This was accompanied by the upregulation of additional factors such
as Glast, Fabp7 and Nestin, all of which are associated with radial glial progenitor
cells which in vivo, give rise to a large portion of neurons in the central nervous
system (CNS) (Bibel et al., 2007; Barry et al., 2014). It also became evident that
pluripotency factors were being repressed markedly more strongly compared to
day 2, as Oct4, Nanog and Sox2 were all significantly downregulated at this stage
of differentiation (Fig. 7.14). Additionally, amongst genes downregulated were
many of those that had been induced upon withdrawal of LIF such as Fgf5 and
Otx2 (Fig. 7.11). The treatment of cells with retinoic acid also resulted in the
upregulation of genes involved in RA signalling, such as Rarb and Rxra, nuclear
receptors of RA, and Crabp1/2, RA binding proteins involved in its transport
into cells (Fig. 7.15).
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Figure 7.13 Enrichment of transcription factor binding sites in
differentially expressed genes in day 8 E14 control cells. Transcription
factor binding motifs enriched in genes significantly upregulated (yellow, top panel)
and down regulated (blue, bottom panel) in day 8 E14 control relative to day 2.
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Figure 7.14 Expression of key pluripotency factors in E14 control
throughout differentiation. Log(2) foldchange of expression of pluripotency
factors in E14 control cells at each timepoint relative to undifferentiated ESCs.
Significant changes in expression (p value ≤0.05) are marked by an asterisk.
Figure 7.15 Expression of NPC markers and retinoic acid interactors
in E14 control cells throughout differentiation. Log(2) foldchange of
expression of neural progenitor marker genes and retinoic acid interacting genes in
E14 control (E14 WT) cells at each timepoint relative to undifferentiated E14
control. Significant changes in expression (p value ≤0.05) are marked by an
asterisk.
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Day 15 Terminally differentiated neuron stage
Considerable changes in gene expression were observed between the neural
progenitors of day 8 to the adherent, neurite-displaying cells of day 15. Nearly
4310, or close to 20% of all protein coding genes were significantly upregulated
while 3200 or almost 15% were downregulated relative to the day 8 E14 control
cells (Fig. 7.16). As cells developed into more mature neurons their proliferative
capacity was reduced, which was reflected in the GO term enrichments of
downregulated genes being associated with cell cycle and mitosis. Chromatin
organisation as well as DNA processing and packaging were also enriched
among downregulated genes, as would be expected in non-cycling cells that
no longer need to condense chromosomes in preparation for cell division. The
increasingly differentiated state of cells at this stage was reflected in the continued
upregulation on day 15 of genes associated with neuronal development as well as
synapse signalling and the formation of neuronal projections.
For upregulated genes, TF motifs were again found to be enriched for CG rich
sequences. This was also true, although to a lesser extent, in genes downregulated
for which the transcription factors with the most enriched binding motifs all
belonged to the E2F family. The E2F family of transcription factors was also
present amongst those with binding motifs most enriched in upregulated genes
(Fig. 7.17). This family of transcription factors is a major actor in the control
of cell proliferation and has been found to act both as an activator and a
repressor of transcription (Müller and Helin, 2000). Its presence at both up-
and downregulated genes again suggests changes in the rate of cell cycling.
Reflecting the state of the neurons at this stage of differentiation, there was an
increase in the expression of genes such as Fabp7 and TrkB as well as Vgat and
Vglut, transporters of GABA and glutamate, respectively, (Fig. 7.18), identifying
these cells as GABAergic and glutamatergic neurons (Bibel et al., 2004). Pax
6 was downregulated at this stage in differentiation, indicating that the cells
had progressed past the neural progenitor phase (Fig. 7.15). The retinoic acid
interacting genes were also mostly found be downregulated at this stage, returning
to levels of expression similar to that of the undifferentiated ESCs. The silencing
of pluripotency factors that I observed on day 8 was maintained at this stage
(Fig. 7.14) as well as that of Otx2 and Fgf5 (Fig. 7.11).
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Figure 7.16 Differential gene expression in day 15 E14 control cells
relative to day 8. Top panel - Pie chart representing expression of all
protein coding genes in day 15 E14 control (E14 WT) cells relative to day 8.
Genes significantly upregulated are shown in shades of yellow, genes significantly
downregulated are shown in shades of blue. Darker shades correspond to genes
differentially expressed by more than a log(2) foldchange of 1 or -1 over day 8.
Lower panels - GO term enrichment of significantly upregulated (yellow) and
downregulated (blue) genes.
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Figure 7.17 Enrichment of transcription factor binding sites in
differentially expressed genes in day 15 E14 control. Transcription factor
binding motifs enriched in genes significantly upregulated (yellow) and down
regulated (blue) in day 15 E14 control (E14 WT) relative to day 8.
Ezh1 and Ezh2 have been shown to have different expression levels in proliferating
and non-proliferating cells, with EZH1 being more highly expressed in adult
tissues than EZH2 (Laible et al., 1997; Margueron et al., 2008). I sought to
identify the dynamics of expression of the two subunits throughout differentiation.
I found that on day 2 and 8, expression of Ezh2 was maintained at the same level
as was seen in the mESCs, but was then significantly downregulated by more
than twofold by day 15. Ezh1 on the other hand was significantly upregulated
on day 2 but its expression then decreased again to remain at the same level
as was detected in ESCs for the remainder of the timepoints (Fig. 7.19). I
also found that Eed and Suz12, the other essential core subunits of PRC2 were
progressively downregulated throughout differentiation. This correlates with the
role of EZH1 as being more significant in more differentiated cell types. The
considerable decrease in expression of Eed and Suz12 suggests there is an overall
lower abundance of the PRC2 complex at these later stages of differentiation.
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Figure 7.18 Expression of neuronal marker genes in E14 control cells
throughout differentiation. Log(2) foldchange of expression of neuronal lineage
genes in E14 control at each timepoint relative to undifferentiated E14 control.
Significant changes in expression (p value ≤0.05) are marked by an asterisk.
Figure 7.19 Expression of PRC2 subunits in E14 control cells
throughout differentiation. Log(2) foldchange of expression of PRC2 core
subunits in E14 control cell lines at each timepoint relative to undifferentiated
ESCs. Significant changes in expression (p value ≤0.05) are marked by an asterisk.
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7.5.2 Global differences in gene expression in Polycomb
mutant cell lines throughout differentiation
The principle component analysis over all samples showed that the mutants were
clustered closely with the E14 control cells at the beginning of differentiation,
however, they became progressively more different with each successive timepoint
(Fig. 7.20). As expected, I found that throughout differentiation, the mutant
background with the largest number of differentially expressed genes was the
EZH1/2 dKO cell lines. The EZH2 single mutant lines clustered closely with the
E14 control samples until day 2, however, they diverged significantly beginning
on day 8. Additionally, I observed for all mutants that there seemed to be a
greater sample-to-sample variation than in the E14 control samples. This may
reflect an effect caused by the CRISPR editing or may result directly from the loss
of PRC2 function and a potential associated decrease in fidelity of maintaining
gene expression patterns.
Figure 7.20 Principle component analysis across all RNA-seq samples.
E14 control (WT mESC), EZH2 Y726A (EZH2 CI), EZH2 KO, EZH1/2
KO/Y726A (EZH1/2 KO/CI) and EZH1/2 dKO samples were separated into
individual replicates. Day 0 samples correspond to undifferentiated ESCs,
previously discussed in Chapter 6.
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7.5.3 Differential gene expression day 2 EB state
Day 2 corresponds to the second day of EB growth, in which cells have been
growing in suspension in the absence of LIF and with 10% serum content for
approximately 48 hours. The RNA-seq data from this time point showed that
on day 2 there was very little difference in gene expression between the EZH2
single mutant and the E14 control backgrounds, whereas a large number of genes
was found to be misregulated for the EZH1/2 dKO background, similar to the
situation observed in ESCs.
Figure 7.21 Differential gene expression on day 2 in EZH2 single
mutant and EZH1/2 dKO cells. Pie charts representing expression of all
protein coding genes in day 2 EZH2 Y726A, EZH2 KO and EZH1/2 dKO relative
to day 2 E14 control. Genes significantly upregulated are shown in shades of yellow,
genes significantly downregulated are shown in shades of blue. Darker shades
correspond to genes differentially expressed by more than a log(2) foldchange of 1
or -1 over day 2 E14 control.
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Overall changes in gene expression and overlap between mutant
background
Consistent with what I observed in ESCs, there were very few genes significantly
differentially expressed in the EZH2 single mutants as compared to the E14
control. As can be seen in Fig. 7.21, no more than 40 protein coding genes
were significantly affected in either condition. When focusing on the overlap of
the genes that did undergo a significant up- or down-regulation in these cell lines
I found that approximately one third of these genes were affected in both cell
lines (Fig. 7.22). Similar to what was seen for ESCs, a much greater number of
genes were differentially expressed in the EZH1/2 dKO cells as compared to the
E14 control. More than 2300 protein coding genes underwent significant up- or
downregulation in these cells, with more than twice as many genes upregulated
by more than twofold as downregulated by this same factor.
GO terms associated with differentially expressed genes
In line with the minor differences in gene expression between the EZH2 single
mutant cell lines and the E14 control, there were similarly very few GO terms
associated with significantly up- or downregulated genes (Fig. 7.22). In the
EZH2 Y726A cells the upregulated genes were enriched for terms associated with
senescence associated heterochromatin, as well as the Sgk3 homodimer complex,
although this second term was only just over the threshold of significance. These
cells were found to downregulate genes associated with 4 different TF classes, 3 of
which shared a similar GAAA sequence in their binding motifs. In the EZH2 KO
background the Sgk3 homodimer complex was again upregulated with a similar
significance as seen in the EZH2 CI, as well as pathways involved in regulating
stem cell pluripotency. There were no GO terms found to be associated with any
significantly downregulated genes in the EZH2 KO.
In the EZH1/2 dKO cells there was a significant enrichment of GO terms related
to embryo development, cell differentiation, and body patterning amongst the
upregulated genes, terms strongly represented within Polycomb target genes (Fig.
7.23). Fewer GO terms were found to be associated with the downregulated genes
and mostly involved certain developmental abnormalities as well as the DNA
polymerase delta complex. In genes both up- and downregulated there was an
enrichment of many GC rich transcription factors binding motifs associated with
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a variety of transcription factor families (Fig. 7.24).
These findings for the gene expression patterns on day 2 of differentiation strongly
correlate with those observed in the undifferentiated mESCs with no increase
detected in the number of differences between the PRC2 mutants and the E14
control. This suggests that the contribution of PRC2 to this transition from ESCs
to early stage EBs is minimal.
Figure 7.22 Gene ontology of genes differentially expressed on day 2
in EZH2 single mutant cells (A)Venn diagram representing overlap of genes
differentially expressed in EZH2 Y726A and EZH2 KO. (B) GO terms enriched in
genes significantly upregulated (yellow) and downregulated (blue) in day 2 EZH2
single mutants relative to day 2 E14 control.
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Figure 7.23 Gene ontology of genes differentially expressed on day 2
in EZH1/2 dKO cells. Go terms enriched in genes significantly upregulated
(yellow) and downregulated (blue) in day 2 EZH1/2 dKO relative to day 2 E14
control.
Figure 7.24 Enrichment of transcription factor binding sites in genes
differentially expressed on day 2 in EZH1/2 dKO cells. Transcription
factor binding motifs enriched in genes significantly upregulated (yellow) and down
regulated (blue) in day 2 EZH1/2 dKO relative to day 2 E14 control.
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Individual gene expression patterns
When analysing genes known to be affected by withdrawal of LIF I found that
in both EZH2 single mutants, the expression of genes either upregulated or
downregulated in E14 control cells was not significantly altered, even though
Klf4 and Tbx3 were expressed to higher levels albeit not above the threshold
of significance (Fig. 7.25). In the EZH1/2 dKO background, however, there
were some differences observed. Although both Otx2 and Fgf5 were found to
be expressed at similar levels to what was observed in the E14 control, Klf4
or Tbx3 were both upregulated in this mutant compared to the E14 control
background, indicating that these genes were not appropriately silenced in
response to LIF withdrawal. I found that these genes were also overexpressed
in the undifferentiated EZH1/2 dKO ESCs as compared to the E14 control.
Interestingly, when comparing expression at these 2 timepoints I noticed that
expression of Klf4 and Tbx3 did actually decrease upon withdrawal of LIF in the
EZH1/2 dKO cell lines, however, repression was less effective than in the E14
control cells.
Figure 7.25 Expression of developmental genes in PRC2 mutants on
day 2 of differentiation. Log(2) foldchange of expression of genes known to be
affected by withdrawal of LIF in EZH2 Y726A (EHZ2 CI), EZH2 KO and EZH1/2
dKO relative to E14 control on day 2. Significant changes in expression (p value
<0.05) are marked by an asterisk.
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Overall, with the exception of Klf4 and Tbx3, expression of this subset of genes
known to display dynamic expression in response to the withdrawal of LIF was
similar between the mutants backgrounds and E14 control cells. However it did
appear that there was some slight disruption of this process in the EZH1/2 dKO
cells, specifically in silencing of genes.
7.5.4 Differential gene expression day 8 transition to neural
progenitor state
Day 8 corresponded, in the E14 control, to the stage at which cells had become
Pax6 positive neural progenitors, more specifically, of the radial glial type as
denoted by their expression of Glast, Fabp7, and Nestin. The principle component
analysis showed that this was the timepoint at which the EZH2 single mutant cell
lines began to strongly diverge from the E14 control cells. I therefore analysed
changes in expression at this time point in greater detail.
Overall changes in gene expression and overlap between mutant
backgrounds
By day 8 the number of differentially expressed genes in the EZH2 single mutant
cells was greatly increased as compared to what was observed on day 2 (Fig.
7.26). The EZH2 Y726A cells were found to have more than 2300 protein coding
genes differentially expressed of which nearly 1000 genes were upregulated and
just over 1300 were downregulated. In the EZH2 KO cell lines these numbers were
almost doubled with more than 4000 protein coding genes differentially expressed
of which nearly 2000 genes were upregulated.
Most of the genes affected in the EZH2 Y726A background were found to
be similarly misregulated in the EZH2 KO, however around half of the genes
differentially expressed in the KO were not found to be significantly altered in
the EZH2 Y726A background compared to the E14 control cells at that stage (Fig.
7.27). In light of this considerable difference, I decided to compare gene expression
in the two mutants to each other to reveal genes differentially expressed between
EZH2 Y726A and EZH2 KO. Surprisingly however, I found that, despite the
apparent large difference between the 2 mutants, only 6 genes were significantly
differentially expressed between them, one of which was EZH2 itself (Fig. 7.27).
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Figure 7.26 Differential gene expression on day 8 in EZH2 single
mutant and EZH1/2 dKO cell lines. Pie charts representing expression of all
protein coding genes in day 8 EZH2 Y726A, EZH2 KO and EZH1/2 dKO relative
to day 8 E14 control. Genes significantly upregulated are shown in shades of yellow,
genes significantly downregulated are shown in shades of blue. Darker shades
correspond to genes differentially expressed by more than a log(2) foldchange of 1
or -1 over day 8 E14 control cells.
Pax2, a transcription factor involved in development of the CNS amongst other
systems, was also downregulated in the EZH2 KO cells. I hypothesised that this
very low number of significantly differentially expressed genes might indicate that
the genes that were significantly misregulated compared to the E14 control in the
EZH2 KO background only may still follow a similar trend in expression in the
EZH2 Y762A cell lines and vice versa, but the significance threshold was only
reached in one or the other of them.
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Figure 7.27 Comparison of gene expression between EZH2 Y726A and
EZH2 KO cells. (A.) Venn diagram representing overlap of genes differentially
expressed in day 8 EZH2 Y726A and EZH2 KO compared to E14 control cells.
(B.) Table of all genes found to be differentially expressed between EZH2 Y726A
and EZH2 KO cell lines at day 8. Adjusted p values are labelled as padj, threshold
column indicates if p value is below 0.05 and if log(2) foldchange is greater than 1
or below -1.
With over 5300 genes, or nearly a quarter of all protein coding genes, misregulated
as compared to the E14 control, the EZH1/2 dKO was again found to have
more genes differentially expressed than either of the 2 EZH2 single mutant cell
lines (Fig. 7.26). Overall, more than 2300 genes were found to be significantly
downregulated while nearly 3000 were upregulated. Of the genes significantly
upregulated, more than 2000 were increased in expression by more than twofold,
nearly twice as many as the 1026 genes found to decrease in expression by the same
factor. These large-scale differences in gene expression reflect the considerable
difference in EB morphology and divergence of these cells from the E14 control at
this stage of differentiation. As expected following the depletion of a repressive
complex, most misregulated genes were upregulated, incidentally, this number
was close to the total number of Polycomb bound genes identified in ESCs (Mohn
et al., 2008). More surprising was the number of downregulated genes, some
of which may be repressed as an indirect consequence of the upregulation of
Polycomb targeted repressors. Other downregulated genes may simply fail to be
upregulated in a PRC2 depleted context.
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GO terms associated with differentially expressed genes
Both EZH2 single mutant cell lines displayed an enrichment for GO terms
associated with spermatogenesis and meiosis amongst the genes that were
upregulated. Additionally, in the EZH2 Y726A there was an upregulation of
factors involved in the immune response, while in the EZH2 KO there was
an upregulation of genes associated with the response to LIF. Amongst the
downregulated genes in both EZH2 single mutant backgrounds the GO terms
most strikingly enriched were those associated with neuronal development and cell
differentiation, indicating that they failed to be correctly upregulated as compared
to the E14 control cells (Fig. 7.28 and 7.29).
Figure 7.28 Gene ontology of genes differentially expressed on day 8
in EZH2 Y726A cells. Go terms enriched in genes significantly upregulated
(yellow) and downregulated (blue) in day 8 EZH2 Y726A cells relative to day 8
E14 control.
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Figure 7.29 Gene ontology of genes differentially expressed on day 8 in
EZH2 KO cells. Go terms enriched in genes significantly upregulated (yellow)
and downregulated (blue) in day 8 EZH2 KO cells relative to day 8 E14 control.
Only 2 transcription factor binding motifs were enriched in the genes upregulated
in the EZH2 Y726A, but there were many more found in those upregulated in
the EZH2 KO background. Of these, many belonged to transcription factors
known to be Polycomb target genes such as Otx2, Pax6 and Hoxa13, or retinoic
acid nuclear receptors such as RXR-alpha and RXR-gamma (Fig. 7.30 and 7.31).
The enrichments of TF binding motifs in the genes downregulated in both EZH2
single mutant backgrounds were very numerous and often CG rich sequences, and
many were identified in both cell lines. Of note were motifs for GKLF, Kaiso,
ZF5, RNF96 and MOVO-B all of which were found to to be enriched in the
upregulated genes for the E14 control cells on day 8, further demonstrating a
lack of upregulation of neuronal factors in the EZH2 single mutant cells at this
timepoint.
128
Figure 7.30 Enrichment of transcription factor binding sites in genes
differentially expressed on day 8 in EZH2 Y726A cells. Transcription
factor binding motifs enriched in genes significantly upregulated (yellow) and down
regulated (blue) in day 8 EZH2 Y726A cells relative to day 8 E14 control.
Figure 7.31 Enrichment of transcription factor binding sites in genes
differentially expressed on day 8 in EZH2 KO cells. Transcription factor
binding motifs enriched in genes significantly upregulated (yellow) and down
regulated (blue) in day 8 EZH2 KO cells relative to day 8 E14 control.
The EZH1/2 dKO cells also saw an upregulation of factors associated with
the immune response as well as transmembrane transport, while similarly
experiencing a downregulation of genes involved in the development of the nervous
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system (Fig. 7.32). In addition, there was a downregulation of genes associated
with certain metabolic systems in these cells as well as certain factors involved in
DNA packaging and chromosome organisation, suggesting a slowdown in rates of
cell division. As was seen in the single mutants at this time point, there was an
enrichment in downregulated genes of binding motifs for ZF5 which is known to
positively regulate neuronal development. FOXN4, a transcription factor involved
in cell fate decisions in the developing CNS amongst others (Xiang and Li, 2013),
also saw an enrichment of its binding site amongst downregulated genes (Fig.
7.33). As with the EZH2 single mutant cells at this timepoint, there was a
general failure to upregulate neuronal genes in the EZH1/2 dKO on day 8. The
upregulation of genes associated with the immune response may reflect the overall
decreased viability of these cells at this stage of differentiation as they displayed
a noticeably higher rate of cell death even by day 6 (see Fig. 7.2).
Figure 7.32 Gene ontology of genes differentially expressed on day 8
in EZH1/2 dKO cells. Go terms enriched in genes significantly upregulated
(yellow) and downregulated (blue) in day 8 EZH1/2 dKO relative to day 8 E14
control.
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Figure 7.33 Enrichment of transcription factor binding sites in genes
differentially expressed on day 8 in EZH1/2 dKO cells. Transcription
factor binding motifs enriched in genes significantly upregulated (yellow) and down
regulated (blue) in day 8 EZH1/2 dKO relative to day 8 E14 control.
Individual gene expression patterns
Of the markers of neural precursor cell identity mentioned above, I found that in
the EZH2 single mutants, none were upregulated to the extent that was seen
in the E14 control cells (Fig. 7.37). Of the pluripotency factors assessed I
found that both Oct4 and Nanog failed to be properly downregulated in both
EZH2 single mutant cells, however Sox2 was repressed as was seen in the E14
control (Fig. 7.34). Despite this significant difference in the expression of Oct4
and Nanog in the EZH2 single mutants relative to the E14 control on day 8
however, as compared to the levels detected in ESCs (day 0) the genes were both
considerably downregulated (Fig. 7.35 and 7.36). Both Fgf5 and Otx2 were
downregulated in the EZH2 single mutants however Otx2 was still expressed
to a level that was significantly higher than that found in the E14 control,
as was also the case for Tbx3 in both mutants (Fig. 7.38). Of the retinoic
acid transporters and nuclear receptors I found that some but not all failed to
undergo the induction of expression observed in the E14 control cells, as some
were significantly underexpressed in the EZH2 single mutants (Fig. 7.37).
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Figure 7.34 Expression of pluripotency factors in PRC2 mutant cells
on day 8 of differentiation. Log(2) foldchange of expression of pluripotency
factors in EZH2 Y726A, EZH2 KO and EZH1/2 dKO relative to E14 control on
day 8. Significant changes in expression (p value ≤0.05) are marked by an asterisk.
Figure 7.35 Expression dynamics of pluripotency factor Oct4 between
day 0 and day 8. Average number of transcripts per million detected for Oct4
across the three replicates of E14 control (E14 WT), EZH2 Y726A, EZH2 KO and
EZH1/2 dKO on day 0 and day 8. Error bars represent SEM across the three
replicates.
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Figure 7.36 Expression dynamics of pluripotency factor Nanog
between day 0 and day 8. Average number of transcripts per million detected
for Nanog across the three replicates of E14 control (E14 WT), EZH2 Y726A,
EZH2 KO and EZH1/2 dKO on day 0 and day 8. Error bars represent SEM
across the three replicates.
Figure 7.37 Expression of NPC markers and retinoic acid interactors
in PRC2 mutant cells on day 8 of differentiation. Log(2) foldchange of
expression of neural progenitor marker genes and retinoic acid interacting genes
in EZH2 Y726A, EZH2 KO and EZH1/2 dKO relative to E14 control on day 8.
Significant changes in expression (p value ≤0.05) are marked by an asterisk
In the EZH1/2 dKO cells, although I found no upregulation of the markers of the
neural progenitor phenotype, I did observe that pluripotency factors as well as
Fgf5 were silenced to similar levels as were seen in the E14 control (Fig. 7.37 and
133
Figure 7.38 Expression of developmental genes in PRC2 mutant cells
on day 8 of differentiation. Log(2) foldchange of expression of genes known to
be affected by withdrawal of LIF in EZH2 Y726A, EZH2 KO and EZH1/2 dKO
relative to E14 control on day 8. Significant changes in expression (p value ≤0.05)
are marked by an asterisk.
7.38). Although there was no significant difference in the levels of Oct4 and Nanog
detected in the EZH1/2 dKO as compared to the E14 control at this timepoint
(Fig. 7.34) there was a higher average number of transcripts detected for both
genes in this cell line, suggesting a high level of variability between samples here
(Fig. 7.35 and 7.36) Similarly to what I observed in the EZH2 single mutants, I
found that in the EZH1/2 dKO the retinoic acid binders were not all upregulated
as they were in the E14 control (Fig. 7.37).
Hox gene expression was found to go through a drastic change between day 2
and day 8 in the E14 control cells, with the majority of Hox genes becoming
upregulated on day 8 (Fig. 7.39A). I found that none of the Hox genes for which
silencing was maintained in the E14 control were significantly overexpressed in
either of the EZH2 single mutant backgrounds on day 8 (Fig. 7.39B). However,
almost all of these genes were derepressed in the EZH1/2 dKO (Fig. 7.39). Of the
Hox genes significantly upregulated in the E14 control, those with only modest
increases in expression compared to day 2 were not significantly differentially
expressed in either EZH2 single mutant background on day 8, but their expression
was significantly higher in the EZH1/2 dKO background. For the Hox genes which
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saw a strong induction in the E14 control from day 2 to day 8, however, I found
that both in the EZH2 single mutants and the EZH1/2 dKO the expression of
almost all of these genes was significantly lower. These results suggest that while
the EZH2 single mutants were able to maintain a certain level of gene repression
that the EZH1/2 dKO failed to achieve, all 3 mutants were lacking an activating
factor that is required for the Hox genes to reach the level of expression seen in
the E14 control on day 8.
Figure 7.39 Expression of Hox genes on day 8 of differentiation. (A.)
Log(2) foldchange of expression of Hox genes in E14 control on day 8 relative to
day 2 E14 control. Significantly upregulated genes (p value ≤0.05 ) are marked
by an asterisk. (B.) Log(2) foldchange of expression of Hox genes in EZH2
Y726A, EZH2 KO and EZH1/2 dKO on day 8 relative to day 8 E14 control.
Significantly upregulated genes (p value ≤0.05 ) are marked by an asterisk of the
colour corresponding to each mutant cell line.
7.5.5 Day 15 differential gene expression
In the E14 control on day 15 cells had progressed through differentiation to a
more mature neuronal phenotype, expressing factors such ad TrkB, Vgat and
Vglut, and downregualting Pax6. As on day 8, the EZH2 single mutants were
considerably divergent from the E14 control. As previously mentioned, by day
15 there were no surviving EZH1/2 dKO cells on the plates.
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Overall changes in gene expression and overlap between mutants
On day 15 both EZH2 single mutants were found to misregulate an even greater
number of genes than on day 8. The EZH2 Y726A cells were found to differentially
express more than 5000 protein coding genes of which a similar number were
found to be upregulated as were downregulated. The EZH2 KO cells were again
found to differentially express more genes than the EZH2 Y726A at almost 6300
protein coding genes of which there were around 400 more genes upregulated than
downregulated. In both mutants there were more genes downregulated by more
than twofold than there were genes upregulated by this same factor (Fig. 7.40).
Figure 7.40 Differential gene expression in day 15 EZH2 single
mutants. Pie charts representing expression of all protein coding genes in day 15
EZH2 Y726A and EZH2 KO relative to day 15 E14 control. Genes significantly
upregulated are shown in shades of yellow, genes significantly downregulated are
shown in shades of blue. Darker shades correspond to genes differentially expressed
by more than a log(2) foldchange of 1 or -1 over day 15 E14 control.
Nearly 4000 genes were found to be differentially expressed in both EZH2 KO
and EZH2 Y726A as compared to the E14 control with just over 1000 genes only
affected in the EZH2 Y726A and more than twice as many only affected in the
EZH2 KO (Fig. 7.41A). When I compared gene expression between the 2 mutant
cell lines at this timepoint, I found there to be just under 300 genes differentially
expressed. Of these genes nearly 200 were found to be upregulated in the EZH2
KO as compared to the EZH2 Y726A, while just under 100 were downregulated
(Fig. 7.41B). This was a greater difference than was observed between each of
the cell lines on day 8 (see Fig. 7.27) however compared to the number of genes
differentially expressed as compared to the E14 control, this was still relatively
low. This suggests that by day 15 the EZH2 KO and EZH2 Y726A cells were
becoming more divergent from each other than they had been throughout the
earlier stages of differentiation.
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Figure 7.41 Comparison of gene expression between EZH2 Y726A
and EZH2 KO on day 15. (A.) Venn diagram representing overlap of genes
differentially expressed in day 15 EZH2 Y726A and EZH2 KO. (B.) Pie chart
representing expression of all protein coding genes in EZH2 KO relative to EZH2
Y726A on day 15. Genes significantly upregulated in EZH2 KO are shown
in shades of yellow, genes significantly downregulated are shown in shades of
blue. Darker shades correspond to genes differentially expressed by more than
a log(2) foldchange of 1 or -1 over EZH2 Y726A. (C.) GO terms enriched in genes
significantly up (yellow) and downregulated (blue) in EZH2 KO relative to EZH2
Y726A on day 15.
GO terms associated with differentially expressed genes
By day 15 both EZH2 single mutants were found to upregulate genes associated
with several metabolic and biosynthetic processes involved in generating nucleic
acids and aromatic compounds, among others. In the EZH2 KO there was also an
up regulation of genes associated with the processing of RNA as well as translation
and gene expression. Both cell lines were found to downregulate many terms
associated with neuronal development and cell signalling (Fig. 7.42 and 7.43).
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Figure 7.42 Gene ontology of genes differentially expressed on day 15
in EZH2 Y726A cells. Go terms enriched in genes significantly upregulated
(yellow) and downregulated (blue) in day 15 EZH2 Y726A relative to day 15 E14
control.
Figure 7.43 Gene ontology of genes differentially expressed on day 15
in EZH2 KO. Go terms enriched in genes significantly upregulated (yellow) and
downregulated (blue) in day 15 EZH2 KO relative to day 15 E14 control.
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Binding sites for different sets of TFs were enriched in each EZH2 single mutant
amongst upregulated genes. The EZH2 Y726A was mostly enriched for binding
sites of the ZF5 and E2F factors (Fig. 7.44). Surprisingly, some of the TFs whose
binding sites were enriched amongst the upregulated genes in the EZH2 Y726A
cells were also enriched in genes upregulated in the E14 control on day 15. In
the EZH2 KO there was a larger variety of factors, including some Polycomb
targets such as Otx2 and Pitx3, as well as the ARNTlike factor, found to be
downregulated on day 8 in the E14 control (Fig. 7.45). The downregulated
genes in both EZH2 single mutants were enriched in binding sites for a similar
set of TFs, which was also very close to those found in the genes downregulated
on day 8, many of which are associated with neuronal development (Fig. 7.44
and 7.45). Of the genes found to be differentially expressed between EZH2 KO
and EZH2 Y726A those that were upregulated in the EZH2 KO cells were found
to be associated with response to LIF. Many genes found to be downregulated
in the EZH2 KO cells as compared to EZH2 Y726A were associated with both
cardiac and striated muscle (Fig. 7.41C). This suggests that the EZH2 KO may
be behaving in a manner that bears some resemblance to a stem cell-like state.
In contrast, the EZH2 Y726A cells although certainly divergent from the E14
control, may be behaving marginally more similarly to the differentiated state.
Figure 7.44 Enrichment of transcription factor binding sites in genes
differentially expressed on day 15 in EZH2 Y726A cells. Transcription
factor binding motifs enriched in genes significantly upregulated (yellow) and down
regulated (blue) in day 15 EZH2 Y726A relative to day 15 E14 control.
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Figure 7.45 Enrichment of transcription factor binding sites in genes
differentially expressed on day 15 in EZH2 KO cells. Transcription factor
binding motifs enriched in genes significantly upregulated (yellow) and down
regulated (blue) in day 15 EZH2 KO relative to day 15 E14 control.
Individual gene expression patterns
At the end of the differentiation protocol both the EZH2 Y726A and EZH2 KO
cell lines were still overexpressing pluripotency factor Oct4, as was also seen by
immuno-staining of day 15 cells (Fig. 7.8). EZH2 KO cells also overexpressed
Nanog and Sox2 on day 15 (Fig. 7.46). As expected at this timepoint, all genes
used as markers both of neural progenitors and mature neurons were significantly
underexpressed in both EZH2 single mutant cell lines, as is shown in Fig. 7.48 and
7.49. In the case of Pax6, although this gene was strongly downregulated in the
E14 control at this stage, its expression was still significantly lower in both of the
EZH2 single mutant cell lines on day 15. I also found that both Otx2 and Fgf5,
markers of early ectoderm development, were upregulated in both EZH2 single
mutant cell lines on day 15 (Fig. 7.47), despite initially having been silenced on
day 8. This may indicate a deficiency in the maintenance of a silenced state at
these genes in the EZH2 Y726A and EZH2 KO.
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Figure 7.46 Expression of pluripotency factors in EZH2 singles mutant
cell lines on day 15. Log(2) foldchange of expression of pluripotency factors
in EZH2 Y726A and EZH2 KO cells on day 15 relative to day 15 E14 control.
Significant changes in expression (p value ≤0.05) are marked by an asterisk.
Figure 7.47 Expression of developmental genes in EZH2 single mutant
cell lines on day 15. Log(2) foldchange of expression of genes known to be
affected by withdrawal of LIF in EZH2 Y726A and EZH2 KO cells on day 15
relative to day 15 E14 control. Significant changes in expression (p value <0.05)
are marked by an asterisk.
141
Figure 7.48 Expression of NPC markers and retinoic acid interactors
in EZH2 single mutant cell lines on day 15. Log(2) foldchange of expression
of neural progenitor marker genes and retinoic acid interacting genes in EZH2
Y726A and EZH2 KO cells on day 15 relative to day 15 E14 control. Significant
changes in expression (p value ≤0.05) are marked by an asterisk.
Figure 7.49 Expression of neuronal genes in EZH2 single mutant cell
lines on day 15. Log(2) foldchange of expression of neuronal genes in EZH2
Y726A and EZH2 KO cells on day 15 relative to undifferentiated day 15 E14
control. Significant changes in expression (p value ≤0.05) are marked by an
asterisk.
As previously discussed, the vast majority of EZH1/2 dKO cells did not survive




The experiments in this chapter demonstrated that all of the PRC2 mutant cell
lines, both EZH2 single and EZH1/2 double mutants, failed to complete neural
differentiation, although there were differences in viability of the single and double
mutant cell lines, as well as in the genes misregulated. They further showed
that the presence of a catalytically inactive EZH2 had little influence on gene
expression as a whole throughout this process.
As expected, although all of the PRC2 mutants showed at least a slight difference
in size and shape of EBs, the EZH1/2 dKO cell lines displayed a more exaggerated
phenotype than the EZH2 single mutants. The latter only displayed marginally
smaller EBs that the E14 control and were generally similar in shape while the
former were significantly smaller in size and much more irregularly shaped, with
higher rates of cell death. This was also the case for the EZH1/2 KO/Y726A cells,
indicating that the catalytically inactive form of EZH2 was not able to compensate
in any considerable way for the loss of EZH1. Indeed, upon dissociation of the
EBs and plating of neural progenitor cells, there was a very low survival rate
of the EZH1/2 double mutants, further suggesting that the catalytic activity
of either EZH2 or EZH1 is critical for survival at this stage of differentiation.
The EZH2 single mutant cell lines, in contrast, were able to survive and divide,
although failed to form neuron-like cells. There was no discernible difference
between the morphology of the EZH2 KO cells and the EZH2 Y726A cells at
this stage, with both exhibiting a fibroblast like appearance devoid of neuronal
protrusions, further suggesting that the catalytic activity of EZH2 is essential for
neural differentiation.
Indeed, there was little difference in gene expression between either EZH2 single
mutant by RT-qPCR analysis. Neither were able to sufficiently upregulate any of
the neuronal markers assayed, and both failed to correctly repress pluripotency
markers a trait which has been previously reported for EZH2 KO cells (Pasini
et al., 2007; Shen et al., 2008). However, both mutants were capable of correctly
expressing the early ectoderm marker Otx2 in the early stages of differentiation,
suggesting that the stage at which the EZH2 mutants become limiting for the
progression of differentiation is after the addition of retinoic acid, whereas initial
non-directed differentiation at the EB stage appears to be largely unperturbed.
The RNA-seq analysis provided further insight into the defects caused by the
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mutations of EZH1 and EZH2. The principle component analysis showed that,
in agreement with the RT-qPCR data, the biggest changes in the EZH2 single
mutants occurred by day 8, further suggesting the addition of retinoic acid was
a critical stage that requires a fully functioning PRC2 complex.
Consistently across every time point analysed, the EZH1/2 double mutants
showed a higher misregulation of genes than either of the EZH2 single mutant
cell lines. This indicated that although EZH1 is much less active than EZH2 and
is not able to maintain levels of H3K27me3 seen in the E14 control, it is sufficient
to maintain some level of gene regulation as opposed to when the PRC2 complex
is lost completely. This could be down to the H3K27me3 that is still present in
these cells, or may potentially arise from some other activity of the EZH1 protein
itself.
It seemed that in general across all timepoints except day 15, there was very little
significant difference between the gene expression profiles of EZH2 KO and EZH2
Y726A. Although the EZH2 KO cells were consistently found to have a larger
number of differentially expressed genes as compared to the E14 control than the
EZH2 Y726A, there were only ever a handful of genes found to differ significantly
between the 2 mutants. This suggested that although the EZH2 Y726A mutant
was still considerably divergent from the E14 control, the catalytically inactive
complex may have been able to maintain a certain level of dampening to changes
in expression at some genes. This effect was, however, subtle and much less
significant than that conveyed by the presence of EZH1. One hypothesis for
how this effect may be produced is through the simple obstruction of binding
of activating factors by the presence of the catalytically inactive PRC2, a large
protein complex, at promoters. It could also involve the interaction of PRC2
with additional factors that may themselves possess a repressive influence on
transcription.
Despite EZH1 being able to compensate for EZH2 in mESCs and day 2 of
differentiation, there were a few genes consistently differentially expressed in
both of the EZH2 single mutant cell lines. Of these Cdkn2a has previously been
shown to become upregulated in PRC2 depleted cells (Bracken et al., 2007). The
majority of the remaining upregulated genes have CGIs in their promoter region
and had at least a small enrichment of H3K27me3 in E14 control cells, although
there was no common trait amongst these genes that I was able to identify that
could explain why these select few were upregulated.
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The comparison of gene expression in the EZH2 single mutant cell lines and the
EZH1/2 dKO on day 8 showed that although neither were able to differentiate, the
residual EZH1 in the EZH2 single mutant cells was able to maintain the repression
of many Polycomb target genes, which was not observed in the EZH1/2 dKO.
This suggests that the role of EZH2 at this stage of differentiation may not only
involve silencing genes but also acting as an activator of certain factors, as seen
by the large-scale downregulation (as opposed to the expected upregulation) of
genes in the mutant backgrounds. This could either occur directly through the
action of EZH2 in some capacity, or through the silencing of additional repressors
to allow previously silenced genes to become expressed. This could also involve
the pluripotency factors that were not entirely silenced in the PRC2 mutant
cell lines. It has been shown that ectopic expression of these factors inhibits
cell differentiation (Hochedlinger et al., 2005), so it may be that in these PRC2
mutants their overexpression was inhibiting the upregulation of certain factors
required for commitment to the neural lineage. In both EZH2 single mutants
I observed an upregulation of genes involved in spermatogenesis and meiosis on
day 8. These genes have been shown to be enriched in H3K27me3 in mouse
embryonic day 6.25 epiblast (Zylicz et al., 2015), which corresponds to the phase
of embryonic development immediately prior to gastrulation. This could point
to a failure of the EZH2 single mutants to maintain repression of this subset
of Polycomb genes at this stage. Again, there appeared to be little difference
between the EZH2 KO and EZH2 Y726A in how these genes were overexpressed.
Overall these differentiation experiments along with the RNA-seq data allowed
me to gain some insight into when PRC2 is required during development. My data
suggests that in the earlier stages of differentiation, the low levels of H3K27me3
produced by EZH1 are sufficient to maintain repression of Polycomb genes that
would otherwise become derepressed. It also appeared that many of the changes
in gene expression that happen in a wild-type background in the first few days of
EB formation occur largely independently of PRC2. However, with the change in
signalling cues from the addition of retinoic acid, the cells require a catalytically
active EZH2 in order to correctly downregulate pluripotency factors and allow the
expression of neuronal lineage genes. EZH1 may become insufficient at this stage
because of its lower catalytic activity, or perhaps differences in how it is recruited,
both or either of which may mean it is not able to bind to novel Polycomb target
genes as cells differentiate. It could also be the case that there is a deficiency in
the establishment of the required chromatin state earlier in differentiation, and





Although there has been extensive research into the functions and mechanisms
behind Polycomb group protein activity, the role of the H3K27me3 mark has not
been completely distentangled from that of the PRC2 complex itself. The aim
of this project was to establish a system in which these two aspects of PRC2
function could be decoupled in order to ascertain how much of Polycomb activity
relies on the methylation of H3K27. The experiments described here showed that
although the catalytic activity of EZH2 was largely dispensable to maintain the
majority of Polycomb function in the presence of EZH1 in mESCs, it was essential
for the correct regulation of gene expression upon differentiation of cells towards
the neural lineage. In this chapter I will first discuss the findings on the state
of Polycomb bound genes and the expression of the PRC2 complex itself in the
PRC2 mutant cell lines, before detailing how this affects gene expression in the
undifferentiated mESCs. Finally, I will discuss how these mutations in PRC2
affect the ability of these cells to differentiate into neurons, the consequences for
gene expression, and the timing of PRC2 requirement throughout this process.
8.1 Characteristics of chromatin state at Poly-
comb target genes
While neither the catalytic inactivation of EZH2 nor a knockout of this protein
appeared to have much of an effect on the expression of the other PRC2 subunits,
the additional knockout of the EZH1 subunit did lead to some increased variation
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in the expression of EED and SUZ12, with some clones expressing considerably
lower levels of these subunits than the E14 control cells (see Fig. 3.10). A similar
marginal decrease in expression of these subunits has recently been observed in
independent strains of EZH1/2 dKO cells (Højfeldt et al., 2018; Lavarone et al.,
2019) and decreased expression of other PRC2 subunits was noted in an earlier
study with SUZ12 KO (Pasini et al., 2007). This may be the result of a feedback
loop of the PRC2 complex in which decreased levels of the fully assembled complex
may lead to decreased expression of the individual subunits. Alternatively this
may simply reflect an increased stochasticity in gene expression in the EZH1/2
double mutants due to the lack of a major regulatory complex.
Despite these subtle effects on the expression of PRC2 subunits I found that
the catalytically inactive EZH2 protein was still detectable at Polycomb target
genes, both in the presence and absence of EZH1 and residual H3K27me3 (see
Fig. 4.3). This indicates that PRC2 can be recruited to chromatin independently
of H3K27me3, likely through a combination of the following mechanisms: the
interaction with accessory factors, recruitment via the H2AK119ub mark placed
by PRC1, and the binding of SUZ12 to CGIs (Hauri et al., 2016; Holoch and
Margueron, 2017; Blackledge et al., 2014; Cooper et al., 2014; Højfeldt et al.,
2018).
This binding of EZH2 Y726A to Polycomb target genes did however appear
significantly reduced in the EZH1 KO background, and was still below wild-type
levels even in the EZH2 Y726A single mutant cells. This suggests that, although
not essential, H3K27me3 may contribute to the robust binding of PRC2 to its
target sites, likely by providing an additional interaction site for the complex with
chromatin, through the binding of the WD40 domain of EED (Margueron et al.,
2009). There may also be an involvement of the EZH1 subunit itself in recruiting
or stabilising the binding of EZH2 (Son et al., 2013). This may involve the
dimerisation of PRC2 which can occur between two PRC2 complexes containing
EZH1 and EZH2 respectively (Davidovich et al., 2014). A recent study, in which
a catalytic mutant of EZH2 was generated by mutating the same residue targeted
in this project, saw a similar maintenance of PRC2 binding to its target sites in
the absence of H3K27me3 and EZH1 (Lavarone et al., 2019).
Once recruited to its target sites, PRC2 is thought to spread H3K27me3 across
a broader region centred on the TSS of target genes via a mechanism which
requires the allosteric activation of EZH2 which is triggered by the binding of
EED to H3K27me3 (Margueron et al., 2009; Oksuz et al., 2018). The data
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generated in the EZH2 ChIP-seq experiments should provide further information
the requirement of this mechanism for the binding of PRC2 to its target sites,
specifically by comparing the spread of the EZH2 enrichments across target
genes in EZH2Y726A cells to those seen in the E14 control cells. If EED-
bound H3K27me3 is required for spreading of PRC2 activity from its initial
recruitment site the EZH2 signal should be broader in the E14 control cells than
in the EZH2 Y726A. Additionally, Oksuz et al. classified Polycomb targets into
nucleation sites, which they defined as the primary target sites for Polycomb
binding, and spreading sites that required physical contact with these nucleation
sites to acquire PRC2 binding and H3K27me3 deposition (Oksuz et al., 2018).
This spreading of PRC2 from the nucleation sites was found to be lost in cells with
a mutation in the EED subunit that abolished its binding of H3K27me3. It would
be interesting to determine whether EZH2 Y726A is confined to the nucleation
sites identified in this study, or if it is also found at the so called spreading sites,
which would suggest that there are additional factors enabling its recruitment to
these targets.
Future experiments that will be undertaken concerning PRC2 binding to
chromatin will involve cell lines recently generated in the lab in which we have
introduced a mutation to disable the catalytic activity of the EZH1 subunit. The
comparison of EZH2 binding to it targets in EZH1/2 KO/Y726A cells and in
cells with a catalytically inactive EZH1 in a EZH2 Y726A background will help
further elucidate the role of EZH1 in EZH2 binding to chromatin independently
from H3K27me3.
As has been previously described (Margueron et al., 2008; Lavarone et al., 2019),
I found that very little H3K27me3 was deposited by EZH1 in the absence of
EZH2 (see Fig. 4.2). Further analysis of the H3K27me3 ChIP-seq data may
provide more insight into which genes retain the most and the least H3K27me3
in absence of EZH2, and whether this correlates at all with the genes found to be
misregulated in these cells. This experiment will reveal more information about
the target preference of EZH1 as compared to EZH2, and the comparison of the
EZH2 KO to the EZH2 Y726A cells should demonstrate whether the presence of
the catalytically inactive EZH2 at these sites has any influence on the activity or
the targeting of EZH1. It will additionally be interesting to compare the sites that
retain the most H3K27me3 in the EZH2 single mutant cells lines to the so called
nucleation sites defined in the study by Oksuz et al. As EZH1 is known not to
respond to the allosteric activation provided by EED in presence of H3K27me3,
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it might be expected that it would only be found at the nucleation sites and not
the spreading sites defined in this study (Oksuz et al., 2018; Lee et al., 2018).
A surprising effect of the EZH2 single and EZH1/2 double mutations was that
on the binding of RING1B. As was shown in Fig. 4.5, in both EZH2 single
mutant cell lines there was a slight reduction of RING1B binding to the set
of Polycomb genes assayed, however this effect was much more striking in the
EZH1/2 double mutant cells, with little to no RING1B bound in these cell lines.
This suggests that the recruitment of PRC1 to these genes occurs predominantly
via the hierarchical model, in which the H3K27me3 placed by PRC2 allows the
binding of PRC1 through recognition of this mark by the CBX subunit (Wang
et al., 2004). The small reduction in binding of RING1B observed for the EZH2
single mutants was surprising given how little H3K27me3 remains at these sites
(see Fig. 4.2), suggesting that very low levels of H3K27me3 are sufficient to
maintain recruitment of canonical PRC1. This finding indicates that Polycomb
silencing is a mechanism that is able to withstand small variations in expression
of the subunits or in catalytic activity without this strongly affecting the levels
of expression of its target genes. This is an unsurprising characteristic for a
regulatory network that is so crucial in development, particularly as many of the
genes targeted by Polycomb, such as the Hox genes, are themselves developmental
regulators, small changes in the expression of which can have considerable effects
on tissue specification and body patterning in the developing embryo (Lewis,
1978; Zink and Paro, 1989; O’Carroll et al., 2001; Pasini et al., 2004). This
finding, in addition to the results from chapters 5 and 6, also helps to explain why
EZH1 is able to fully take over from EZH2 once cells are terminally differentiated
despite its much lower catalytic activity, by showing that even in cells where EZH2
is the dominant subunit, EZH1 is able to maintain the vast majority of Polycomb
function in cells that are not transitioning through differentiation (Laible et al.,
1997; Bracken, 2003; Margueron et al., 2008).
It would be interesting to assess the binding of RING1B genome wide to determine
if this effect is seen at all Polycomb sites, particularly those for which there is
no H3K27me3 detected in the EZH2 single mutant cells. The double EZH1/2
catalytic mutant cells may also be of use here as a further confirmation that the
low levels of H3K27me3 placed by EZH1 are indeed sufficient to recruit PRC1.
A recent study in which a conditional catalytic mutant of PRC1 was generated
found that the catalytic activity of this complex was essential for the majority of
Polycomb gene repression as well as Polycomb domain formation and long-range
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interactions between Polycomb target sites (Blackledge et al., 2019). Additionally
this study also found that the loss of PRC1 catalytic activity significantly
decreased PRC2 and H3K27me3 occupancy at target sites. While the binding of
the canonical PRC1 complex to target sites was found to be dependent on PRC1
catalytic activity, the occupancy of the variant form of PRC1 was found to be
largely unaffected by the loss of catalysis. These results reaffirmed the model
in which the binding of PRC1 and PRC2 is mutually reinforced at target sites
where a low level of transcription enables significant deposition of H2AK119ub,
likely first initiated by the variant form of PRC1. This study is in agreement with
my findings regarding the requirement for PRC2 activity for the recruitment of
PRC1 and the role of PRC1 in mediating the Lhx5 enhancer-promoter contact.
In light of the results of this study it would be interesting to assess the levels of
H2AK119ub at Polycomb genes, particularly in the EZH1/2 double mutants in
which I found the RING1B binding to be reduced to undetectable levels while
maintaining binding of the EZH2 Y726A mutant (see Fig. 4.3 and 4.5). This
experiment would provide insight into the contribution of H2AK119ub to the
recruitment of PRC2 to these sites, and how the loss of EZH2 catalytic activity
may affect the ability of PRC1 to deposit its mark.
Additional changes to histone modifications were noted in the PRC2 mutants,
notably for H3K4me3 which co-localises with H3K27me3 at bivalent genes, and
which was studied in more detail in chapter 4. The H3K4me3 mark was found
to increase at bivalent genes in all PRC2 mutant mESCs, although this increase
was the most striking in the EZH1/2 double mutant cells (see Fig. 4.4). As
H3K4me3 and H3K27me3 are known to be deposited by mutually antagonistic
processes (Schmitges et al., 2011; Voigt et al., 2012), this result was to be expected
given the decrease of H3K27me3 that occurs in each PRC2 mutant cell line, with
the most complete depletion of this mark induced in the EZH1/2 double mutant
cells. One surprising finding was that the increase in H3K4me3 at bivalent genes
appeared to be stronger in the EZH1/2 KO/Y726A cells than in the EZH1/2
dKO. This result suggests that the catalytically inactive PRC2 bound to these
genes may somehow favour the deposition of H3K4me3. This correlates with some
unpublished in vitro experiments that have been performed in the lab in which
the presence of a catalytically inactive PRC2 complex led to an increased activity
of MLL2 in catalysing H3K4me3. If this phenomenon is confirmed by further
analysis of the H3K4me3 ChIP-seq data it could contribute to the explanation of
how a bivalent chromatin state is established, or how H3K4me3 is maintained in
ESCs at sites which carry inherently repressive features.
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Alternatively this increase in H3K4me3 may reflect the activation of transcription
of these genes, which may involve multiple H3K4 methyltransferases. In order
to confirm the role of MLL2 in this phenomenon, inactivation of this complex,
by knockout, mutation of the SET domain or an inhibitor will be required in
addition to the PRC2 mutations to verify that H3K4me3 is indeed deposited by
this complex alone at these sites.
A recent study found a similar positive effect on methylation from the presence of
a catalytically inactive methyltransferase, Dnmt3b (Nowialis et al., 2019). This
study compared a catalytically inactive Dnmt3b to a Dnmt3b KO in mESCs
and found that this protein had accessory functions that were independent of
its catalytic activity which largely rescued the phenotype of the KO mutant.
Catalytically inactive Dnmt3b was found to be able to restore the majority of the
DNA methylation lost upon the full KO of this protein, possibly through a non-
catalytic function which supports the methyltransferase activity of other Dnmts.
Unlike my findings for EZH2 Y726A however, the catalytically inactive Dnmt3b
maintained wild-type expression levels for the majority of genes which underwent
misregulation in Dnmt3b KO cells. This was found in many cases to be due to the
maintenance of DNA methylation by the catalytically inactive Dnmt3b, but for
some genes, such as Wnt9b, due to a direct repressive effect of Dnmt3b binding
to gene promoters independent of DNA methylation. As previously stated, the
analysis of the ChIP-seq data for H3K27me3 in the EZH2 single mutant cells may
reveal whether EZH2 Y726A has a comparable accessory function in directing the
methyltransferase activity of EZH1 to target sites.
Further analysis of gene expression differences between the EZH2 Y726A and
EZH2 KO cells at sites which are EZH2 positive but H3K27me3 negative in the
E14 WT cells may also reveal any direct inhibitory effects of EZH2 that would
be entirely independent of catalysis, analogous to the effect of Dnmt3b on Wnt9b
observed in this study.
The experiments in chapter 5 demonstrated that, similarly to all other Polycomb
targets assayed previously in this project, PRC1 is primarily recruited to the
Lhx5 gene by its binding to H3K27me3 (see Fig. 5.2B). These experiments also
showed that although the contact between the Lhx5 enhancer and promoter was
lost in the absence of the PRC2 complex (see EED KO and EZH1/2 dKO Fig.
5.5), this contact was maintained in the presence of EZH1. However, this contact
was additionally shown not to be directly mediated by PRC2 but PRC1 as the
knockout of RING1B led to dissociation of the Lhx5 enhancer and promoter,
152
but did not result in a reduction of H3K27me3 levels at these sites (see Fig. 5.5
and 5.2A). The additional loss of contact observed in the CBX7 F11A mutant
further confirmed that at this site, PRC2 is required only insofar as it enables
the recruitment of PRC1. Interestingly, although this contact has been shown to
be required for the timely expression of this gene upon cell differentiation (Cruz-
Molina et al., 2017), it would appear from these experiments that the dissociation
of this contact upon loss of Polycomb also leads to upregulation (see Fig. 5.6).
This Polycomb dependent contact of the enhancer and promoter of Lhx5 may
then serve the dual purpose of both maintaining transcriptional repression of
this gene in ESCs, whilst also setting up a conformation that will enable its
expression at the correct moment upon differentiation. The results in this chapter
are preliminary and require additional biological replicates as well as the inclusion
of the EZH1/2 KO/Y726A cells. Again, the EZH1/2 double catalytic mutant
may be of use in these experiments to rule out any role of the EZH1 protein
itself in these contacts besides the H3K27me3 that it catalyses. As this was only
performed for the enhancer-promoter contact of one gene it cannot be ruled out
that PRC2 may be directly involved in the contact of different types of long-
range contacts. In the longer term, it would be interesting to expand this study
to additional sites that have been found to form PRC2 clusters and/or long-range
contacts with other sites, or even perform a genome wide study using one of the
”C” methods of chromatin conformation capture. This may be of particular
interest for the subset of Polycomb targets that are not bound by the PRC1
complex (Ku et al., 2008).
Additionally, further study of Polycomb-dependent contacts at different stages
of differentiation may be interesting. As EZH1 becomes insufficient to maintain
proper gene expression throughout this process it may also lose its ability to
maintain contacts in this context as well.
8.2 Consequences of EZH2 and EZH1 muta-
tions on gene expression and pluripotency
in mESCS
Following the evaluation of the chromatin state at Polycomb bound genes in the
PRC2 mutant cell lines, I next moved on to assess the effects these mutations had
on gene expression. In undifferentiated mESCs, as has been previously reported
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(Pasini et al., 2007; Chamberlain et al., 2008; Shen et al., 2008; Riising et al.,
2014), the loss of EZH2 alone had a limited effect on gene expression and it was
only when the activity of both EZH1 and EZH2 were lost that large-scale changes
in gene expression occurred (see Fig. 6.3, 6.4 and 6.5). This appeared not to affect
the expression of pluripotency factor Oct4 (see Fig. 6.1) and self renewal of these
cell lines appeared to be largely unaffected as well. These results along with
those of previous chapters, further demonstrate that in mESCs, EZH1 is largely
able to compensate for EZH2 in the maintenance of a Polycomb silenced state,
despite its much lower catalytic activity. It remains to be seen however, whether
EZH1 would also be able to rescue all PRC2 function if it were re-expressed in the
EZH1/2 dKO cells. It may be that the maintenance of Polycomb gene silencing
achieved by EZH1 in the EZH2 single mutant cell lines, may only have been
possible because these sites were already established as Polycomb bound genes.
In both the presence and absence of EZH1, the presence of EZH2 Y726A produced
a very similar gene expression pattern in cells as the EZH2 KO, demonstrating
that the presence or absence of H3K27me3 is much more influential on Polycomb
gene regulation than the presence or absence of the complex itself. The RNA-seq
data did seem to suggest that there might be a higher degree of variance in gene
expression from sample to sample in the knockout background as compared to
the EZH2 Y726A background, but as there were only 3 biological replicates for
each genotype it was difficult to assign any statistical significance to this finding.
There was however, both in the EZH2 single mutants and the EZH1/2 double
mutants, a larger number of genes misregulated in the EZH2 KO background
than the EZH2 Y726A background. This suggests that the catalytically inactive
EZH2 may have a small effect on gene expression by its continued binding at these
sites. This could occur simply by its presence on chromatin blocking the binding
of additional transcription factors, or perhaps by inhibiting the progression of Pol
II along the gene. As PRC2 has been shown to interact with nascent RNAs this
may also be happening with EZH2 Y726A, which could disrupt the processing
and maturation of these transcripts (Kaneko et al., 2013; Kaneko et al., 2014;
Skourti-Stathaki et al., 2019). Alternatively the presence of PRC2 at these genes
may maintain a certain level of clustering of Polycomb genes together into a less
transcriptionally active chromatin domain.
There were a small number of genes that were misregulated in the EZH2 single
mutants, most of which were affected in both the EZH2 KO and EZH2 Y726A.
It would be interesting to investigate further why these genes in particular are
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affected by the loss of EZH2 activity alone. It might also be interesting to see
how the state of Pol II occupancy is affected in these cell lines as it is known
that is is bound in a poised state at the promoters of bivalent genes (Stock et al.,
2007; Brookes et al., 2012).
8.3 Consequences of EZH2 and EZH1 muta-
tions on neural differentiation
The aim of the neural differentiation experiments in chapter 7 was to clarify the
requirements of PRC2 during this process. It was evident from these experiments
that H3K27me3 is essential for neural differentiation, specifically that deposited
by EZH2. This is in contrast to the previous results in this project which
demonstrated that the residual levels of H3K27me3 placed by EZH1 are largely
sufficient to maintain Polycomb repression in mESCs.
The results of these experiments additionally suggested that PRC2 is largely
dispensable for many of the events that occur within the first few days of embryoid
body formation, as the number of genes significantly misregulated in the PRC2
mutants as compared to the E14 control did not increase between day 0 and day
2 of the differentiation (see Fig. 7.21). Instead, PRC2 seemed critical for the
changes in gene expression that occur in response to the addition of retinoic acid
(see Fig. 7.26). A critical role of PRC2 at this point during the differentiation
is perhaps somewhat surprising given this result that both EED and SUZ12 see
a decrease in their expression levels at this same timepoint in the E14 control
(see Fig. 7.19), suggesting a downregulation of PRC2 activity around that stage
of the protocol. This later timing for PRC2 requirement is perhaps surprising
given the early lethality of Polycomb knockouts in embryonic development
(Faust et al., 1998; O’Carroll et al., 2001; Pasini et al., 2004). However, the
experimental conditions of this differentiation protocol are considerably different
to the environment in the early embryo so the comparison between the two
situations is not easy to make.
Many of the genes that were differentially expressed during differentiation in
the PRC2 mutant cells were developmental genes from the neural lineage. This
was not necessarily the expected phenotype, as PRC2 is a repressive complex,
compromised silencing would seem more likely than an inability to upregulate
genes. This further suggests that the bivalent state at many of these genes is
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required for their induction at the correct time during differentiation.
From both the gene expression patterns and cell morphology it was clear that the
EZH1/2 double mutant cell lines had a greater, and earlier, defect in their ability
to differentiate than the EZH2 single mutant cells (see Fig. 7.2, 7.3 and 7.4). It
was found that while the EZH1/2 dKO mutation led to the upregulation of many
Polycomb target genes both in ESCs and throughout differentiation, this was not
the case in the EZH2 single mutants. This demonstrated that while EZH1 was
not able to compensate completely for EZH2 throughout this process, it was able
to maintain a certain level of repression at genes that were Polycomb bound in
the undifferentiated ESC state. An example of this can be seen in Fig. 7.39: the
Hox genes that do not become actively transcribed in the E14 control cells are
not derepressed in either of the EZH2 single mutant cell lines, however there is
an overexpression of these genes in the EZH1/2 dKO. For those Hox genes that
were strongly upregulated in the E14 control on day 8 however, neither the EZH2
single mutant cells nor the EZH1/2 dKO expressed these genes to the level seen
in the E14 control, despite all of these genes being upregulated in the EZH1/2
dKO as compared to the E14 control in the undifferentiated state (see Fig. 6.12).
This suggests that even if the Polycomb repression is removed from these genes,
they require an additional activating factor to achieve the levels of expression
seen in the E14 control on day 8. This factor appears to be missing in both the
EZH2 single and the EZH1/2 dKO cells. This could be because a repressor of
this activator is not being silenced in these cells. In this case one of the ways in
which EZH1 is not able to compensate for EZH2 during differentiation may be
an inability to locate to new targets or at least to establish a Polycomb repressive
state at these loci where repression is newly required.
One theory to explain this deficiency involves EZH1’s much reduced response
to allosteric activation by EED (Lee et al., 2018). This effect has been shown
to be reproduced by the binding of the methylated K116 of JARID2 by EED
(Sanulli et al., 2015; Kasinath et al., 2018) which has been proposed to aid in
the targeting of PRC2 to novel, previously unmethylated sites. In the case of
EZH1 this stimulation of activity would not occur, perhaps impairing its binding
to new sites. However, there are additional methods of recruitment for PRC2
that do not require H3K27me3, for example it has been recently shown that
the N-terminal VEFS domain of SUZ12 is able to bind CGIs in the absence of
H3K27me3 (Højfeldt et al., 2018). The existence of these additional modes of
recruitment suggest the deficiencies of EZH1 during differentiation may not be
due to compromised targeting of EZH1 but rather due to its reduced activity
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being insufficient for the robust establishment of an enrichment of H3K27me3 at
these sites.
Another factor possibly preventing the upregulation of neuronal lineage genes
in the PRC2 mutant cells may be the higher expression levels of pluripotency
factors such as Oct4 and Nanog (see Fig. 7.34). Their continued expression may
be maintaining the activation of repressors that inhibit the expression of factors
involved in the response to retinoic acid and neural differentiation in general.
However, though the expression of these pluripotency factors was found to be
significantly higher in the PRC2 mutant cells than in the E14 control by day
8 (around 5 times higher in the EZH2 single mutant cells and 10 times in the
EZH1/2 dKO), these levels were still much reduced as compared to those detected
in the undifferentiated mESCs, approximately 10 times lower for Oct4 and around
5 times lower for Nanog (Fig. 7.35 and 7.36). This has been previously observed
in EED KO cells upon embryoid body formation (Obier et al., 2015). This study
also showed that many of the genes that acquire H3K27me3 during EB formation
were bound by OCT4 in ESCs, further demonstrating the antagonistic activity
of this factor to Polycomb regulation of gene expression. Given these findings,
it is conceivable that the low amount of pluripotency factors remaining in the
PRC2 mutant cells by day 8 may be sufficient to maintain some expression of
their target genes, particularly if said genes are not being efficiently bound by
PcG proteins.
To further investigate this, ChIP experiments could be performed at this time
point to determine if EZH1 is able to bind to novel targets and deposit H3K27me3.
ChIP for OCT4 and NANOG could also be performed to ascertain whether the
low levels of expression detected for these genes by RNA-seq in the PRC2 mutant
cells translate to detectable levels of these proteins still bound to their target
genes by day 8. Although these factors are known to be bound by Polycomb in
differentiated cells (Pasini et al., 2007; Obier et al., 2015), their downregulation
in the EZH1/2 dKO cells demonstrates that their downregulation is mediated
by factors independent of PRC2, suggesting that Polycomb functions here as a
marker of already silenced genes, serving to maintain the repressive state rather
than establishing it, as has been previously demonstrated (Riising et al., 2014).
A similar observation was made in early studies of PcG proteins in Drosophila
in which they were found to be dispensable for the establishment of a repressed
state and only required for its maintenance (Struhl and Akam, 1985; Jones and
Gelbart, 1990; Simon et al., 1992).
157
As was observed in the undifferentiated mESCs, the EZH2 Y726A cells misregu-
lated slightly fewer genes than the EZH2 KO at each timepoint studied (see Fig.
6.4, 7.21, 7.26 and 7.40). This further highlights the possibility that EZH2 Y726A
may be able to maintain a certain level of regulation of gene expression that is
lost in the EZH2 KO and is independent of H3K27me3. As was discussed above,
there are several potential mechanisms for how this might be achieved by the
catalytically inactive complex. Further investigations into how this process occurs
could be done with a reporter gene to which PRC2 could be artificially recruited.
Expression levels of this gene could then be compared in presence of a wild-type
or catalytically inactive PRC2 or a PRC2 KO. By adding transcription factor
binding sites to this reporter gene, we could also determine whether a catalytically
inactive PRC2 can significantly affect the recruitment of transcription factors.
This assay could also be used to determine whether binding of a catalytically
inactive PRC2 is sufficient to co-localise the reporter gene with other Polycomb
targets within the nucleus.
To further investigate the requirements of PRC2 throughout the different stages
of differentiation we intend to make use of the auxin-inducible degron system.
This system evolved in plants and leads to the rapid degradation of proteins by
ubiquitylation in response to auxin, a plant hormone, and has been developed
to function in multiple different cell types (Nishimura et al., 2009). We have
generated cell lines with an auxin degron-tagged EZH2 which enables us to induce
the degradation of this protein upon treatment with auxin. Using these cell lines
neural differentiation experiments will be performed throughout which EZH2 will
be removed at different stages. The aim of these experiments will be to determine
whether PRC2 truly is dispensable in the early stages of EB formation before the
addition of retinoic acid, as suggested by the differentiation data, or whether it
is perhaps needed to establish the correct chromatin state at this time that is
required for proper gene expression later. These experiments will also determine
whether PRC2 is required once cells have already established a Pax6 expressing
neural progenitor state, for the continued differentiation towards mature neurons.
It is conceivable that once certain key genes have been expressed, regulatory
networks are activated that will control the expression of the required genes for the
continued progression towards the neural lineage without any major requirements
from PRC2.
As the loss of H3K27me3 induced such strong changes in gene regulation, it
proved difficult to discern the more subtle effects that could be mediated by the
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PRC2 complex itself. One approach to further explore the potential catalysis-
independent functions of the complex would be to use a system in which PRC2
is absent from its target genes but the H3K27me3 is maintained. We hope to
use the auxin degron-tagged EZH2 cells for these experiments, as the protein is
degraded within the first 24 hours of treatment, but H3K27me3 is maintained
for at least 48 hours, giving us a window in which genes still retain the histone
modification but are now devoid of PRC2.
An interesting additional PRC2 mutation to study would be an overactive EZH1.
Some cancers have been found to harbour overactive EZH2 mutants that with
higher catalytic activity than the wild-type protein (Morin et al., 2010; Bodor
et al., 2013; Harms et al., 2014). This has also been identified in one case
for EZH1 (Calebiro et al., 2016). Introducing this mutation into an EZH2
KO or EZH2 Y726A background would be interesting from several perspectives.
First, this could help establish whether there are any substantial differences in
targeting or additional activities of EZH1 and EZH2. Second, by using these
cells in differentiation assays, it would be possible to determine whether the lower
catalytic activity of wild-type EZH1 is the only reason it is not able to compensate
for EZH2 during this process or whether there are additional factors at play.
Additionally, this overactive form of EZH1 could be expressed in EZH1/2 double
mutant cells to test whether it is sufficient to re-establish Polycomb repression in
these cells.
8.4 Summary and final remarks
Overall this project provided a greater understanding of how the PRC2 complex
functions, both in mESCs and throughout neural differentiation. Although
it began with a focus on the EZH2 subunit, the early findings of this thesis
broadened the scope of the project to include questions regarding the separate
functions of EZH2 and EZH1, as the latter proved to be of more consequence
in undifferentiated cells than originally anticipated. I found that in mESCs very
little H3K27me3 is required for the maintenance of Polycomb function, including
gene repression, the recruitment of PRC1 and the contact of the enhancer and
promoter of Polycomb target gene Lhx5, and that EZH1 alone was capable of
fulfilling this requirement. However, it remains possible that EZH1 has further
roles beyond placing residual H3K27me3 that can contribute to maintenance of
repression. In the absence of any H3K27me3, I found that Polycomb genes became
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derepressed in mESCs, and this was only weakly mitigated by the presence of a
catalytically inactive EZH2. This indicates that the catalytic activity of PRC2 is
essential for the vast majority of its function in mESCs.
In neural differentiation I found that in the earliest stages of EB formation, the
effect of the loss of PRC2 function on gene expression did not differ greatly
from that observed in the undifferentiated mESCs. The presence of EZH1 and
the residual H3K27me3 was sufficient to maintain the correct expression of the
vast majority of genes at this early timepoint. However, the catalytic activity
of EZH2 was essential for correct gene expression upon treatment with retinoic
acid. During this process EZH1 was able to maintain repression of genes that
were Polycomb targets in mESCs, however it did not allow for the upregulation
of genes of the neural lineage, nor full repression of pluripotency factors. The
presence of the catalytically inactive EZH2, again, was not able to maintain
correct gene expression patterns required for neural differentiation, but there were
a consistently lower number of genes differentially expressed in these cells than in
the EZH2 KO cells, suggesting that PRC2 containing catalytically inactive EZH2
is able to maintain binding and some degree of function.
Based on the findings of this thesis I propose the following working model: in
undifferentiated cells in which the set of genes targeted by the Polycomb group
proteins does not change, low levels of H3K27me3 are sufficient to maintain
the required repression and chromatin state at Polycomb target genes, and
EZH1 is sufficient for this purpose. However, in a dynamic system, such as
during differentiation, where Polycomb binding is required at novel sites, EZH2
is required for the binding of PRC2 to new genes and depositing high levels of
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